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ABSTRACT 
 
Kathryn Michelle Louise Taylor:  Development of Nanoscale Metal-Organic Frameworks 
and Hybrid Silica Nanoparticles for Biomedical Applications 
(Under the direction of Wenbin Lin) 
 
 This dissertation describes the use of several different types of nanoparticles for 
biomedical applications including imaging, drug delivery, and sensing.  Several novel 
contrast agents for magnetic resonance imaging have been developed using different 
nanoparticle platforms.  First, highly efficient T1-weighted contrast agents were developed 
using mesoporous silica nanoparticles.  This system was also extended to form a 
biodegradable contrast agent based on the same mesoporous silica nanoparticle platform.  By 
incorporating paramagnetic metal ions Gd3+ and Mn2+ into nanoscale metal-organic 
frameworks, new contrast agents for magnetic resonance imaging have also been developed.  
All of these systems can also be modified to include either an organic fluorophore or 
luminescent lanthanide ion, forming multimodal contrast agents that can be used for both 
optical and magnetic resonance imaging.   
 The use of nanoscale metal-organic frameworks for drug delivery will also be 
presented.  Highly porous nanoscale metal-organic frameworks were synthesized using Fe3+ 
and an organic bridging ligand.  After the nanoparticles were synthesized, a platinum based 
anticancer drug was covalently attached to the porous framework.  These nanoparticles have 
also been functionalized with organic fluorophores to create optical contrast agents. 
 Finally, the use of a nanoparticle sensor for the detection of dipicolinic acid, a 
chemical marker for bacterial endospores (such as Anthrax), is demonstrated.  Several
different nanoparticle sensors were developed, and they are advantageous over the molecular 
complexes because they allow for the incorporation of an internal standard, which eliminates 
the need for instrument specific calibration curves. 
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CHAPTER 1 
 
Hybrid Nanoparticles for Biomedical Applications 
 
1.1 Introduction 
 Purely inorganic or organic nanomaterials have been used extensively for a variety of 
biomedical applications.  Semiconductor nanoparticles, or quantum dots (QDs), are 
nanomaterials generally composed of II-VI and III-V elements.1-5  These nanoparticles show 
some unique optical properties, including sharp and symmetrical emission spectra, high 
quantum yields, broad absorption spectra, good chemical and photo-stability and size 
dependent emission wavelength tunability.3  As a result, they have been evaluated 
extensively for use as optical imaging probes both in vitro and in vivo.  Another class of 
inorganic nanoparticles that have been evaluated for biomedical imaging applications are 
metal oxides, including superparamaganetic iron oxide nanoparticles along with Gd2O3 and 
MnO nanoparticles.  These materials have been used as contrast agents for magnetic 
resonance imaging, and one formulation of iron oxide nanoparticles has received FDA 
approval for clinical use.   
 Organic polymer nanoparticles have also found use in biomedical applications.  There 
have been many reports on the use of polymeric hydrogel nanoparticles as delivery vehicles 
for a variety of drugs and other therapeutics.6-15  Dendrimers and other organic polymers 
have also been extensively evaluated for their potential in drug delivery applicatons.16-21 
 Hybrid nanoparticles incorporate some of the advantages of both inorganic and 
organic nanomaterials, while also possessing some unique advantages over the other two 
types.  The main advantage provided by hybrid nanomaterials is the modular nature that 
allows for systematic tuning of the properties of the resultant material by careful selection of 
the different components.  This chapter will give a brief overview of current hybrid 
nanomaterials used for biomedical applications, mainly as magnetic resonance imaging 
contrast agents and drug delivery platforms. 
 
1.2 Magnetic Resonance Imaging 
 1.2.1 Introduction 
Magnetic resonance imaging (MRI) is a non-invasive imaging technique whereby 
images are generated based on the nuclear magnetic resonance (NMR) signals of the water 
proton (1H) nuclei in the specimen.22  The spin-lattice (longitudinal) relaxation time (T1) and 
the spin-spin (transverse) relaxation time (T2) of the proton spins along with the proton 
density determine the MR signal intensity from a particular tissue.  T1-weighted MR images 
are generated based on the rate of longitudinal relaxation (∝1/T1) of the water 1H nuclei.  
When the protons resonating at an equilibrium frequency are excited with a radiofrequency 
pulse, a change in their net magnetization will occur as a result of the over-population of the 
higher energy states of the nuclear spins.  Protons having more rapid longitudinal relaxation 
(i.e., shorter T1) will relax back to their equilibrium state faster, yielding higher net 
electromagnetic signals to afford more intense signals in the MR image.  T2-weighted MR 
images, on the other hand, are generated based on the rate of transverse relaxation (∝1/T2) of 
the water 1H nuclei.  A faster transverse relaxation leads to more rapid dephasing of 
individual spins, resulting in reduced signal intensity in the MR image.  Owing to its 
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incredibly high spatial resolution, excellent soft tissue contrast, and large penetration depth, 
MRI has become a very powerful diagnostic tool in medicine. 
 
1.2.2 MRI Contrast Agents 
The main drawback of MRI, however, is its intrinsically low sensitivity.  As a result, 
large doses of contrast agents are typically administered to alter the water 1H relaxation times 
in order to enhance image contrast of specific tissues.  Approximately half of clinical MR 
scans are performed with the aid of contrast agents.23  Most of the current MR contrast agents 
are highly paramagnetic gadolinium (Gd) chelates which can reduce water proton T1 values 
to result in increased (hyper-intense) signal intensity.  The efficiency of a contrast agent to 
increase the rate of relaxation is expressed by the relaxivity value (r1) which is defined as the 
slope of a plot of 1/T1 vs. concentration in the units of mM-1·s-1.  Gd chelates typically have 
modest r1 values of ~4-5 mM-1·s-1 and discernible contrast in the MR image can be achieved 
with sub mM concentrations of Gd chelates in the tissue.24  Alternatively, superparamagnetic 
iron oxide nanoparticles are clinically used to enhance water transverse relaxation (r2 
relaxivity), leading to reduced (hypo-intense) MR signals, or so-called negative 
enhancement. 
A straightforward strategy for disease diagnosis is to selectively and specifically 
deliver imaging contrast agents by conjugation to affinity molecules that target the 
biomarkers over-expressed by diseased cells.  Such an approach has been successfully used 
to design target-specific positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) contrast agents by tagging radionuclides or their complexes 
with antibodies or other cell-targeting molecules.25,26   
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Because of the need for high concentrations of paramagnetic Gd chelates, it remains a 
great challenge to develop T1-contrast agents that specifically target diseased tissues and 
overcome the drawbacks of negative contrast enhancement afforded by iron oxide 
nanoparticles.  Sufficient T1-weighted MR image contrasts are typically achieved in the 
presence of sub mM concentrations of the Gd(III)-chelates, which is several orders of 
magnitude higher than that of over-expressed biomarkers.24  There is thus an urgent need for 
synthetic strategies that allow for the delivery of a very large payload of Gd chelates with 
each cell-targeting molecule.  Nanometer-scale materials offer one possible solution.  They 
have several desirable characteristics for use as MR contrast agents, including, large payloads 
of the paramagnetic metal ions; decreased tumbling rates, which result in increased 
relaxivities; and the ability to alter the pharmacokinetics by modifying the surface of the 
particles to make them longer circulating or target specific.  For T1-weighted MRI contrast 
enhancement, these materials continue to require paramagnetic metals ions such as Gd3+ and 
Mn2+, necessitating the development of hybrid cargo platforms.   
 
1.2.3 Nanoparticle MRI Contrast Agents – T2-Weighted 
Superparamagnetic iron oxide (SPIO) nanoparticles were initially shown to improve 
the detection of focal liver lesions over Gd diethethylenetriaminepentaacetic acid (Gd-
DTPA) enhanced MRI scans, leading to their FDA approval for clinical use in 1996.27,28  
SPIOs are composed of either maghemite (γ-Fe2O3) or magnetite (Fe3O4) phases that can be 
prepared by a variety of methods, most commonly by a co-precipitation reaction of a mixture 
of ferrous and ferric salts in aqueous media in the presence of stabilizers such as hydrophilic 
polymers.29  They have extraordinary ability to shorten T2 relaxation times due to their large 
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magnetization and result in large negative enhancements (darkening of images).  The early 
clinical targets of SPIOs were liver diseases because of their selective uptake by the liver 
Kupffer cells.30,31  If the normal liver architecture is destructed by a hepatic disease, such as 
hepatocellular carcinoma or liver metastasis, the region will have a reduced density of 
Kupffer cells.  Due to the low uptake by the abnormal liver, the SPIO provides a strong 
contrast between normal and abnormal tissue, thereby enabling the detection of focal liver 
lesions. 
As pioneered by Weissleder and co-workers, recent efforts have been focused on 
developing SPIO/biomolecule conjugates for target-specific MR imaging of cancers and 
other diseases.  In one formulation, SPIOs were coated with cross-linked dextran, a naturally 
occurring glucose-based polysaccharide capable of complexing iron.  Several variations of 
the formulation exist and are called cross-linked iron oxide (CLIO) and ultrasmall 
superparamagnetic iron oxide (USPIO, <50 nm).  CLIO is composed of materials on the 
generally regarded as safe (GRAS) list and has been approved by the FDA.  CLIO has been 
extensively used to image diseases in animals and humans, such as cancers, as well as to 
delineate biological processes in vivo. 
Surface modification with dextran that is crosslinked with epichlorohydrin is of key 
importance to achieve longer blood circulation times (Scheme 1.1).  The dextran can be 
chemically modified to allow for conjugation of targeting molecules,32 however, dextran-
coated iron oxide nanoparticles can also be used without any further functionalization to 
show image enhancement of disease states.  Due to dextran’s ability to evade the 
reticuloendothelial system (RES), signal void in circulation can be detected due to the T2 
relaxation of the water protons.  Upon capture, the CLIO contrast enhancement allows the 
 5
delineation of RES abnormalities.  Weissleder et al. showed such imaging capabilities in a 
clinical study of eighty prostate cancer patients33 as well as other cancers34,35. The CLIO was 
shown to be lymphtrophic and could be effectively used to image nodal abnormalities that 
were otherwise undetectable.   
Epichlorohydrin
Ammonia
NH2
NH2
NH2
NH2
NH2
NH2
NH2
H2N
H2N
NH2
H2N
Dextran coated iron oxide nanoparticles Cross-linked iron oxide (CLIO)
 
Scheme 1.1.  Preparation of iron oxide nanoparticles with cross-linked dextran surface 
coating and amino functional groups for bioconjugation. 
 
The dextran coating can be chemically modified to allow the conjugation of affinity 
molecules to endow the SPIOs target-specificity.  Peptides and proteins have been used as 
functional conjugates with these nanoparticles to image prostate, hepatic, splenic, pancreatic, 
and glial neoplasia (Fig. 1.1).33,35-37  When conjugated to E-selectin or VCAM-1, CLIO was 
used to detect endothelium specific proteins to monitor tumor angiogenesis.38  Apoptotic 
cells can also be detected when the CLIO particles are functionalized with Annexin V, a 
calcium dependent protein that has high affinity for the phosphatidylserine apoptosis marker 
in the cell membrane.39  Though extensively studied and considered relatively mature, the 
SPIO contrast agents continue to be at the forefront of biomedical imaging research. 
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Figure 1.1.  Cross-linked iron oxide nanoparticles for T2-weighted images in rodent 
pancreatic cancer:  preinjection of CLIO (left), postinjection of CLIO (center), and higher 
magnification of postinjection image (right) with the arrow indicating tumor.37 
 
As shown in the model developed by Koenig and Keller, spin-spin relaxation is 
dependent on the magnetic moment of the nanoparticles (μ) according to Equation 1:40  
   ),(1 22
2
2 DNP
NP
JC
Dd
a
T
R τωμγ==    (Eq 1) 
Where a is a constant, dNP the diameter of the nanoparticle, D the diffusion coefficient, μ the 
magnetic moment of the nanoparticles, γ the gyromagnetic ratio of the water proton, CNP the 
concentration of the nanoparticles, and J(ω, τD) the spectral density function. 
Eq 1 shows the quadratic dependence of r2 on the magnetization of the nanoparticle.  
It is also established that the magnetic properties of nanoparticles are strongly dependent on 
their size, shape, and surface property.  The magnetization of a nanoparticle can be 
significantly reduced as a result of the surface defects as described by Eq 2:41 
3]/)[( rdrMm SS −=     (Eq 2) 
 
Where mS is the saturation magnetization of the nanoparticle, MS the saturation magnetization 
of the bulk material, r the size of the nanoparticle, and d the thickness of the disordered 
surface layer. 
The r2 relaxivities of SPIO and related ferrite nanoparticles can be optimized by 
enhancing their magnetic properties via 1) the intrinsic material properties such as material 
composition and crystal structure, and 2) extrinsic factors such as crystallinity, size, and 
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shape.  Over the past decade, many synthetic protocols have been developed for 
monodisperse and highly crystalline iron oxide and related ferrite nanoparticles, most notably 
via thermal decomposition of metal precursors in organic surfactant solutions at high 
temperatures of > 300 oC.42  The resulting hydrophobic nanoparticles had uniform sizes (σ < 
10%), and their sizes (from 4 to 25 nm) could be finely controlled by modifying synthetic 
parameters.  In particular, Hyeon et al. reported the large-scale production of various metal 
oxide nanoparticles from the thermal decomposition of metal-surfactant complexes.43  Cheon 
and coworkers systematically studied the relationships among size, magnetism, and relaxivity 
of uniform-sized iron oxide nanoparticles (Fig. 1.2).44  Larger iron oxide nanoparticles have 
larger magnetizations and high r2 relaxivities, which makes it possible to increase the 
contrast in T2-weighted images.  Various bimetallic ferrite nanoparticles including CoFe2O4, 
MnFe2O4, and NiFe2O4 have also been tested as T2 contrast agents. The MnFe2O4 
nanoparticles (MnMEIO) have been found to have a very high magnetization and large 
relaxivity (Fig. 1.3).45 
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Figure 1.2.  Effect of Fe3O4 nanoparticle size on relaxivity.  (a) TEM images of Fe3O4 
nanocrystals of 4, 6, 9, and 12 nm. (b) Size-dependent T2-weighted MR images of Fe3O4 
nanocrystals in aqueous solution at 1.5 T. (c) Size-dependent changes from red to blue in 
color-coded MR images based on T2 values.44 
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Figure 1.3.  Magnetism-engineered iron oxide (MEIO) nanoparticles and effects of their 
magnetic spin on MRI. (a) TEM images of MnFe2O4 (MnMEIO), Fe3O4 (MEIO), CoFe2O4 
(CoMEIO) and NiFe2O4 (NiMEIO).  All nanoparticles were synthesized to be ~12 nm.  Scale 
bar, 50 nm. (b) Mass magnetization values of MFe2O4. (c,d) Schematics of spin alignments 
of magnetic ions in spinel structures under external magnetic field, and magnetic spin 
moment of MFe2O4 nanoparticles.  (e,f) T2-weighted spin echo MR images, their color maps 
and relaxivity (r2) of a series of MEIO nanoparticles at 1.5 T.  In (f), the r2 of CLIO is also 
presented, for comparison.45 
 
Since the above uniform and crystalline superparamagnetic nanoparticles were 
synthesized in organic media, their hydrophobic surfaces have to be modified with 
hydrophilic coatings to ensure their aqueous dispersibility and biocompatibility as well as to 
allow for their reactivity with targeting molecules (such as antibodies).  Several new coating 
strategies have recently been developed for metal oxide nanoparticles, in particular, iron 
oxide nanoparticles.  For example, several functional groups were immobilized on iron oxide 
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nanoparticles via dopamine,46,47 hydroxamic acid,48 and 2,3-dimercaptosuccinic acid 
(DMSA).45  The DMSA-coated iron oxide nanoparticles were dispersible in water and used 
for in vivo MRI.45  Several strategies have also been developed to coat SPIOs with 
biocompatible polymers such as poly(ethylene glycol) (PEG).49 
Superparamagnetic nanoparticles with suitable surface coatings were conjugated with 
affinity molecules such as antibodies, peptides, and oligonucleotides to afford target-specific 
contrast agents for efficient lesion detection.  Cheon et al., for example, demonstrated that 
Herceptin-conjugated MnFe2O4 nanoparticles showed more sensitive in vivo cancer imaging 
with large r2 relaxivity (Fig. 1.4).45  The shells of the nanoparticles can also provide novel 
functions in addition to MR imaging.  For example, Hyeon synthesized discrete and 
monodisperse core-shell nanostructures with a magnetite nanocrystal core and a mesoporous 
silica shell loaded with a fluorescent dye and an anticancer drug.50  The resulting composite 
core/shell nanoparticles were applied to simultaneous MR and optical imaging and drug 
delivery (Fig. 1.5). 
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Figure 1.4.  In vivo MR detection of cancer after administration of magnetic nanoparticles-
Herceptin conjugates. MnFe2O4 nanoparticles (a-c) show higher signal enhancement than 
crosslinked iron oxide (CLIO) (d-f).45 
 
 
Figure 1.5.  The synthesis of magnetite nanoparticle/mesoporous silica core–shell 
nanostructures and their in vivo dual modal imaging (MRI and optical imaging).50 
 
1.2.4 Nanoparticle MRI Contrast Agents – T1-Weighted 
Superparamagnetic nanoparticles typically act as negative contrast agents which 
decrease the proton MR signal from the tissue.  The resulting dark signal can be confused 
with other pathogenic conditions and cause undesired false positives.  Moreover, the high 
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susceptibility of the T2 contrast agents induces distortion of the magnetic field on 
neighboring normal tissues. This distortion of the background is called the susceptibility 
artifact or ‘blooming effect’, which generates obscure images and distorts the background 
around the lesions.51  There is thus a very strong interest in creating nanoparticles for 
efficient T1-weighted MR imaging. 
Wickline and Lanza have developed perfluorocarbon-based microemulsion contrast 
agents and extensively examined their utility in target-specific MR imaging in vivo.52  The 
nanoparticles of ~250 nm in diameter are composed of a perfluorocarbon core and a 
monolayer lipid shell.  The particles can be synthesized by emulsification of 
perfluorooctylbromide, surfactants, and glycerin to form a stable nanoparticle with a few 
hundred homing ligands and extraordinarily high payloads of paramagnetic metal centers, 
about 100,000 or more Gd chelates per nanoparticle.  These Gd-containing nanoparticles 
possess extremely large MR relaxivities on per particle basis.53   
Targeting molecules can be incorporated into the stabilizing surface lipids to allow 
for their selective delivery to specific sites.  Ligands for over-expressed disease biomarkers 
that have been used for this material include small molecules, integrins, fibrin, and 
antibodies.  The targeted derivatives of the perfluorocarbon-lipid nanoparticles were used 
extensively to image tumors and angiogenesis54,55 as well as neovascularization in 
atherosclerosis.56   
The perfluorocarbon core also allows for the unique capability of an additional MRI 
probe using the 19F signal.  19F MRI is an advantageous imaging tool because the magnetic 
resonance sensitivity is nearly as high as 1H (83%), there is a low abundance of endogenous 
19F in biological systems, and the natural abundance of the 19F isotope is 100%.  
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Perfluorocarbon emulsions encapsulated by lipid-surfactant monolayers have been used to 
prepare MRI contrast agents with high 19F payloads.  Perfluorocarbon-based microemulsion 
nanoparticles are thus multimodal and prove to be versatile in the early detection of cancers.   
Oil-in-water microemulsions have been used as templates to engineer stable wax 
nanoparticles containing Gd chelates for potential use as MRI contrast agents.57  Gd was 
incorporated into the lipid layer by forming chelates with dimyristoyl phosphoethanolamine 
diethylenetriamine pentaacetate.  The wax nanoparticles have a payload of approximately 105 
Gd(III) per nanoparticle, as determined by inductively coupled plasma atomic emission 
spectroscopy.  In a 4.7 T MR scanner, relaxivities were determined to be r1 = 7.1 and r2 = 
13.0 s-1 per mM Gd.  These nanoparticles were also pegylated to increase blood circulation 
times, and the pegylated wax nanoparticles were used in MR imaging of nude mice bearing 
A549 lung carcinoma xenografts by taking advantage of the enhanced permeability and 
retention (EPR) effect.58   
Liposomes are lipid vesicles consisting of an aqueous core enclosed in a lipid bilayer 
membrane.  Gd-labeled liposomes have been prepared and extensively examined for in vivo 
MR imaging.59-61  The first Gd(III)-containing liposomes were confirmed to be viable as MRI 
contrast agents for imaging the liver and spleen of normal Balb/c mice.59-61  Later 
formulations were reported to show contrast enhancement of hepatic metastases in rats.62-64  
Liposomes can also be rendered target-specific by adding cell-targeting moieties to the 
bilayer surface.  A number of target-specific liposome-based contrast agents have already 
been explored for imaging IGROV-1 xenograft tumors and hepatic metastases in rodents 
(Fig. 1.6).54,65 
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 Figure 1.6.  (a) Preinjection MR images of induced IGROV-1 tumors under the right flanks 
of nude Balb/c mice: large white circle represents zoomed image of tumor area marked with 
small circle. (b) MR images 24 h post i.v. injection of Gd-liposomes; the color map shows 
enhancement of tumor area: large white circle is zoomed image of tumor area marked with 
small circle. (c) T1 measurements were obtained from tumor slices. (d) Image enhancement is 
supported by a 60% measured reduction in tumor T1 values 24 h post i.v. injection relative to 
control liposomes (no Gd complexed).65 
 
Inorganic nanoparticles composed of highly paramagnetic metal ions such as Gd3+ 
and Mn2+ have also been developed as new T1 contrast agents.  Large surface-to-volume 
ratios of such ultrasmall nanoparticles should allow facile interactions between the metal ions 
at or near the surface with surrounding water molecules, leading to fast longitudinal 
relaxation of the water protons.  Nanoparticles of Gd2O3,66 GdF3,67 and GdPO468 have been 
investigated as MRI contrast agents.  They exhibited signal enhancing contrast in T1-
weighted images.  The Gd2O3 nanoparticle-based agents are composed of small cores of < 5 
nm and stabilizing shells of dextran, PEG and silica.66  Water dispersible GdF3 nanoparticles 
were prepared with either a positively charged surface by conjugation with 2-aminoethyl 
phosphate groups or a negatively charged surface by coating with citrate groups.67  Dextran-
coated GdPO4 nanoparticles were synthesized by a hydrothermal process in the presence of 
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dextran.68  The clinical utility of such Gd-based nanoparticles is however uncertain because 
of the potential leaching of free Gd3+ ions which are the culprit of the recently discovered 
nephrogenic systemic fibrosis (NSF) syndrome. 
 MnO nanoparticles were recently examined as T1 contrast agents for in vivo MR 
imaging.69,70  MnO nanoparticles conjugated with a tumor-specific antibody were used for 
the selective imaging of breast cancer cells in a metastatic brain tumor (Fig. 1.7).70  Metallic 
nanoparticles have also recently been shown to be promising T1 contrast agents.  Dai and 
coworkers synthesized FeCo nanoparticles stabilized with single graphitic carbon shell 
(FeCo/GC).71  After non-covalent functionalization with phospholipid–poly(ethylene glycol) 
(PL-PEG) molecules, the FeCo/GC nanoparticles were long-circulating and provided positive 
contrast enhancement in depicting the artery in a rabbit model.  Despite their promise as T1 
contrast agents, the detailed contrast enhancement mechanisms in both MnO and FeCo/GC 
nanoparticles have yet to be elucidated.   
 
 
Figure 1.7.  Breast cancer cells were selectively enhanced in T1-weighted MRI by the 
Herceptin-functionalized MnO nanoparticles.70 
 
Inspired by the microemulsion and liposomal contrast agents, our group prepared 37 
nm hybrid silica nanoparticles containing embedded [Ru(bpy)3]Cl2 luminophore and a shell 
of Gd chelates.72  Unlike the microemulsion and liposomal systems, the hybrid silica 
particles have a tunable size from 20-100 nm.  The large Stokes shift of the [Ru(bpy)3]Cl2 
fluorophore (Excitation: 525 nm; emission: 610 nm) in the core significantly reduces the 
 16
background signal from biological systems.  Furthermore, [Ru(bpy)3]Cl2 is much more 
photostable than organic fluorophores such as fluorescein.  The luminescence of the hybrid 
silica nanoparticles is thus highly compatible with biological imaging applications.   
The Gd chelates were immobilized onto the surface of the silica nanoparticles in 
either a monolayer or multilayer fashion.  The surface-immobilized Gd chelates effectively 
relax water protons.  The resulting nanoparticle has relaxivities five orders of magnitude 
higher than the constituent Gd chelate due not only to the greatly increased Gd payload but 
also to the much enhanced per Gd relaxivity as a result of the reduced tumbling rates.  
Notably, the particles with multilayers of Gd chelates had reduced relaxivities compared to 
those with the monolayer coating, likely due to the reduced water accessibility of the Gd-
chelates.  Murine monocyte cells were successfully labeled with the hybrid silica 
nanoparticles and T1-weighted signal enhancement of the cell pellet was observed in a 3 T 
MR scanner.72  The efficacy of the hybrid silica nanoparticles as a dual optical and MR 
contrast agent was also demonstrated in a collagen-induced arthritis mouse model.   
One strategy developed in our group in order to circumvent the reduced relaxivities 
found in the solid silica particles with multilayer coatings involved the use of a 
polyelectrolyte layer-by-layer (LbL) self-assembly approach to increase the Gd payload 
while maintaining the relaxivity on per Gd basis.73  Positively charged MR-enhancing Gd-
chelate oligomers were deposited onto negatively charged silica nanoparticles possessing a 
Gd-DTTA monolayer via electrostatic interactions.  The resulting positively charged particle 
was further treated with negatively charged polystyrenesulfonate to provide a net negative 
charged layer.  These steps were repeated to form the multilayer architecture as shown in 
Scheme 1.2.  TEM and fluorescence studies indicated the consecutive deposition of 
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polymeric electrolytes onto the particle, whereas MR phantom studies demonstrated that 
nanoparticles with more layers of the Gd-DOTA polymers had the expected higher 
relaxivities on per particle basis.  The relaxivities on a per Gd basis remained constant, 
regardless of the number of layers deposited.  The LbL self-assembly thus increases the Gd 
payload without deleteriously affecting the MR relaxivity on per Gd basis, presumably as a 
result of the flexible and disordered nature of the polyelectrolyte LbL assembly which allows 
ready water access to the Gd(III) centers.   
 
Scheme 1.2.  Layer-by-layer self-assembly of multifunctional hybrid nanoparticles for an 
increased Gd payload. 
 
A peptide sequence containing arginine-glycine-aspartate (RGD) and seven 
consecutive lysine (K) residues (K7RGD) was adsorbed onto the particles terminated with 
negatively charged PSS layer via electrostatic interactions.  The RGD peptide is known to 
bind strongly to the integrin cell surface receptors that are upregulated in angiogenic cancer 
cells.  The RGD-terminated nanoparticles allowed target-specific optical and MR imaging of 
HT-29 human colon cancer cells (Figure 1.8). 
 
 
 
 
 
 
 
 18
 
Figure 1.8.  (a) TEM images and (b) schematic representation of LbL self-assembled 
nanoparticles decorated with RGD-peptides for integrin targeting.  (c) T1-weighted MR 
images of HT-29 cells that have been incubated with various nanoparticles.  From left to 
right: control cells without any nanoparticle, cells with LbL nanoparticles, cells with LbL 
nanoparticles that were functionalized with RGD peptide, and cells with LbL nanoparticles 
that were functionalized with GRD peptide. (d) Phase contrast optical (left) and confocal 
fluorescence (right) images of HT-29 cells incubated with LbL nanoparticles that were 
functionalized with RGD peptide. 
 
Another approach that was taken to increase the payload of Gd without sacrificing the 
per Gd relaxivity was to use mesoporous silica nanoparticles (MSN) as a platform.74  The 
extremely high surface area of MSN allows for a high payload of Gd chelates with enhanced 
water accessibility which is the key to high r1 relaxivity.  MSNs were first prepared by a 
surfactant-templated, base-catalyzed condensation of tetraethylorthosilicate.  Subsequently, a 
monolayer of Gd-chelates was grafted by refluxing in toluene.  The resulting MSNs exhibited 
exceptionally high relaxivities both on a per Gd and per particle basis.  The detailed synthesis 
and characterization of this contrast agent, as well as in vitro and in vivo MR imaging results 
will be described in Chapter 2.  Chapter 3 describes the synthesis and characterization of 
biodegradable version of this MSN based contrast agent.   
 
 
 
 
a) c) b) 
d) 
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1.3 Nanoscale Metal-Organic Frameworks (NMOFs) 
 1.3.1 Introduction to NMOFs 
Coordination polymers or metal-organic frameworks are built from metal ions or 
metal ion clusters that have two or more vacant coordination sites and polydentate bridging 
ligands.  Prussian blue and mixed-metal cyanometallates are the classic examples of 
coordination polymers.75  Numerous reports on the syntheses and characterization of 
cyanometallate nanoparticles have been published over the last decade,76-82 and they exhibit 
unique size-dependent properties such as superparamagnetism,76 photo-induced 
superparamagnetism,77 and spin-glass-like behavior.78  Coordination polymers however are 
not limited to the cyanometallates, and can be synthesized from a wide range of metal and 
organic building blocks.  The tunable nature of coordination polymers has allowed them to 
be engineered for a number of bulk-scale applications, including gas storage,83 catalysis,84 
and nonlinear optics.85  By scaling them down to the nanometer-regime, the scope of 
coordination polymer nanoparticles can be vastly expanded.  Recent reports on nanoscale 
coordination polymers have shown their application in a variety of areas, ranging from 
heterogeneous catalysis to anticancer drug delivery. 
 
1.3.2 Use of NMOFs for Biomedical Imaging 
By including paramagnetic metal ions such as Gd3+ and Mn2+, NMOFs can be 
synthesized as efficient contrast agents for MR imaging.  Our group has previously 
demonstrated the use of Gd3+ containing NMOFs as MR contrast agents.  Nanorods of 
Gd2(BDC)3(H2O)4 (BDC is 1,4-benzenedicarboxylate) were synthesized using water-in-oil 
microemulsions (Fig. 1.9).86  The morphology and size of the crystalline Gd NMOFs could 
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be controlled by the water to surfactant molar ratio (i.e., W-value).  Using 1,2,4-
benzenetricarboxylate as the bridging ligand afforded NMOFs with a plate-like morphology 
rather than nanorods. 
 
Figure 1.9.  SEM images of Gd(BDC)1.5(H2O)2 nanorods synthesized using a microemulsion 
with W = 5 (left) and W = 10 (right).  BDC is 1,4-benzenedicarboxylate. 
 
The Gd NMOFs display a longitudinal relaxivity (r1) of 35.8 mM-1s-1, a value almost 
an order of magnitude higher than that of a commercially available T1 contrast agent.  The 
Gd NMOFs contain a large number of Gd metal centers and thus exhibit an r1 of 2.5 x 107 s-1 
per mM nanorod.  The Gd centers at or near the surface of the NMOF are likely responsible 
for the observed relaxivities.  By doping the Gd NMOFs with 5% of Eu or Tb, the nanorods 
exhibited characteristic red or green luminescence, respectively.  The Gd NMOFs however 
leached µM concentrations of Gd3+ ions in water, which precludes their in vivo applications 
as MRI contrast agents due to the toxicity of Gd3+ ions.  Attempts were made to stabilize the 
NMOFs by coating them with a silica shell.87  The release of Gd3+ ions from the NMOF-
silica core-shell nanostructures was significantly retarded but not entirely eliminated.   
By varying the bridging ligand, and synthesis conditions, the size and morphology of 
the resulting NMOF can be changed.  Chapter 4 describes the synthesis and characterization 
1 μm
500 nm
2 μm
1 μm
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of four new Gd3+ containing NMOFs synthesized using two different techniques.  Because 
Mn2+ ions are much less toxic than Gd3+ ions, several NMOFs were synthesized using Mn2+ 
and two different bridging ligands.  Chapter 5 describes the synthesis, characterization, and 
in vitro and in vivo imaging of two Mn2+ containing NMOFs.  
 
1.3.3 Use of NMOFs for Drug Delivery 
Our group has recently demonstrated the use of amorphous nanoscale coordination 
polymers (NCPs) as drug delivery vehicles.88  NCPs based on a Pt containing anticancer drug 
were synthesized using a precipitation method whereby a poor solvent was added to an 
aqueous solution of the precursors, disuccinatocisplatin (DSCP) and TbIII, inducing the 
formation of the nanoparticles (Scheme 1.3).  In order to stabilize the particles against rapid 
dissolution they were coated with a silica shell.  The half-life (t1/2) for the release of DSCP, 
an analog of the anticancer drug cisplatin, from NCPs of the composition Tb2(DSCP)3-
(H2O)12 could be tuned from approximately 5.5 hours to 9 hours by increasing the shell 
thickness from approximately 2 nm to 7 nm.  In comparison, the as-synthesized NCPs had a 
t1/2 for dissolution of only 1 hour.  In vitro cytotoxicity assays showed that the Pt-based NCP 
particles displayed anticancer efficacies superior to the cisplatin standards.  These results 
were significant because they clearly demonstrated the feasibility of using NCPs as delivery 
vehicles for clinically relevant cargos. 
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Scheme 1.3.  Synthesis of NCPs based on the anticancer drug disuccinatocisplatin (DSCP). 
 
 Another approach to using NMOFs as drug delivery vehicles is to covalently graft an 
anticancer drug into the channels of a porous NMOF.  Chapter 6 describes the synthesis and 
characterization of several Fe(III) NMOFs.  These NMOFs were then loaded with various 
cargoes, including organic fluorophores and Pt based anticancer drugs, using post-synthetic 
modification. 
 
1.4  Use of Nanoparticles for Biological Sensing Applications 
 A major concern in the event of biological warfare is the rapid detection of Bacillus 
anthracis endospores, which have been used in previous anthrax attacks.  There are several 
techniques currently used for the detection of bacterial endospores, including 
immunoassays,89-90 polymerase chain reaction (PCR),91-93 surface-enhanced Raman 
spectroscopy,94-96 and Tb(III) luminescence.87,97-101  Tb(III) luminescence detection has been 
shown to be a rapid, sensitive, and inexpensive method for endospore detection.  The 
luminescence detection is based on the sensing of dipicolinic acid (DPA) which can account 
for up to 15% of the dry mass of endospores.  By combining the Tb(III) luminescence 
detection of DPA with a nanoparticle platform, a useful sensor can be created.  The use of a 
nanoparticle platform allows for the incorporation of an internal standard, which eliminates 
the need for instrument specific calibration curves for quantifying amounts of DPA present in 
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an unknown sample.  Chapter 7 describes the synthesis, characterization, and evaluation of 
several nanoparticle based sensors, which can detect DPA at nanomolar concentrations. 
 
1.5 Conclusions 
 This chapter has introduced the use of nanomaterials for several biological 
applications, including imaging, drug delivery, and sensing.  The use of nanomaterials for 
biomedical applications, especially MR imaging, offers several advantages including 
increased payload and the ability to modify the surface of the particles to increase circulation 
time in vivo or to impart target specificity.  While much of the research done in this area has 
focused on the use of purely inorganic or organic nanomaterials, hybrid nanomaterials have 
begun to emerge as a useful platform.  The combination of inorganic and organic 
components allows for an almost unlimited tunability, giving way to the design of materials 
for a variety of applications.  
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CHAPTER 2 
 
 
Mesoporous Silica Nanoparticles as Contrast Agents for Magnetic Resonance Imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Portions of this chapter were adapted from Taylor, K. M. L.; Kim, J. S.; Rieter, W. J.; An, 
H.; Lin, W.; Lin, W. J. Am. Chem. Soc. 2008, 130 (7), 2154-2155.) 
 
 
 
 
 
2.1 Introduction 
 
Contrast enhanced magnetic resonance imaging (MRI) is a noninvasive diagnostic 
tool that cannot only provide high resolution anatomical images of soft tissue, but also 
quantitatively assess disease pathogenesis by measuring up-regulated biomarkers.  However, 
currently used MRI contrast agents are mainly small molecule gadolinium chelates that lack 
sensitivity and often cannot provide sufficient image contrast enhancement in early disease 
stages.  Nanoparticulate MR contrast agents are much more sensitive owing to the enhanced 
relaxivity (on per magnetic center basis) as a result of reduced tumbling rates and large 
payloads of active magnetic centers.  For example, Weissleder et al. and others have used 
iron oxide nanoparticles as T2 contrast agents to image tumor angiogenesis, inflammation, 
and gene expression.1  Lanza, Wickline, and co-workers have developed Gd3+-containing 
microemulsions as efficient T1-contrast agents for intravascular MR imaging.2  Several other 
Gd3+-containing solid nanoparticles have also been recently evaluated as potential MRI 
contrast agents.3-6 
Our recent results indicate that the accessibility of the magnetic center to water 
molecules is key to designing highly efficient nanoparticulate MR contrast agents,5-6 
underscoring the need of developing new strategies for the synthesis of nanoparticles that can 
allow ready access of water molecules to the magnetic centers.  Our group has previously 
developed a solid silica nanoparticle based MRI contrast agent, which consists of 37 nm 
particles coated with either a monolayer coating or a polymeric multilayer coating of Gd3+ 
chelates.  The results from these two systems revealed that the particles with a multilayer 
coating had reduced efficiency, or lower relaxivities, on a per Gd3+ basis.  This was due to 
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the fact that the Gd chelates on the inner layers were not as accessible to the surrounding 
water molecules.5   
In order to address the problem of reduced efficiency, while still increasing the 
number of metal centers per particle, an alternative method for forming the nanoparticle 
based contrast agents was developed.  This method involved the use of a layer-by-layer 
electrostatic assembly of the particle coating.  Using this method up to 7 bilayers of 
alternating negatively charged polystyrenesulfonate and a cationic Gd(III)-DOTA oligomer 
were assembled.  Results from this nanoparticle system showed the relaxivity on a per Gd 
basis remained constant, independent of the number of layers assembled.  The relaxivity on a 
per particle basis increased linearly with the increasing number of layers deposited.  These 
results indicated that the disordered structure of the layer-by-layer assembly allows for 
efficient interaction of all the Gd(III) centers with the surrounding water. 6 
Another approach to designing a system that can incorporate a large number of Gd 
chelates while keeping them all accessible to the surrounding water is to use a porous 
platform.  Mesoporous materials can provide an ideal platform for the development of MR-
enhancing hybrid materials due to their high surface areas and tunable pore structures.  
MCM-41 type materials, for example, possess a hexagonal array of one dimensional channels 
with diameters that can be tuned from 2–10 nm.7-8  More recently, synthetic procedures have 
been developed for controlling the morphologies of MCM-41 materials,9-10 leading to 
mesoporous silica nanospheres (MSNs) with diameters ranging from 60 to 1100 nm that have 
been utilized in a variety of applications including catalysis11 and drug delivery.12-13  Victor 
Lin has also reported a co-condensation method used to incorporate various organic 
functional groups into the pores of MSN.14-15  We surmised that grafting or incorporating of 
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Gd chelates onto MSNs can provide an ideal platform for designing highly efficient MR 
contrast agents because of the ability to carry a large payload of Gd centers and the enhanced 
water accessibility of the Gd chelates.  We have synthesized and characterized several highly 
efficient MSN-based MR contrast agents and evaluated their application in in vitro and in 
vivo MR imaging. 
 
2.2 Results and Discussion 
 2.2.1 Ligand and Gd Complex Synthesis 
Two different DTPA based ligands were synthesized for this work.  First, 3-
aminopropyl(trimethoxysilyl)diethylenetriamine tetraacetic acid (Si-DTTA), was synthesized 
by reacting 3-(trimethoxysilylpropyl)diethylene triamine with 4 equivalents of bromo acetic 
acid under basic conditions.  This formed a Gd chelating ligand containing one trialkoxy 
silane functional group for attachment to the silica based particles.  The second, bis(3-
aminopropyl triethoxysilyl)diethylenetriamine pentaacetic acid (Si2-DTPA) was synthesized 
by reacting 2 equivalents of 3-aminopropyltriethoxysilane with DTPA dianhydride in 
anhydrous pyridine.  This provided a Gd chelating ligand with two trialkoxysilane functional 
groups to allow for incorporation into the mesoporous silica.  The corresponding Gd(III) 
complexes for each ligand were formed by reacting 1 equivalent of GdCl3 with the 
deprotonated form of the ligand. 
 
2.2.2 Synthesis of MSN-Gd Using Grafting Method (2-1) 
The MSN nanoparticles (2-0) were first synthesized using a surfactant templated, 
base-catalyzed condensation procedure.16  Briefly, cetyltrimethylammonium bromide 
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(CTAB) (0.100 g, 0.274 mmol) was dissolved in 48 mL of distilled water along with 0.35 mL 
of 2 M NaOH.  The solution was heated to 80 °C before the addition of 0.5 mL of 
tetraethylorthosilicate (TEOS).  The reaction mixture was stirred for an additional 2 hours at 
80 °C.  The particles were isolated by centrifuging and washed with water and ethanol.  The 
surfactant template was then extracted with either a 1 wt% solution of NaCl in methanol or a 
1 volume% solution of HCl in methanol. 
The Si-DTTA-Gd complex was grafted onto the MSN particles through the siloxane 
linkages by adding an aqueous solution of the complex to a suspension of extracted MSN 
particles in toluene (Scheme 2.1-2.2).  The reaction was then heated to reflux for 18 hours.  
After cooling, the particles (2-1) were isolated by centrifuging, washed with water, ethanol, 
and a pH 3 solution.  Finally, the particles were dialyzed against distilled water to remove 
any free chelates adsorbed into the channels. 
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Scheme 2.1.  Schematic showing the Si-DTTA-Gd complexes residing in the hexagonally 
ordered nanochannels of 2-1 MSN. 
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Scheme 2.2.  Schematic presentation of the Si-DTTA-Gd chelates that have been grafted 
onto the interior walls of the MSN nanoparticles 2-1 via the siloxane linkage. 
 
Fluorescently labeled particles (2-1a) were also synthesized by immobilizing a 
rhodamine B derivative onto the particles.  Rhodamine B isothiocyanate (RITC) was reacted 
with 3-aminopropyltriethoxysilane to give a rhodamine B derivative with a triethoxysilane 
group that can be used for covalent attachment to the silica particles.  To synthesize the 
fluorescently labeled particles, 4 mol% of the rhodamine B-aminopropyltriethoxysilane 
(relative to Si-DTTA-Gd) was added along with the Gd complex during the coating reaction. 
 
2.2.3 Synthesis of MSN-Gd Using the Co-Condensation Method 
Several MSN-Gd contrast agents were also synthesized by incorporating varying 
amounts of the Si-DTTA-Gd or Si2-DTPA-Gd complexes into the particles using a co-
condensation method.  Particles were synthesized using 10 wt% Si-DTTA-Gd (2-2) and 10, 
20, 30, and 40 wt% Si2-DTPA-Gd complexes (2-3 through 2-6) (relative to the amount of 
TEOS added), using a similar procedure as was used to synthesize the bare MSN particles.  
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For example, particles 2-3 (10 wt% Si2-DTPA-Gd) were synthesized as follows.  0.200 g 
(0.549 mmol) of CTAB was dissolved in 240 mL of water containing 0.7 mL of 2 M NaOH 
(1.40 mmol).  This solution was heated at 80 °C for 30 minutes before adding 1.0 mL (0.93 
g, 4.48 mmol) of TEOS and 0.79 mL of a 0.17 M aqueous solution of the Si2-DTPA-Gd 
complex.  The reaction was then stirred at 80 °C for 2 hours.  The particles were isolated by 
centrifuging and washed with water and ethanol.  The surfactant template was then extracted 
with a 1 wt% solution of NaCl in methanol at room temperature.  In order to ensure the 
removal of any free Gd3+ ions the particles were also washed with a pH 3 solution. 
 
2.2.4 Characterization 
Scanning electron and transmission electron microscopies (SEM and TEM) were used 
to evaluate the particle size and morphology.  For MSN-Gd 2-1 the as-synthesized particles 
were fairly uniform spherical particles with a mean diameter of 75 nm (Fig. 2.1).  No change 
in the particle size or morphology was seen after extraction of the solvent or grafting of the 
Si-DTTA-Gd chelate (Figs. 2.2-2.5).  Particles 2-2 through 2-6 were more polydisperse 
compared to the bare MSN particles.  The particle size also generally increased with 
increasing wt% of the Gd complex (Fig. 2.6-2.14).  The SEM and TEM images also showed 
some evidence of aggregation and fusing of particles prepared using the co-condensation 
method. 
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2 μm 
 
Figure 2.1.  SEM image of as-synthesized bare MSN nanoparticles (2-0). 
 
 
Figure 2.2.  SEM images of surfactant-extracted bare MSN nanoparticles (2-0). 
 
 
Figure 2.3.  TEM images of surfactant-extracted bare MSN nanoparticles (2-0). 
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Figure 2.4.  SEM images of MSN-Gd (2-1) particles. 
 
 
Figure 2.5.  TEM images of MSN-Gd (2-1) particles. 
 
Figure 2.6.  SEM images of 2-2 particles. 
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Figure 2.7.  TEM images of 2-2 particles. 
 
 
Figure 2.8.  SEM images of 2-3 particles. 
 
 
Figure 2.9.  TEM images of 2-3 particles. 
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Figure 2.10.  SEM images of 2-4 particles. 
 
Figure 2.11.  TEM images of 2-4 particles. 
 
 
Figure 2.12.  SEM images of 2-5 particles. 
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Figure 2.13.  TEM images of 2-5 particles. 
 
 
Figure 2.14.  SEM images of 2-6 particles. 
 
 
The pore structure of the particles was evaluated using powder X-ray diffraction 
(PXRD) and nitrogen gas sorption measurements.  The bare MSN particles exhibit PXRD 
peaks at 2θ values of 2.8, 4.6, and 5.4° that are characteristic of the (100), (110), and (200) 
planes of the MCM-41 material, respectively (Fig. 2.15).  Nitrogen gas sorption 
measurements indicated that the surfactant-extracted bare MSN (2-0) is highly porous with a 
surface area of 1633 m2/g (BJH method - Barrett-Joiner-Halenda) and a pore diameter of 2.4 
nm, whereas the MSN-Gd (2-1) material has a reduced surface area of 1470 m2/g and a pore 
diameter of 0.9-1.0 nm (Fig. 2.16-2.17).  A pore size can also be estimated using the d-
spacing from the (100) peak at 2.8° in the PXRD.  From this 2θ value, a d-spacing of 31.8 Å 
is calculated, which corresponds to a repeat unit of 3.67 nm.  If a pore-wall thickness of 1 nm 
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is assumed, the pore diameter is calculated to be 2.67 nm, which corresponds well to the 
nitrogen sorption measurements. 
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Figure 2.15.  Powder X-ray diffraction pattern of bare MSN particles (2-0), showing peaks at 
2.8°, 4.6°, and 5.4°. 
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Figure 2.16.  Nitrogen sorption isotherm of surfactant-extracted bare MSN (2-0) (black-
adsorption; green-desorption) and MSN-Gd (2-1) (blue-adsorption; red-desorption). 
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Figure 2.17.  Pore size distribution of surfactant-extracted bare MSN (2-0) (black-
adsorption; green-desorption) and MSN-Gd (2-1) (blue-adsorption; red-desorption). 
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 Nitrogen sorption measurements also showed that the co-condensation particles (2-2 
through 2-6) have large surface areas and pore diameters ranging from 1.4 to 2.9 nm in 
diameter (Fig. 2.18-2.27).  The surface areas and pore sizes decrease with increasing 
incorporation of the Gd complexes (Table 2.1). 
Table 2.1.  Summary of surface areas and pore sizes for co-condensed MSN samples. 
Particles Amnt. Gd complex BJH Surface Area BJH Pore Size 
2-2 10 wt% Si-DTTA-Gd 832 m2/g 1.94 nm 
2-3 10 wt% Si2-DTPA-Gd 1674 m2/g 2.91 nm 
2-4 20 wt% Si2-DTPA-Gd 1095 m2/g 2.75 nm 
2-5 30 wt% Si2-DTPA-Gd 923 m2/g 2.46 nm 
2-6 40 wt% Si2-DTPA-Gd 149 m2/g 1.41 nm 
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Figure 2.18.  Nitrogen sorption isotherm of 2-2 (black-adsorption; green-desorption). 
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Figure 2.19.  Pore size distribution of 2-2 (black-adsorption; green-desorption). 
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Figure 2.20.  Nitrogen sorption isotherm of 2-3 (black-adsorption; green-desorption). 
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Figure 2.21.  Pore size distribution of 2-3 (black-adsorption; green-desorption). 
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Figure 2.22.  Nitrogen sorption isotherm of 2-4 (black-adsorption; green-desorption). 
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Figure 2.23.  Pore size distribution of 2-4 (black-adsorption; green-desorption). 
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Figure 2.24.  Nitrogen sorption isotherm of 2-5 (black-adsorption; green-desorption). 
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Figure 2.25.  Pore size distribution of 2-5 (black-adsorption; green-desorption). 
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Figure 2.26.  Nitrogen sorption isotherm of 2-6 (black-adsorption; green-desorption). 
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Figure 2.27.  Pore size distribution of 2-6 (black-adsorption; green-desorption). 
 
Thermogravimetric analysis (TGA) was used to verify the complete extraction of the 
surfactant template, and the grafting of the Si-DTTA-Gd complex for 2-1 (Fig. 2.28).  The 
as-synthesized particles show an initial weight loss of approximately 6 wt% from room 
temperature to ~125 °C from adsorbed solvent, and a second weight loss of approximately 34 
wt% from 150-400 °C from the loss of the surfactant template.  Complete extraction of the 
surfactant is verified by the disappearance of the second weight loss; only a single weight 
loss of about 10 wt% is observed from room temperature to ~125 °C resulting from the loss 
of adsorbed solvent.  After grafting of the Si-DTTA-Gd chelate, a weight loss of ~12 wt% is 
observed from about 220-500 °C, resulting from the loss of the organic portion of the Gd 
complex.  The precise amount of Gd complex on each particle was determined by digesting a 
sample of the particles in concentrated nitric acid and then measuring the [Gd] using direct 
current plasma spectroscopy (DCP).  Using DCP, the loading of Si-DTTA-Gd complex was 
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found to range from 15.7 to 20.1 wt%.  This corresponds to an average of ~36,900 Gd 
chelates on each 75 nm particle. 
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Figure 2.28.  TGA curves of as-synthesized bare MSN (black), surfactant-extracted bare 
MSN (2-0) (red), and 2-1 (blue).   
 
 TGA was also used to characterize the amount of Gd chelate that had been 
incorporated in each of the products from the co-condensation reactions (Fig. 2.29-2.33).  
After extraction of the surfactant, the weight loss in the 230-450 °C temperature range 
corresponds to the organic portion of the incorporated Gd complexes.  The precise amount of 
Gd complex that had been incorporated was then determined by measuring the [Gd] of a 
digested particle solution using DCP.  The TGA and DCP gave fairly consistent results as to 
the amount of incorporated Gd complex (Table 2.2) 
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Figure 2.29.  TGA of 2-2 before (black) and after (red) surfactant extraction. 
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Figure 2.30.  TGA of 2-3 before (black) and after (red) surfactant extraction. 
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Figure 2.31.  TGA of 2-4 before (black) and after (red) surfactant extraction. 
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Figure 2.32.  TGA of 2-5 before (black) and after (red) surfactant extraction. 
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Figure 2.33.  TGA of 2-6 before (black) and after (red) surfactant extraction. 
Table 2.2.  Summary of TGA and DCP results for co-condensed MSN samples. 
Particles TGA - Organic Wt. Loss DCP - Wt% Gd DCP - Calc. Wt% Ligand 
2-2 15.99 wt% 5.32 wt% 15.17 wt% 
2-3 14.47 wt% 3.81 wt% 15.09 wt% 
2-4 23.12 wt% 4.70 wt% 18.61 wt% 
2-5 27.68 wt% 6.76 wt% 26.77 wt% 
2-6 28.77 wt% 8.08 wt% 32.01 wt% 
 
In order to confirm that all free Gd chelates had been removed from 2-1 during the 
dialysis process and that the chelates were stable, a leaching experiment was performed.  11 
mg of 2-1 was dispersed in water was dialyzed against 250 mL of distilled water (pH = 7.4) 
at 37 °C.  Aliquots of the dialysis water were removed at different time points and dried.  The 
residue was then redissolved in nitric acid, diluting to a final nitric acid concentration of 1 M.  
The [Gd] was then measured using DCP.  It was found that essentially no Gd was released 
from the particles after 46 hours (Fig. 2.34). 
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Figure 2.34.  Percentage of Gd-containing species that have been released from the MSN-Gd 
materials in water at 37 °C as a function of time.   
 
2.2.5 Relaxivity Measurements 
The MR relaxivities of 2-1 were measured using both a 3.0 T (Fig. 2.35) and a 9.4 T 
(Fig. 2.36) MR scanner.  The particles exhibited very large longitudinal (r1) and transverse 
(r2) relaxivities.  On a per mM Gd basis, 2-1 has an r1 of 28.8 mM-1s-1 at 3 T and 10.2 mM-1s-
1 at 9.4 T.  The r2 relaxivities are 65.5 mM-1s-1 at 3 T and 110.8 mM-1s-1 at 9.4 T, 
respectively.  Since each particle of 2-1 contains approximately 36,900 Gd ions, the r1 and r2 
values on a per mM of particle basis are 1.06×106 mM-1s-1(3 T) / 3.76×105 mM-1s-1 (9.4 T) 
and 2.42×106 mM-1s-1 (3 T) / 4.09×106 (9.4 T), respectively.  These relaxivity values are 
much larger than the solid silica nanoparticles that are coated with multilayers of Gd-DTPA 
derivative that was previously reported by our group.5  We attributed the enhanced MR 
relaxivity to the ready access of water molecules through the nanochannels of the MSN-Gd 
particles. 
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Figure 2.35.  r1 (blue) and r2 (red) relaxivity curves of 2-1 measured at 3 T.   
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Figure 2.36.  r1 (blue) and r2 (red) relaxivity curves of 2-1 measured at 9.4 T.   
The relaxivities for the particles obtained using the co-condensation method were all 
measured using a 3 T MR scanner.  The relaxivities for these particles were generally lower 
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than what was obtained for 2-1, however there was relatively little difference in the per Gd 
relaxivities across samples with varying amounts of incorporated Gd complex (Table 2.3).  
The r1 values ranged from 4.1 to 8.4 mM-1s-1, and the r2 values ranged from 16.1 to 32.7  
mM-1s-1 (Fig. 2.37-2.41).  The lower relaxivity values for the co-condensed samples may be 
due to the fact that some of the Gd chelates that were incorporated into the particles are not at 
the surface, and therefore are not available to undergo water exchange with the solvent. 
Table 2.3.  Summary of relaxivities for co-condensed MSN samples measured at 3 T. 
Particles r1 (mM-1s-1) r2 (mM-1s-1) 
2-2 6.2 32.7 
2-3 5.1 16.1 
2-4 4.1 25.3 
2-5 4.8 22.9 
2-6 8.4 25.6 
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Figure 2.37.  r1 (blue) and r2 (red) relaxivity curves of 2-2 measured at 3 T.   
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Figure 2.38.  r1 (blue) and r2 (red) relaxivity curves of 2-3 measured at 3 T.   
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Figure 2.39.  r1 (blue) and r2 (red) relaxivity curves of 2-4 measured at 3 T.   
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Figure 2.40.  r1 (blue) and r2 (red) relaxivity curves of 2-5 measured at 3 T.   
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Figure 2.41.  r1 (blue) and r2 (red) relaxivity curves of 2-6 measured at 3 T.   
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2.2.6 In Vitro Experiments 
An immortalized murine monocyte cell line was used for the in vitro studies because 
of its phagocytic capacity.17  Laser scanning confocal fluorescence microscopic studies 
indicated the efficient uptake of 2-1a by monocyte cells (500,000) after they were incubated 
with 2 mL of medium containing 4 µg of 2-1a for 30 minutes.  The rhodamine B 
fluorescence is clearly visible in the confocal image of monocyte cells incubated with 2-1a, 
but completely absent in the confocal image of monocyte cells alone (Fig. 2.42).  We have 
observed significant MR image enhancement of the labeled monocytes when compared with 
a control of unlabeled monocytes.  To prepare the cells for MR imaging, we incubated 
~5×106 cells in 3 mL of media containing 0.3 mg of 2-1 for 1 hour.  The cells were isolated, 
washed twice with fresh media, pelleted, and finally covered with 200 μL of saline solution.  
As shown in Figure 2.43, significant positive signal enhancement in the T1-weighted image 
and negative signal enhancement in the T2-weighted image were observed for the labeled 
cells, depending on the MR pulse sequence employed when compared to the unlabeled cells.  
The T1- and T2-weighted image enhancement was corroborated with the reduction of T1 and 
T2 relaxation times observed on the relaxation time maps (Fig. 2.44).  Cell viability assays 
showed that 2-1 particles were not toxic to monocyte cells; they were completely viable even 
after incubation with a nanoparticle loading of 10 µg per 5000 monocyte cells for 26 hours 
(Fig. 2.45).  More than 85% cells were viable after incubating with 100 µg of 2-1 per 5000 
cells for 26 hours. 
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Figure 2.42.  Confocal fluorescence microscopy images of rhodamine B labeled MSN-Gd 
(2-1a) in monocyte cells.  Fluorescence is overlaid on DIC images of live monocytes 
incubated with no nanoparticles (top) and 4 μg 2-1a per 500,000 cells (bottom). 
 
 64
Figure 2.43.  (a) T1-weighted MR images of monocyte cell pellets incubated without 2-1 
(left) and with 0.3 mg 2-1 for 5×106 cells in 3 mL of media (right).  (b) T2-weighted MR 
images of monocyte cell pellets incubated without 2-1 (left) and with 0.3 mg 2-1 for 5×106 
cells in 3 mL of media (right). 
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Figure 2.44.  (A) T1-Relaxation time maps for monocyte cell pellets incubated without 2-1 
(left) and with 0.3 mg 2-1 for 5×106 cells in 3 mL of media (right).  (B) T2-Relaxation time 
maps for monocyte cell pellets incubated without 2-1 (left) and with 0.3 mg 2-1 for 5×106 
cells in 3 mL of media (right). 
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Figure 2.45.  Monocyte cell viability assay after incubation with different amounts of 2-1. 
 
 
2.2.5 In Vivo Experiments 
We have also evaluated the effectiveness of 2-1 as an in vivo MR contrast agent using 
a 9.4 T scanner.  Upon tail vein injection of a dose of 2-1 corresponding to 2.1 µmol of Gd 
per kg of body weight, significant T1-weighted enhancement is clearly visible in the aorta of 
a DBA/1J mouse 15 minutes post injection (Fig. 2.46), indicating the utility of 2-1 as an 
intravascular MR contrast agent.  This dose level is much lower than what is typically 
required of currently used contrast agents (0.1-0.3 mmol/kg).  We have also shown that 2-1 
can be an efficient T2-weighted contrast agent at a higher dosage.  After tail injection of a 
dose of 2-1 corresponding to 31 µmol of Gd per kg of body weight, significant loss of MR 
signal was observed in the liver of the DBA/1J mouse 30 minutes post injection, indicating 
the ability of 2-1 to enhance T2-weighted images (Fig. 2.47).  The liver signal loss is 
probably a result of phagocytosis of the MSN-Gd particles by the liver macrophage cells, as 
already shown by the efficient uptake of 2-1 by the related monocyte cells.  This result 
suggests the possibility of using 2-1 for MR imaging of liver abnormalities such as liver 
tumors which can be currently carried out with iron oxide nanoparticles.18  The T2-weighted 
enhancement could be observed up to 17 days after injection, indicating a slow clearance of 
the particles.  A third study was performed using a dose corresponding to 4.15 µmol of Gd 
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per kg of body weight.  At this lower dose T1-weighted signal enhancement was observed in 
the liver (Fig. 2.48-2.49).   
b) a) 
 
Figure 2.46.  (a) Pre-contrast and (b) post-contrast (2.1 µmol/kg dose) T1-weighted mouse 
MR image showing aorta signal enhancement.   
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 A. B.  
C. D. 
E. F. 
 
Figure 2.47.  Midbody images showing T2-weighted signal enhancement in the liver.  (A) 
pre-contrast, (B) 30 minutes, (C) 1 day, (D) 2 days, (E) 4 days, and (F) 17 days post contrast 
administration via intravenous injection of a 31 µmol/kg dose of 2-1. 
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  A. 
 
 B. 
 
 C. 
 
 D. 
 
Figure 2.48.  MR imaging and the associated T1 relaxation time mapping (A) pre-contrast 
injection, (B) 15 minutes, (C) 1 hour, and (D) 24 hours post-contrast administration via 
intravenous injection of a 4.15 µmol/kg dose of 2-1. 
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 A. B. 
 
Figure 2.49.  MR images (A) pre-contrast and (B) 1 hour post-contrast (4.15 µmol/kg dose) 
after rescaling using data from T1 relaxation time maps.   
 
 
2.3 Conclusion 
We have designed and characterized several hybrid mesoporous silica nanospheres 
(MSN-Gd) with extraordinary ability to enhance MR images.  Two different approaches 
were used to incorporate the Gd chelates, a post-synthetic grafting strategy and a co-
condensation method.  Their utility as contrast agents for optical and MR imaging has been 
clearly demonstrated in vitro. We have also shown that 2-1 is a highly efficient T1 contrast 
agent for intravascular MR imaging and an excellent T2 contrast agent for MR imaging of 
soft tissues when applied at a higher dosage.   
 
2.4 Experimental Details 
 2.4.1 Materials and Methods 
Cetyltrimethylammonium bromide (CTAB), GdCl3·6H2O, bromoacetic acid, and 
tetraethyl orthosilicate (TEOS) were purchased from Aldrich and used without further 
purification.  3-(trimethoxysilylpropyl)diethylene triamine and 3-aminopropyltriethoxysilane 
were purchased from Gelest.  Thermogravimetric analysis (TGA) was performed using a 
Shimadzu TGA-50 equipped with a platinum pan and a heating rate of 3 °C per minute, 
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under air.  Powder X-ray diffraction (PXRD) patterns were collected on a Bruker SMART 
APEX II diffractometer using Cu radiation.  The PXRD patterns were processed with the 
APEX 2 package using phase ID plug-in.  A Hitachi 4700 field emission scanning electron 
microscope (SEM) and a JEM 100CX-II transmission electron microscope (TEM) were used 
to determine particle size and morphology.  A Cressington 108 Auto Sputter Coater equipped 
with a Au/Pd (80/20) target and an MTM-10 thickness monitor was used to coat the samples 
with a 5 nm thick conductive layer before taking SEM images.  Each SEM sample was 
prepared by suspending the nanoparticles in ethanol.  A drop of the suspension was then 
placed on a glass slide and the solvent was allowed to evaporate.  TEM samples were also 
prepared from ethanolic particle dispersions on amorphous carbon coated copper grids.  An 
Applied Research Laboratories (ARL) SpectraSpan 7 DCP spectrometer was used to measure 
Gd3+ concentration.   
MR images were acquired on a Siemens 3 T Allegra (Siemens Medical Systems, 
Erlangen, Germany) with a CP head coil, and a 9.4 T Bruker BioSpec (Bruker Biospin, 
Ettlingen, Germany) system with a 35 mm quadrature RF transmit and receive coil.  For the 3 
T scanner, a 3D FLASH sequence was utilized to compute T1 maps with seven different flip 
angles (2, 5, 10, 20, 30, 40, and 60).  Imaging parameters were:  FOV=190 x 190*64 mm3, 
Matrix size=128 x 128 *32, TR/TE= 40/1.64 ms, total data acquisition time was 19 minutes.  
A 2-D multiple echo spin echo sequence was used to estimate T2 maps.  In total, 32 echoes 
with an echo spacing of 6.2 ms were obtained.  The first echo time was 6.2 ms.  TR was 3000 
ms.  FOV and matrix size were set to 190 x 190 mm2 and 128 x 128.  The slice thickness was 
2 mm.  The total data acquisition time was about 6 minutes and 29 seconds.  For the 9.4 T 
scanner, two 2D multiple echo spin echo sequences were used to estimate T2 maps for a wide 
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range of T2.  FOV and matrix size were set to 35 x 30 mm2 and 128 x 128.  The slice 
thickness was 1 mm.  In total, 32 echoes with an echo spacing of 3.7 ms for sequence 1 and 
40 echoes with an echo spacing of 10 ms for sequence 2 were obtained.  The TR/TE1 were 
3.7/3000 ms and 10/4114 ms for each sequence, respectively.  The total data acquisition time 
was about 10 minutes.  T1 maps were obtained with a variable TR rapid acquisition relaxation 
enhanced (RARE) sequence with a TE=5.14 ms.  Twenty two variable TRs (TR=18, 25, 40, 
60, 90, 120, 160, 200, 250, 300, 380, 500, 700, 1000, 1500, 2000, 2500, 3000, 4000, 5000, 
6000, 7000 ms) were used with a FOV of 35 x 30 mm2 and a matrix size of 128 x 128.  
RARE factor was 3 and total data acquisition was about 24 minutes. 
  
2.4.2 Ligand and Gd Complex Synthesis 
3-aminopropyl(trimethoxysilyl)diethylenetriamine tetraacetic acid (Si-DTTA).  
Bromoacetic acid (0.5558 g, 4.00 mmol) and 3-(trimethoxysilylpropyl)diethylene triamine 
(0.2654 g, 1.00 mmol) were dissolved in 1.0 mL of distilled water and 2.0 mL 2 M sodium 
hydroxide (4.00 mmol) with magnetic stirring.  The reaction solution was subsequently 
heated to 50 °C, and an additional 3.0 mL of 2 M NaOH were added dropwise over 
approximately 30 minutes.  After stirring for an additional 2 hours at 50 °C, the solvent was 
removed under reduced pressure to yield a viscous yellow oil.  An off-white hygroscopic 
powder was isolated from the oil in high yield (>90%) by precipitation with ethanol, and 
subsequent drying under vacuum.  MS (ESI negative ion): m/z 542.2 [M-H]- for the 
silanetriol from a basic solution. NMR: 1H (D2O, 300 MHz, ppm): 0.47 (2H), 1.55 (2H), 
2.62-2.78 (10H), 3.14-3.21 (8H). 
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Synthesis of Si-DTTA-Gd Complex.  The gadolinium complex was prepared by 
dissolving the isolated Si-DTTA product (108.6 mg, 0.2 mmol) in 4 mL of distilled water 
with magnetic stirring at room temperature.  GdCl3 (380 μL of a 0.50 M solution, 0.19 mmol) 
was slowly titrated into the solution while maintaining a pH of ~9 with the dropwise addition 
of 2 M NaOH.  The reaction was then stirred at room temperature for an additional 2 hours.  
The resultant solution was used directly. 
Bis(3-aminopropyl triethoxysilyl)diethylenetriamine pentaacetic acid (Si2-
DTPA).  Diethylenetriamine pentaacetic acid dianhydride (5.000 g, 13.995 mmol) was 
dissolved in 110 mL of anhydrous pyridine under a steady flow of nitrogen.  Using standard 
Schlenk line techniques 3-aminopropyl triethoxysilane (6.85 g, 31.00 mmol) was added and 
the resultant reaction mixture was magnetically stirred under nitrogen for 24 hours.  The 
product was then precipitated with copious amounts of hexane, isolated via centrifuge, 
washed with additional aliquots of hexanes, and dried to yield 10.436 g (93.2 %) of the 
desired compound (Si2-DTPA).  MS (ESI negative ion): m/z 631.3 [M-H]- for the silanetriol 
from a basic solution.  NMR: 1H (DMSO, ppm): 0.52 (t, 4H), 1.14 (t, 18H), 1.44(p, 4H), 2.81 
(t, 4H), 2.92 (t, 4H), 3.04 (q, 4H), 3.22 (s, 6H), 3.34 (s, 4H), 3.73 (q, 12H), 8.06 (t, 2H).  
13C{1H} (DMSO, ppm): 8.0 (2C), 18.8 (18C), 23.4 (2C), 41.8 (2C), 51.2 (2C), 52.8 (2C), 
55.9 (2C), 56.7 (2C), 58.3 (1C), 58.4 (6C), 170.7 (2C), 173.4 (3C). 
Synthesis of Si2-DTPA-Gd Complex.  To prepare the gadolinium complex, Si2-
DTPA (1.77 g, 2.22 mmol) was dissolved in ~3 equivalents of NaOH (6.0 mL of a 1.0 M 
solution) with magnetic stirring for 30 minutes. To this solution was added 0.90 equivalent of 
GdCl3 (4.0 mL of a 0.5 M solution, 0.002 mol) and the mixture was magnetically stirred at 
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room temperature for several hours, the volume of the solution was adjusted to 10 mL to 
yield a visibly clear yellow 0.20 M solution of the modified gadodiamide complex. 
 
2.4.3 MSN-Gd Synthesis 
Bare MSN Synthesis.  0.100 g (0.274 mmol) of cetyltrimethylammonium bromide 
(CTAB) was dissolved in 48 mL of distilled H2O, along with 0.35 mL of 2 M sodium 
hydroxide.  This solution was then heated to 80 °C.  Once the reaction had reached 80 °C, 
0.50 mL (0.47g, 2.24 mmol) of tetraethylorthosilicate (TEOS) was rapidly injected.  The 
reaction was then stirred for an additional 2 hours at 80 °C.  At the completion of the reaction 
the particles were isolated by centrifuging at 10,000 rpm for 10 minutes.  They were then 
washed with H2O and ethanol, before being redispersed in 30 mL of ethanol.  Yield: 171 mg 
 Extraction.  The surfactant was extracted from the mesoporous materials using either 
a 1 wt% solution of sodium chloride in methanol or a 1 volume % solution of HCl in 
methanol.  The particles were dispersed in the NaCl/MeOH or HCl/MeOH solution at a 
concentration of approximately 3.5 mg/mL.  After stirring at room temperature for 3 hours, 
the particles were isolated by centrifuging, and then redispersed in another aliquot of the 
methanol solution.  The extraction was performed for a total of three times.  After the final 
extraction, the particles were washed with distilled H2O and ethanol, before being 
redispersed in ethanol. 
Synthesis of MSN-Gd using grafting method (2-1).  Approximately 160 mg of 
extracted MSN particles were suspended in 10 mL of toluene.  0.78 mL (0.075 mmol) of a 
0.097 M aqueous solution of Si-DTTA-Gd was then added.  The mixture was then heated to 
reflux overnight.  The particles were isolated by centrifuging, and washed with distilled 
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water and ethanol, before being redispersed in ethanol.  Yield: 132 mg.  In order to ensure 
there was no excess Gd remaining on the silica, the particles were washed twice with a pH 3 
solution by sonicating for 10 minutes.  They were then washed once with distilled water 
before being redispersed.  The particles were also dialyzed against distilled water for 6 hours, 
changing the water once an hour.  The dialysis was performed using dialysis tubing with a 
molecular weight cut off of 3500. 
Synthesis of co-condensed MSN with “10 wt%” Si-DTTA-Gd (2-2).  0.0400 g 
(0.1098 mmol) of CTAB was dissolved in 48 mL of H2O containing 0.14 mL of 2 M NaOH 
(0.28 mmol).  The solution was heated to 80 °C.  After reaching 80 °C, 0.2 mL of TEOS, and 
2.54 mL (0.0356 mmol) of a 0.014 M aqueous solution of Si-DTTA-Gd were then added.  
The reaction was then stirred for an additional 2 hours at 80 °C.  The product was isolated by 
centrifuging, and was washed with water and ethanol.  The surfactant was extracted using the 
same procedure as used above for the bare MSN particles (1 wt% NaCl in methanol).  Yield: 
32.9 mg.   
 Synthesis of co-condensed MSN with “10 wt%” Si2-DTPA-Gd (2-3).  0.200 g 
(0.549 mmol) of CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH 
(1.40 mmol).  The solution was heated to 80 °C.  After reaching 80 °C, 1.0 mL of TEOS, and 
0.79 mL (0.134 mmol) of a 0.17 M aqueous solution of Si2-DTPA-Gd were then added.  The 
reaction was then stirred for an additional 2 hours at 80 °C.  The product was isolated by 
centrifuging, and was washed with water and ethanol.  The surfactant was extracted using the 
same procedure as used above for the bare MSN particles (1 wt% NaCl in methanol).  Yield: 
150.1 mg.   
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Synthesis of co-condensed MSN with “20 wt%” Si2-DTPA-Gd (2-4).  0.200 g 
(0.549 mmol) of CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH 
(1.40 mmol).  The solution was heated to 80 °C.  After reaching 80 °C, 1.0 mL of TEOS, and 
1.37 mL (0.233 mmol) of a 0.17 M aqueous solution of Si2-DTPA-Gd were then added.  The 
reaction was then stirred for an additional 2 hours at 80 °C.  The product was isolated by 
centrifuging, and was washed with water and ethanol.  The surfactant was extracted using the 
same procedure as used above for the bare MSN particles (1 wt% NaCl in methanol).  Yield: 
326.1 mg.   
Synthesis of co-condensed MSN with “30 wt%” Si2-DTPA-Gd (2-5).  0.200 g 
(0.549 mmol) of CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH 
(1.40 mmol).  The solution was heated to 80 °C.  After reaching 80 °C, 1.0 mL of TEOS, and 
2.04 mL (0.347 mmol) of a 0.17 M aqueous solution of Si2-DTPA-Gd were then added.  The 
reaction was then stirred for an additional 2 hours at 80 °C.  The product was isolated by 
centrifuging, and was washed with water and ethanol.  The surfactant was extracted using the 
same procedure as used above for the bare MSN particles (1 wt% NaCl in methanol).  Yield: 
241.0 mg.   
Synthesis of co-condensed MSN with “40 wt%” Si2-DTPA-Gd (2-6).  0.220 g 
(0.603 mmol) of CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH 
(1.40 mmol).  The solution was heated to 80 °C.  After reaching 80 °C, 1.0 mL of TEOS, and 
3.03 mL (0.455 mmol) of a 0.15 M aqueous solution of Si2-DTPA-Gd were then added.  The 
reaction was then stirred for an additional 2 hours at 80 °C.  The product was isolated by 
centrifuging, and was washed with water and ethanol.  The surfactant was extracted using the 
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same procedure as used above for the bare MSN particles (1 wt% NaCl in methanol).  Yield: 
276.3 mg.   
 
2.4.4 Fluorescently Labeled MSN-Gd 
Synthesis of Rhodamine-APS.  6.8 mg (0.0127 mmol) of rhodamine B 
isothiocyanate was dissolved in 1.1 mL of ethanol.  3.3 µL (3.1 mg, 0.0141 mmol) of 3-
aminopropyltriethoxysilane was then added, and the reaction was stirred at room 
temperature, under N2, and in the dark for 24 hours.  At the completion of the reaction the 
solution was diluted to a total volume of 2 mL with additional ethanol to make a solution 
with a rhodamine-APS concentration of approximately 6 mM. 
Rhodamine B functionalized MSN-Gd (2-1a).  Approximately 50 mg of extracted 
MSN particles were suspended in 4 mL of toluene.  170 µL (0.016 mmol) of a 0.097 M 
solution of a Si-DTTA-Gd aqueous solution and 110 µL (0.00066 mmol) of a 6 mM solution 
of rhodamine-APS in ethanol were then added.  The mixture was then heated to reflux 
overnight.  The particles were isolated by centrifuging, and were washed with distilled water 
and ethanol, before being redispersed in ethanol.  Yield: 48 mg.  In order to ensure there was 
no excess Gd remaining on the silica, the particles were washed twice with a pH=3 solution 
by sonicating for 10 minutes.  They were then washed once with distilled water before being 
redispersed.  The particles were also dialyzed against distilled water for 6 hours, changing the 
water once an hour. 
 
2.4.5  Calculation for Number of Gd per particle 
Density of MCM-41: (0.835 g/cm3) 19 
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Volume of each 75 nm particle: 
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2.4.6 In Vitro Experiments 
Murine monocyte cell culture.  Cells (ATCC# TIB67) were purchased from the 
UNC Lineberger Comprehensive Cancer Center’s Tissue Culture Facility.  Cells were 
maintained in DMEM-H containing 10% FBS and 1% penicillin/streptomycin at 37 ºC and 
5% CO2. 
MTS cell viability assay.  Manufacturer’s (Promega) protocol was used to determine 
cell viability of monocytes in the presence of MSN-Gd nanoparticles.  Briefly, monocytes 
were placed in a 96-well plate at a concentration of 5000 cells (100 µL) per well and various 
amounts of particles (2-1) were added in a 20 µL volume of distilled H2O.  Each particle 
concentration was replicated seven times, and 100% viability was standardized to 20 µL of 
distilled H2O without nanoparticles.  The cells are incubated with the nanoparticles for 22 
hours before addition of MTS.  An additional 4 hours for MTS metabolism was allowed 
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before reading the plate absorbance at 492 nm.  Wells with nanoparticles and without cells 
were used for background correction.   
In vitro labeling of murine monocytes.  Cells were detached from resident flasks 
using a cell scraper and re-plated into 6-well plates at a concentration of 300,000 cells per 
well.  Monocyte containing plates were maintained at 37 ºC and 5% CO2 for 24 hours, at 
which point 4 µg nanoparticles (2-1) per well (2 mL media) were added.  Cells were allowed 
to incubate with nanoparticles at 37 ºC and 5% CO2 for 30 minutes before extensive washing.  
The resulting labeled cells were imaged using an Olympus FV500 Confocal Laser 
Microscope at 60X using a RITC filter and DIC settings.   
 
2.4.7 In Vivo Imaging Experiments 
T2-weighted midbody MR imaging.  A 6-week old male DBA/1J mouse was 
imaged in a Bruker 9.4 T small animal scanner.  After pre-contrast image acquisition of the 
animal midbody, 2.5 mg of 2-1 NPs were intravenously injected via tail vein.  This 
corresponds to a dose of 31 µmol of Gd per kg of body weight.  The animal was imaged at 
time points of 30 minutes, 1 day, 2 days, 4 days, and 17 days post-contrast administration. 
T1-weighted midbody MR imaging and relaxation time mapping.  A 6-week old 
female DBA/1J mouse was imaged in a Bruker 9.4 T small animal scanner.  After pre-
contrast image acquisition of animal midbody, an appropriate dose of 2-1 NPs was 
intravenously injected via tail vein.  The animal was imaged at time points of 15 minutes, 1 
hour, and 24 hours post-contrast administration. 
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CHAPTER 3 
 
Degradable Mesoporous Silica Nanospheres as Contrast Agents for Magnetic 
Resonance Imaging 
 
3.1 Introduction 
 
 As discussed in the previous chapter, there are many advantages to using a 
nanoparticle based contrast agent for magnetic resonance imaging, including large payloads, 
increased relaxivity on a per metal basis, and the ability to modify the surface to alter the 
pharmacokinetics or introduce targeting moieties.  However, in order to make a nanoparticle 
contrast agent potentially useful for clinical applications it must be able to quickly clear from 
the body after the MR imaging studies.  This is particularly important for Gd-containing MRI 
contrast agents since Gd containing MRI contrast agents have recently been shown to be the 
culprit for a potentially fatal condition known as nephrogenic systemic fibrosis (NSF).1,2  
This condition has been reported in patients that have some degree of renal failure, that have 
also received one of the commercially available Gd contrast agents.  It is believed that the 
impaired renal function results in slower clearance of the Gd chelate, and as a result free Gd 
ions begin to leach from the chelates, resulting in toxicity.   
This condition highlights the need to ensure the Gd chelates can be quickly cleared 
from the body.  Based on our preliminary in vivo results using the MSN-Gd contrast agents 
(2-1) we learned that the particles are trafficked to the liver, and are cleared very slowly.  We 
were able to observe significant T2-weighted enhancement in the liver of a mouse up to 17 
days after injection.  We hypothesized that if we can include a degradable linkage from the 
Gd chelate to the particle, the Gd chelate can be cleaved and cleared renally, just as the 
currently used small molecule contrast agents are. 
 There have been several reports on biodegradable polymeric MRI contrast agents.3-7  
These polymers contain Gd chelates either directly in the backbone of the polymer, or in 
pendant side chains.  These polymers also contain disulfide bonds that can be cleaved in vivo 
by endogenous thiols such as cysteine and the reduced form of glutathione.  Once the 
disulfide bonds have been cleaved, the smaller Gd chelates can then be cleared through the 
kidneys.  Using this approach, we have been able to synthesize a degradable contrast agent 
based on MSN particles.  A disulfide bond has been incorporated into the linkage from the 
chelate to the particle.  Once cleaved, the Gd chelate can then be quickly cleared from the 
body, reducing the potential risk of toxicity that can occur if the chelates remain in the body 
too long resulting in the release of free Gd ions.  
 
3.2 Results and Discussion 
 3.2.1 Ligand and Gd Complex Synthesis 
 The diethylenetriaminepenta(acetic acid)-ethyldisulfanylpropyltriethoxysilane-Gd 
complex (Si-S-S-DTPA-Gd) was synthesized by first reacting diethylenetriaminepenta(acetic 
acid) dianhydride with 0.8 equivalents of 2-pyridyldisulfanylethylamine to form the mono 
functionalized ligand (Scheme 3.1).  The Gd complex was then formed by reacting the 
deprotonated form of the ligand with one equivalent of GdCl3.  The Gd complex was isolated 
from the aqueous solution by precipitating with acetone.  A disulfide exchange reaction was 
then performed using 3-mercaptopropyltriethoxysilane to obtain the desired product. 
 83
 Poly(ethylene glycol) was also modified to contain a triethoxy silane group to allow 
for surface functionalization of the particles.  This was obtained by reacting poly(ethylene 
glycol) monomethyl ether (MW 2000) with 1 equivalent of (3-isocyanato-
propyl)triethoxysilane in the presence of Hünig base.   
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Scheme 3.1.  Synthesis of diethylenetriaminepenta(acetic acid)-ethyldisulfanylpropyl-
triethoxysilane-Gd complex. 
 
3.2.2 Nanoparticle Synthesis 
Initial attempts at grafting the Gd complex containing the disulfide bond into MSN 
particles resulted in much lower loading than what was obtained previously with the non-
degradable version (2-1).  We hypothesized that the increase in size of the chelate made 
transportation into the channels much less efficient.  In order to resolve this problem we 
synthesized mesoporous silica nanoparticles with larger pore diameters.  A similar surfactant-
templated technique was used, with mesitylene added as a pore swelling agent.8  Briefly, an 
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aqueous solution of CTAB, sodium hydroxide, and mesitylene was heated to 80 °C.  
Tetraethylorthosilicate (TEOS) was then added, and the reaction was stirred for an additional 
2 hours at 80 °C.  The particles were then isolated by centrifuging, and were washed with 
water and ethanol.  The surfactant was then extracted from the pores using a 1% solution of 
HCl in methanol.   
The Si-S-S-DTPA-Gd complex was grafted onto the large pore MSN particles 
through the siloxane linkages by adding an aqueous solution of the complex to a suspension 
of the extracted large pore MSN particles in toluene.  The reaction was then heated to reflux 
for 18 hours.  After cooling, the particles were isolated by centrifuging, and were washed 
with water and ethanol.  Finally, the particles were dialyzed against distilled water to remove 
any free chelates adsorbed into the channels.  In order to increase the loading of Gd chelates, 
the above procedure was repeated a second time. 
To increase the circulation time of the particles in vivo, the surface was coated with 
poly(ethylene glycol) chains (PEG).  The PEG grafting was performed by adding a solution 
of triethoxysilylpropyl carbamoyl-poly(ethylene glycol) to a suspension of the particles in 
basic ethanol.   The reaction was then stirred at room temperature for 18 hours.  The particles 
were then isolated by centrifuging, washed with ethanol, and then dialyzed against distilled 
water to remove any adsorbed PEG chains from the channels. 
 
3.2.3 Characterization 
Scanning electron and transmission electron microscopies (SEM and TEM) were used 
to evaluate the particle size and morphology.  The as-synthesized particles were fairly 
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uniform, and had an average diameter of 75 nm (Fig. 3.1-3.3).  No change was seen in the 
particle size or morphology upon grafting of the Gd complex. 
 
Figure 3.1.  SEM images of large pore MSN particles. 
 
 
Figure 3.2.  TEM images of large pore MSN particles. 
 
 
Figure 3.3.  TEM images of large pore MSN-S-S-DTPA-Gd particles. 
 
The pore size and surface area of the particles was determined using nitrogen uptake 
measurements (Fig. 3.4-3.9).  The extracted large pore particles showed a similar surface 
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area to the original MSN particles.  The average BJH (Barrett-Joiner-Halenda) surface area 
was 1535 m2/g.  The particles had an average pore diameter of 4.6 nm, compared to 2.4 nm 
for the original MSN particles.  After coating with the Gd complexes, a slight decrease in the 
surface area was observed (1384 m2/g).  The average pore diameter also decreased to 3.8 nm, 
indicating the presence of Gd chelates in the channels.  After coating with PEG, the pore 
diameter remained unchanged, but the surface area decreased to 872 m2/g.   
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Figure 3.4.  Nitrogen sorption isotherm of surfactant-extracted large pore MSN (blue-
adsorption; red-desorption). 
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Figure 3.5.  Pore size distribution of surfactant-extracted large pore MSN (blue-adsorption; 
red-desorption). 
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Figure 3.6.  Nitrogen sorption isotherm of MSN-S-S-DTPA-Gd (blue-adsorption; red-
desorption). 
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Figure 3.7.  Pore size distribution of MSN-S-S-DTPA-Gd (blue-adsorption; red-desorption). 
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Figure 3.8.  Nitrogen sorption isotherm of PEG2000 functionalized MSN-S-S-DTPA-Gd 
(blue-adsorption; red-desorption). 
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Figure 3.9.  Pore size distribution of PEG2000 functionalized MSN-S-S-DTPA-Gd (blue-
adsorption; red-desorption). 
 
Thermogravimetric analysis was used to verify the complete extraction of the 
surfactant template, and the grafting of the Si-S-S-DTPA-Gd complex and PEG (Fig. 3.10).  
The extracted particles show an initial weight loss of 8.52 wt% from room temperature to 
150 °C, followed by a gradual weight loss of 6.63 wt% from 150-600 °C.  After coating with 
the Si-S-S-DTPA-Gd complex, a weight loss of 11.31 wt% is seen from room temperature to 
150 °C, resulting from solvent residing in the channels, followed by a weight loss of 9.08 
wt% from 250-600 °C, resulting from the organic portion of the Gd complex.  After the 
second coating reaction (to increase the loading of the complex), the TGA shows and initial 
weight loss of 6.95 wt% from room temperature to 150 °C, followed by a loss of 12.35 wt% 
from 250-600 °C, consistent with the increased loading of the Gd complex.  Finally, TGA 
results of the PEG2000 functionalized particles shows an initial weight loss of 8.11 wt% 
from room temperature to 150 °C, followed by a weight loss of 17.65% from 250-600 °C, 
confirming PEG functionalization.  The precise amount of Gd was determined using either 
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direct current plasma spectroscopy (DCP) or inductively coupled plasma – mass 
spectroscopy.  The average Gd loading was approximately 2.56 wt% after the first coating 
and 3.69 wt% after the second coating.  
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Figure 3.10.  TGA curves of the surfactant extracted large pore MSN (black), MSN-S-S-
DTPA-Gd (red), recoated MSN-S-S-DTPA-Gd (blue), and PEG2000 functionalized MSN-S-
S-DTPA-Gd (green).   
 
 
3.2.4 Relaxivity Measurements 
In order to evaluate the MRI contrast enhancing ability of the particles, the relaxivity 
values were measured using both a 3 T and a 9.4 T scanner.  The relaxivity values for the 
degradable MSN particles were slightly lower than what was obtained for the non-degradable 
version.  At 3 T the MSN-S-S-DTPA-Gd particles had an r1 relaxivity of 24.7 mM-1s-1 and an 
r2 of 31.1 mM-1s-1 (Fig. 3.11).  Particles that had undergone a second coating reaction had 
similar relaxivities of 24.9 mM-1s-1 and 35.9 mM-1s-1 for r1 and r2, respectively (Fig. 3.12).  
At 9.4 T, the r1 dropped while the r2 increased.  For the coated particles the r1 relaxivity was 
7.1 mM-1s-1 while the r2 increased to 53.3 mM-1s-1 (Fig. 3.13).  The increased loading from 
 91
the second coating reaction resulted in a slight decrease of the relaxivities to 5.0 and 44.8 
mM-1s-1, for r1 and r2, respectively (Fig. 3.14).  Finally, the PEG2000 coating resulted in little 
change to the relaxivity values, these particles had an r1 of 5.7 mM-1s-1 and an r2 of 48.7 mM-
1s-1 (Fig. 3.15). 
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Figure 3.11.  r1 (blue) and r2 (red) relaxivity curves of MSN-S-S-DTPA-Gd measured at 3 T.   
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Figure 3.12.  r1 (blue) and r2 (red) relaxivity curves of recoated MSN-S-S-DTPA-Gd 
measured at 3 T.   
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Figure 3.13.  r1 (blue) and r2 (red) relaxivity curves of MSN-S-S-DTPA-Gd measured at 9.4 
T.   
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Figure 3.14.  r1 (blue) and r2 (red) relaxivity curves of recoated MSN-S-S-DTPA-Gd 
measured at 9.4 T.   
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Figure 3.15.  r1 (blue) and r2 (red) relaxivity curves of PEG2000 functionalized MSN-S-S-
DTPA-Gd measured at 9.4 T.   
 
 
 
 94
3.2.5 Release Profile 
 In order to determine how quickly the disulfide bond will be cleaved to release the Gd 
chelate from the particle, a release profile was carried out in the presence of 10 mM cysteine, 
to simulate the intracellular free thiol concentration.  A suspension of the particles in water 
was placed inside a piece of dialysis tubing with a molecular weight cut off of 3500.  The 
dialysis bag was then submerged in 300 mL of degassed distilled water that had been heated 
to 37 °C.  The entire vessel was kept under a nitrogen atmosphere.  After the bag had been 
submerged for 30 minutes, a 10 mL aliquot was removed to analyze for any Gd that was 
released before adding the cysteine.  This 10 mL aliquot was replaced with 10 mL of an 
aqueous solution containing 0.3636 g (0.003 mol) of L-cysteine to give a cysteine 
concentration of 10 mM.  Aliquots of the dialysis solution were then removed a various time 
points, and the Gd concentration was measured using DCP.  The disulfide bond release was 
found to have a half-life of approximately 50 hours, with approximately 82% of the chelates 
being released after about 5 days (Fig. 3.16).   
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Figure 3.16.  Release profile for MSN-S-S-DTPA-Gd in the presence of 10 mM cysteine at 
37 °C. 
 
 3.2.6 Non-Specific Binding Assay  
 In order to evaluate the effectiveness of the PEG surface functionalization in reducing 
the non-specific binding of proteins a non-specific binding assay was performed using bovine 
serum albumin (BSA).  Particles were incubated with Texas Red labeled BSA for 2 hours, 
after which time they were isolated and washed.  The particles were then redispersed and the 
Texas Red emission intensity was used to quantify the amount of BSA that was adsorbed 
onto the particles.  It was found that unmodified MSN-S-S-DTPA-Gd particles retained 
100% of the BSA added, while those that had been surface functionalized with PEG2000 
retained 87%.  Increasing the PEG chain length to PEG5000 did not improve the results; 
these particles retained 91% of the BSA added.  As a control experiment bare, large pore 
MSN particles were coated with PEG2000 and PEG5000, and the protein binding assay was 
repeated.  In this case the PEG2000 and PEG5000 modified particles retained only 51 and 
53% of the BSA added, respectively.  Based on these results we concluded that in the case of 
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the MSN-S-S-DTPA-Gd particles, the majority of the exterior surface is already coated with 
the Gd complex, leaving little room for further surface functionalization with PEG. 
 
3.3 Conclusion 
 We have developed a potentially biodegradable contrast agent based on mesoporous 
silica nanoparticles.  The Gd chelates are attached to the nanoparticles through a disulfide 
bond that can be cleaved in vivo to release small molecule Gd chelates which can be quickly 
cleared form the body.  We have also modified the surface of the particles with poly(ethylene 
glycol) to increase the circulation time of the particles.  These particles show increased 
relaxivity compared to the small molecule Gd chelate contrast agents currently available, and 
the half life for cleaving the chelates was found to be approximately 50 hours in the presence 
of 10 mM cysteine.  This will allow sufficient time for imaging before the contrast agent is 
cleared. 
 
3.4 Experimental Details 
 3.4.1 Materials and Methods 
All reagents were purchased from Aldrich and used without further purification, 
except 3-mercaptopropyltriethoxysilane and (3-isocyanatopropyl)-triethoxysilane which were 
purchased from Gelest.  (3-isocyanatopropyl)triethoxysilane was purified by vacuum 
distillation prior to use.  Thermogravimetric analysis (TGA) was performed using a 
Shimadzu TGA-50 equipped with a platinum pan and a heating rate of 3 °C per minute, 
under air.  A Hitachi 4700 field emission scanning electron microscope (SEM) and a JEM 
100CX-II transmission electron microscope (TEM) were used to determine particle size and 
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morphology.  A Cressington 108 Auto Sputter Coater equipped with a Au/Pd (80/20) target 
and an MTM-10 thickness monitor was used to coat the samples with a 5 nm thick 
conductive layer before taking SEM images.  Each SEM sample was prepared by suspending 
the nanoparticles in ethanol.  A drop of the suspension was then placed on a glass slide and 
the solvent was allowed to evaporate.  TEM samples were also prepared from ethanolic 
particle dispersions on amorphous carbon coated copper grids.  An Applied Research 
Laboratories (ARL) SpectraSpan 7 DCP spectrometer and a Varian 820-MS Inductively 
Couple Plasma mass spectrometer were used to measure Gd3+ concentrations.   
MR images were acquired on a Siemens 3 T Allegra (Siemens Medical Systems, 
Erlangen, Germany) with a CP head coil, and a 9.4 T Bruker BioSpec (Bruker Biospin, 
Ettlingen, Germany) system with a 35 mm quadrature RF transmit and receive coil.  For the 3 
T scanner, a 3D FLASH sequence was utilized to compute T1 maps with seven different flip 
angles (2, 5, 10, 20, 30, 40, and 60).  Imaging parameters were:  FOV=190x 190*64 mm3, 
Matrix size=128 x 128 *32, TR/TE= 40/1.64 ms, total data acquisition time was 19 minutes.  
A 2-D multiple echo spin echo sequence was used to estimate T2 maps.  In total, 32 echoes 
with an echo spacing of 6.2 ms were obtained.  The first echo time was 6.2 ms. TR was 3000 
ms.  FOV and matrix size were set to 190x 190 mm2 and 128 x 128.  The slice thickness was 
2 mm.  The total data acquisition time was about 6 minutes and 29 seconds.  All images were 
acquired on a 9.4 T Bruker BioSpec (Bruker Biospin, Ettlingen, Germany) system with a 35 
mm quadrature RF transmit and receive coil.  For the 9.4 T scanner, two 2D multiple echo 
spin echo sequences were used to estimate T2 maps for a wide range of T2.  FOV and matrix 
size were set to 35 x 30 mm2 and 128 x 128.  The slice thickness was 1 mm.  In total, 32 
echoes with an echo spacing of 3.7 ms for sequence 1 and 40 echoes with an echo spacing of 
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10 ms for sequence 2 were obtained.  The TR/TE1 were 3.7/3000 ms and 10/4114 ms for 
each sequence, respectively.  The total data acquisition time was about 10 minutes.  T1 maps 
were obtained with a variable TR rapid acquisition relaxation enhanced (RARE) sequence 
with a TE=5.14 ms.  Twenty two variable TRs (TR=18, 25, 40, 60, 90, 120, 160, 200, 250, 
300, 380, 500, 700, 1000, 1500, 2000, 2500, 3000, 4000, 5000, 6000, 7000 ms) were used 
with a FOV of 35x30 mm2 and a matrix size of 128 x 128.  RARE factor was 3 and total data 
acquisition was about 24 minutes. 
 
3.4.2 Ligand and Gd Complex Synthesis 
Diethylenetriaminepenta(acetic acid)-ethyldisulfanylpropyltriethoxysilane-Gd 
complex (Si-S-S-DTPA-Gd).  0.200 g (0.5589 mmol) of DTPA-bisanhydride was dissolved 
in 4 mL of anhydrous DMSO in a 2-neck round bottom flask.  0.0834 g (0.4478 mmol) of 2-
pyridyldisulfanylethylamine was dissolved in 1 mL of anhydrous DMSO.  This solution was 
then added dropwise to the DTPA-bisanhydride solution.  After the addition was complete 
the reaction was stirred at room temperature, under N2, overnight.  The product was then 
precipitated upon the addition of acetone and diethyl ether.  The product (DTPA-PDS) was 
isolated by centrifuging, and was washed with additional acetone and diethyl ether.  Yield: 
0.2671 g, (0.4756 mmol, 106.2 %)  0.200 g (0.3561 mmol) of the DTPA-PDS ligand was 
dissolved in 0.71 mL of 2 M NaOH (1.4244 mmol, 4 eq).  0.1324 g (0.356 mmol) of 
GdCl3·6H2O was dissolved in ~0.5 mL of water.  This solution was then slowly added to the 
ligand solution.  After all the GdCl3 had been added, the solution was stirred at room 
temperature for an additional 30 minutes.  The product was then precipitated upon the 
addition of acetone, and was collected by centrifuging.  Yield: 0.20481 g (0.2787 mmol, 78.3 
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%)  A disulfide exchange reaction was then performed to obtain the desired product.  2.6728 
g (3.637 mmol) of the monoPDS-DTPA-Gd complex was dissolved in 50 mL of methanol.  
The solution was then filtered to remove any insoluble impurities.  0.973 mL (0.960 g, 4.028 
mmol) of 3-mercaptopropyltriethoxysilane was then added, and the reaction was stirred at 
room temperature, under N2, overnight.  The reaction solution was then concentrated, and the 
product was precipitated upon the addition of diethyl ether.  Yield: 2.1583 g (2.503 mmol, 
74.6 %) 
Synthesis of triethoxysilylpropyl carbamoyl-poly(ethylene glycol)2000.  1.000 g 
(0.50 mmol) of poly(ethylene glycol)-2000-monomethylether was dried under vacuum at  
100 °C for 1 hour.  After cooling to room temperature, under N2, the PEG was dissolved in 3 
mL of anhydrous DMSO.  0.124 mL (0.124 g, 0.50 mmol) of distilled (3-
isocyanatopropyl)triethoxysilane was then added, followed by 1 µL of Hünig base (0.742 
mg, 0.0057 mmol, 1.15 mol %).  The reaction was then stirred at room temperature, under 
N2, for 24 hours.  The DMSO was then removed under vacuum at 50°C.  1H NMR (DMSO-
d6, 300 MHz,): δ 0.51 (t, 2H), δ 1.14 (t, 9H), δ 1.43 (t, 2H), δ 2.92 (q, 2H), δ 3.35 (s, 3H), δ 
3.50 (s, 128H), δ 3.73 (q, 6H), δ 4.03 (t, 2H), δ 7.22 (t, 1H). 
 
3.4.3 MSN Synthesis 
Large Pore MSN Particles.  0.400 g (1.096 mmol) of cetyltrimethylammonium 
bromide (CTAB) was dissolved in 192 mL of distilled H2O, along with 1.4 mL of 2 M 
sodium hydroxide and 2.8 mL (19.52 mmol) of mesitylene.  This solution was then heated to 
80 °C.  Once the reaction had reached 80 °C, 2.0 mL (1.868 g, 8.96 mmol) of 
tetraethylorthosilicate (TEOS) was rapidly injected.  The reaction was then stirred for an 
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additional 2 hours at 80 °C.  At the completion of the reaction the particles were isolated by 
centrifuging at 10,000 rpm for 10 minutes.  They were then washed with H2O and ethanol, 
before being redispersed in 80 mL of ethanol.  The surfactant was extracted from the 
mesoporous materials using a 1 volume % solution of HCl in methanol.  The particles were 
dispersed in the HCl/MeOH solution at a concentration of approximately 3.5 mg/mL.  After 
stirring at 60 °C for 3 hours, the particles were isolated by centrifuging, and then redispersed 
in another aliquot of the HCl/MeOH solution.  The extraction was performed a total of three 
times.  After the final extraction, the particles were washed with distilled H2O and ethanol, 
before being redispersed in ethanol. 
Coating of MSN with Si-S-S-DTPA-Gd complex.  Approximately 400 mg of 
extracted MSN particles were suspended in 13 mL of toluene.  0.150 g (0.174 mmol) of the 
Si-S-S-DTPA-Gd complex was then dissolved in 1 mL of distilled water, and this solution 
was added to the reaction mixture.  The mixture was then heated to reflux overnight.  The 
particles were isolated by centrifuging, and were washed with distilled water and ethanol, 
before being redispersed in ethanol.  In order to remove any adsorbed Gd complexes the 
particles were the dialyzed against 250 mL of distilled water for 4.5 hours, changing the 
water once an hour.   
Recoated MSN-LP-Gd.  In order to increase the Gd loading of the particles, the 
above coating procedure was repeated.  Approximately 190 mg of particles were dispersed in 
11 mL of toluene, and 0.075 g (0.087 mmol) of the Si-S-S-DTPA-Gd complex was dissolved 
in 0.75 mL of distilled water and added to the reaction.  The mixture was then heated to 
reflux overnight.  The particles were isolated by centrifuging, and washed with distilled 
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water and ethanol, before being redispersed in ethanol.  After coating, the particles were also 
dialyzed against 250 mL of distilled water for 4.5 hours 
PEG2000 Functionalization.  Approximately 100 mg of MSN-S-S-DPTA-Gd 
particles were dispersed in 8 mL of ethanol.  The pH was adjusted to approximately 9 using 
ammonium hydroxide.  20.8 mg of Si-PEG-2000 was then dissolved in 2 mL of ethanol, and 
this solution was added to the particle suspension.  The reaction was then stirred at room 
temperature 18 hours.  The particles were isolated by centrifuging at 13,000 rpm for 15 
minutes, and were washed twice with ethanol before being redispersed in 12 mL of ethanol.  
The particles were then dialyzed against 250 mL of distilled water for 5 hours, changing the 
water once an hour.   
 
 3.4.4 Release Profile 
 1.5 mL of an 18.08 mg/mL suspension of MSN-S-S-DTPA-Gd particles (27.12 mg) 
was centrifuged to isolate the particles, which were then redispersed in 2 mL of water.  This 
suspension was then placed inside a piece of dialysis tubing (MWCO 3500).  300 mL of 
distilled water was placed in a vessel and was heated to 37 °C in an oil bath.  The water was 
then degassed by bubbling with N2 for 20 minutes.  The dialysis bag containing the particles 
was then submerged.  After 30 minutes, a 10 mL aliquot of the dialysis water was removed, 
and was replaced with a 10 mL solution containing 0.3636 g (0.003 mol) of L-cysteine, 
giving a final cysteine concentration of 10 mM.  Aliquots were then removed at various time 
points.  Each aliquot that was removed was dried, and the residue was redissolved in 1.5 mL 
of 1 M nitric acid.  The Gd concentration of each sample was then measured using DCP. 
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4.1 Introduction 
 
Metal-organic frameworks (MOFs) are an interesting class of hybrid materials that 
are built from metal ion connectors and polydentate bridging ligands and have shown 
potential in a number of applications such as nonlinear optics,1,2 gas adsorption,3-6 catalysis,7-
9 and even controlled drug release.10,11  MOFs on the nanometer scale can offer an interesting 
approach to designing functional nanomaterials for biological and biomedical applications 
because of the ability to systematically tune their compositions via judicious choice of 
building blocks.  This tunability, provided by the ability to choose from a wide selection of 
metal ion connectors and an infinite number of organic bridging ligands, makes this class of 
nanomaterials much different than other well studied nanomaterials that are either purely 
inorganic or organic in composition.  To date, there have been very few publications on these 
nanoscale coordination polymer materials.   
Our group has previously utilized a reverse-phase microemulsion technique to 
synthesize nanoscale metal-organic frameworks (NMOFs) built from Gd3+ ions and two 
benzene carboxylate bridging ligand, 1,4-benzenedicarboxylate and 1,2,4-
benzenetricarboxylate.12 This synthetic technique can be applied to other metal and ligand 
combinations, however in some cases it led to gel-like amorphous materials presumably as a 
result of the rapid and irreversible metal-ligand coordination bond formation at room 
temperature.  As a result, alternative synthetic methods had to be developed in order to take 
full advantage of the intrinsic tunability of NMOFs in designing functional NMOFs for 
ultimate applications in imaging, biosensing, and drug delivery.  Hydrothermal reactions 
have proven to be an excellent method for the synthesis of a variety of nanomaterials.13-16  
Presumably, the elevated temperatures alter the relative kinetics for nucleation and 
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nanocrystal growth in favor of the formation of uniform nanomaterials under hydrothermal 
conditions.17,18   
Using these two techniques we were able to synthesize four new Gd3+ containing 
metal organic frameworks using three different bridging ligands.  Gd(III) NMOFs were 
developed as potential contrast agents for magnetic resonance imaging (MRI).  Contrast 
agents containing paramagnetic metal ions, such as Gd(III) and Mn(II), are often 
administered during an MRI scan in order to enhance contrast.  Incorporation of the 
paramagnetic ion in a nanoparticle platform further serves to increase the contrast enhancing 
ability by reducing the rotational diffusion rate, which results in increased relaxivity.  Using a 
nanoparticle platform also provides an increased payload; hundreds of thousands of metal 
centers can be incorporated into each NMOF particle.  This increased payload allows for the 
potential of site specific imaging because a single targeting moiety can deliver a very large 
payload of contrast agent.  The Gd-containing NMOFs can also be doped with a small 
percentage of other luminescent lanthanide ions, such as Tb(III) and Eu(III), forming 
multimodal contrast agents, i.e. optical and MR. 
 
4.2 Results and Discussion 
 4.2.1 Synthesis of Gd NMOFs 
 Two different Gd containing NMOFs were synthesized using aliphatic dicarboxylate 
ligands, succinic acid and adipic acid.  Both of these NMOFs can be synthesized using a high 
temperature surfactant assisted procedure, and the adipic acid NMOFs can also be obtained 
from a room temperature reaction.  Two different Gd NMOFs were also synthesized using 
benzene hexacarboxylate (BHC) as the bridging ligand.  By varying the pH of the reaction, 
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two different phases can be obtained from the same starting materials.  The Gd-BHC NMOFs 
were also synthesized using the high temperature surfactant assisted procedure. 
 Gd-succinic acid NMOFs (4-1) were synthesized by first forming two separate 
cetyltrimethylammonium bromide (CTAB)/1-hexanol/n-heptane/water microemulsions with 
W-values of 5 (W = water/surfactant ratio), one containing a 0.10 M solution of GdCl3 and 
the other containing a 0.075 M solution of succinic acid methyl ammonium salt.  Once the 
two microemulsions had formed, they were combined and transferred to a Teflon-lined Parr 
reactor.  The reaction was then heated in a 120 °C oven for 16 hours.  After cooling to room 
temperature, the product was isolated by centrifuging, and was washed with ethanol to 
remove the surfactant.  
 The Gd-adipic acid NMOFs (4-2) can be synthesized using either the room 
temperature microemulsion or the high temperature surfactant assisted method.  For the room 
temperature synthesis, two separate CTAB/1-hexanol/n-heptane/water microemulsions with 
W-values of 10 were formed using a 0.075 M solution of adipic acid sodium salt and a 0.10 
M solution of GdCl3.  Once the two microemulsions had formed, they were combined and 
stirred at room temperature for an additional 2 hours.  The product was then collected by 
centrifuging, and was washed with ethanol.  For the high-temperature surfactant assisted 
synthesis a similar procedure as that used for 4-1 was used.  Two W=5 CTAB/1-hexanol/n-
heptane/water microemulsions were formed using a 0.075 M adipic acid sodium salt solution 
and a 0.05 M GdCl3 solution.  After forming, the two microemulsions were combined and 
transferred to a Teflon-lined Parr reactor.  The reaction was then heated in a 120 °C oven for 
2.5 hours.  After cooling to room temperature, the particles were isolated by centrifuging and 
were washed with ethanol. 
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[Gd2(BHC)(H2O)6] nanoparticles (4-3) were synthesized using the high temperature 
surfactant assisted method.  Briefly, two CTAB/1-hexanol/n-heptane/water microemulsions 
with W = 10 were formed using a 0.1 M solution of BHC methylammonium salt and a 0.1 M 
solution of GdCl3.  After forming, the two microemulsions were combined and transferred to 
a Teflon-lined Parr reactor.  The reaction mixture was then heated at 120 °C for 18 hours to 
afford nanoparticles of [Gd2(BHC)(H2O)6].  The nanoparticles of 4-3 were isolated in 84.4% 
yield by centrifugation and washing with ethanol.  Eu3+ and Tb3+ doped nanoparticles of 4-3 
(4-3a and 4-3b, respectively) were also synthesized using a similar procedure, replacing 5 
mol% of GdCl3 with either TbCl3 or Eu(NO3)3.  In order to reduce aggregation the 4-3 
NMOFs were also coated with poly(vinylpyrrolidone) (PVP).  To a suspension of 1 mg of 4-
3 in 2 mL of ethanol was added 20 µL of a 5 mM solution of PVP in ethanol.  The reaction 
was then stirred at room temperature, overnight.  The particles were then isolated by 
centrifuging and were washed with additional ethanol. 
Nanorods of [Gd2(BHC)(H2O)8](H2O)2 (4-4) were also synthesized using a surfactant 
assisted method with microwave heating.  Two CTAB/1-hexanol/iso-octane/water 
microemulsions with W=10 were formed using a 0.1 M mellitic acid (BHC-H6) aqueous 
solution and a 0.2 M GdCl3 aqueous solution.  The two microemulsions were then combined 
and transferred to a microwave vessel.  The reaction was then heated to 60 °C in a 400 W 
microwave, and held at this temperature for 15 minutes.  The particles were then isolated by 
centrifuging and were washed with ethanol.  Using a similar procedure micron sized particles 
of 4-4 can be synthesized by increasing the reaction temperature to 120 °C.  Single crystals 
of 4-4 were synthesized by heating an aqueous solution of mellitic acid and GdCl3 in a 60 °C 
oven, overnight. 
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4.2.2 Characterization of NMOFs 
The NMOFs were characterized using a variety of methods.  First, the size and 
morphology of the particles were determined using scanning electron and transmission 
electron microscopies (SEM and TEM).  As seen in the SEM and TEM images the succinic 
acid NMOFs (4-1) were rods approximately 100-300 nm in diameter and had lengths ranging 
from 2 to 10 microns (Fig. 4.1-4.2).  Both the room temperature and high temperature 
syntheses of 4-2 yielded high aspect ratio nanorods.  The nanorods formed at room 
temperature are approximately 25-50 nm in diameter and range in length from approximately 
400-1500 nm (Fig. 4.3).  The nanorods formed at 120 °C are approximately 50-75 nm in 
diameter and 1 to 1.5 microns in length (Fig. 4.4). 
 
Figure 4.1.  SEM images of succinic acid-Gd nanorods (4-1). 
 
Figure 4.2.  TEM images of succinic acid-Gd nanorods (4-1). 
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Figure 4.3.  SEM images of adipic acid-Gd nanorods (4-2) synthesized at room temperature. 
 
  
Figure 4.4.  SEM images of adipic acid-Gd nanorods (4-2) synthesized at 120 °C. 
 
The SEM and TEM images revealed that NMOFs of 4-3 formed fairly uniform block 
like nanoparticles that are approximately 25 nm by 50 nm by 100 nm (Fig. 4.5-4.7).  NMOFs 
4-3a and 4-3b (Eu3+ and Tb3+ doped) had similar size and morphology to 4-3 (Fig. 4.8-4.11).  
When NMOF 4-4 was synthesized at 60 °C nanorods of approximately 100-300 nm in 
diameter and several microns in length were obtained (Fig. 4.12-4.13).  When the reaction 
temperature was increased to 120 °C, micrometer-sized particles with predominantly 
octahedra and truncated octahedra shapes along with a small fraction of nanorods were 
obtained (Fig. 4.14).   
 110
 
Figure 4.5.  SEM images of [Gd2(BHC)(H2O)6] nanoparticles (4-3). 
 
 
Figure 4.6.  SEM images of PVP coated [Gd2(BHC)(H2O)6] nanoparticles (4-3). 
 
Figure 4.7.  TEM images of [Gd2(BHC)(H2O)6] nanoparticles (4-3). 
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Figure 4.8.  SEM images of [Gd1.9Eu0.1(BHC)(H2O)6] (4-3a) nanoparticles. 
 
Figure 4.9.  SEM images of [Gd1.9Tb0.1(BHC)(H2O)6] (4-3b) nanoparticles. 
 
 
Figure 4.10.  TEM images of [Gd1.9Eu0.1(BHC)(H2O)6] (4-3a) nanoparticles. 
 
 
 
 
 
 
 
 112
 
Figure 4.11.  TEM images of [Gd1.9Tb0.1(BHC)(H2O)6] (4-3b) nanoparticles. 
 
Figure 4.12.  SEM images of [Gd2(BHC)(H2O)8](H2O)2 nanorods (4-4) synthesized at 60 °C. 
 
Figure 4.13.  TEM images of [Gd2(BHC)(H2O)8](H2O)2 nanorods (4-4) synthesized at 60 °C. 
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Figure 4.14.  SEM images of [Gd2(BHC)(H2O)8](H2O)2 nanorods (4-4) synthesized at 120 
°C. 
 
Powder X-ray diffraction was used to determine the crystallinity and in some cases 
the phase of the NMOFs obtained.  Both the succinic acid and adipic acid-Gd NMOFs (4-1 
and 4-2) were crystalline as seen in the PXRD patterns (Fig. 4.15-4.16).  The powder pattern 
obtained for 4-1 did not match any known phases, and the powder pattern for 4-2 was similar 
to a known phase, but not an exact match.19  Both the room temperature and high temperature 
syntheses gave NMOFs of the same phase. 
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Figure 4.15.  PXRD pattern of succinic acid-Gd nanorods (4-1). 
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Figure 4.16.  PXRD patterns for adipic acid-Gd nanorods (4-2) synthesized at room 
temperature (black) and 120 °C (red) compared to the known [Gd2(ad)3(H2O)4]xH2O phase19 
(blue). 
 
Powder X-ray diffraction studies showed that the nanoparticles of 4-3 are crystalline, 
and correspond to a known La bulk phase [La2(BHC)(H2O)6] (Fig. 4.17).20  The slight shift in 
the 2θ values is consistent with the smaller radius of Gd3+ vs. La3+ as a result of lanthanide 
contraction.  The crystal structure of 4-3 can thus be described as a 3D MOF with the (4,8) 
connecting nodes.  The Gd centers are 9-coordinate, binding to two chelating carboxylate and 
two bridging carboxylate groups from four different BHC ligands.  The water molecules 
occupy the three remaining coordination sites (Fig. 4.18a).  The BHC ligand binds to a total 
of eight Gd centers, with four carboxylate groups chelating to four Gd centers and the other 
two carboxylate groups bridging four Gd centers (Fig. 4.18b).  The four-connected Gd 
centers and eight-connected BHC ligands link to each other to form a 3D MOF with the 
fluorite topology (Fig. 4.18c).  Thermogravimetric analysis (TGA) results supported the 
formulation of 4-3 (Fig. 4.19).  TGA showed a weight loss of 4.68% in the 90-125 °C 
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temperature range and a loss of 9.67% from 160-225 °C, corresponding to the three 
coordinating water molecules (14.35% observed; 14.25% expected).  After loss of the BHC 
ligand in the 350-560 °C range, 46.58% of the mass remained, corresponding to Gd2O3 
(47.78% expected).  PXRD also confirmed that the Eu and Tb doped NMOFs (4-3a and 4-
3b) are of the same phase as 4-3 (Fig. 4.20). 
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Figure 4.17.  PXRD pattern of [Gd2(BHC)(H2O)6] nanoparticles (4-3) (red) compared to the 
simulated pattern from the known [La2(BHC)(H2O)6] phase (black). 
 
a c) 
b) 
) 
Figure 4.18.  (a) Gd coordination environment in 4-3.  (b) Linking of BHC ligand to eight 
different Gd centers in 4-3.  (c) Packing of 4-3 as viewed slightly off the b axis.  All the 
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figures were drawn using the cif file of isostructural [La2(BHC)(H2O)6] (the coordinated 
water molecules were omitted for clarity). 
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Figure 4.19.  TGA of [Gd2(BHC)(H2O)6] nanoparticles (4-3).   
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Figure 4.20.  PXRD patterns for [Gd2(BHC)(H2O)6] NMOFs (4-3) (black), Eu-doped (4-3a) 
(red) and Tb-doped (4-3b) (green). 
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PXRD studies indicated that the NMOFs 4-4 obtained from the reactions between 
mellitic acid and GdCl3 at 60 and 120 °C are of the same phase despite their very different 
morphologies (Fig. 4.21).  Single crystal X-ray diffraction studies were carried out using 
single crystals of 4-4.  These studies showed that 4-4 crystallizes in the centrosymmetric 
space group P21/n with one Gd(III) center, one half of the BHC ligand, four coordinating 
water molecules, and one included water solvate molecule in the asymmetric unit.  The BHC 
ligand sits on the inversion center and coordinates to four Gd centers in a chelating fashion 
and to two Gd centers in a monodentate fashion.  Each Gd center coordinates to two 
chelating carboxylates and one monodentate carboxylate from three different BHC ligands 
and four water molecules.  The BHC ligand thus acts as a six-connected node whereas the Gd 
center acts as a three-connected node to lead to a 3D framework with the inverse rutile 
topology (Fig. 4.22-26).  Thermogravimetric analysis (TGA) results supported the 
formulation of 4-4 (Fig. 4.27).  TGA showed a total weight loss of 19.72% in the 85-200 °C 
temperature range corresponding to the loss of 10 water molecules (21.7% expected).  After 
loss of the BHC ligand in the 390-540 °C range, 46% of the mass remained, corresponding to 
Gd2O3 (40.1% expected). 
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Figure 4.21.  PXRD pattern of 4-4 synthesized at 60 °C (blue) and 120 °C (red) compared to 
the simulated PXRD using X-ray structure of [Gd2(BHC)(H2O)8](H2O)2 single crystal 
(black). 
 
a) 
b) 
c) 
 
Figure 4.22.  (a) Gd coordination environment in 4-4.  (b) Linking of BHC ligand to six 
different Gd centers in 4-4.  (c) Packing of 4-4 as viewed slightly off the a axis (the 
coordinated water molecules were omitted for clarity).     
 
 119
 
Figure 4.23.  [Gd2(BHC)(H2O)8](H2O)2 (4-4) as viewed down the a axis.  The water 
molecules are omitted for clarity. 
 
Figure 4.24.  [Gd2(BHC)(H2O)8](H2O)2 (4-4) as viewed slightly off the c axis.  The water 
molecules are omitted for clarity. 
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Figure 4.25.  [Gd2(BHC)(H2O)8](H2O)2 (4-4) as viewed down the b axis.  The water 
molecules are omitted for clarity. 
 
Figure 4.26.  Network connectivity of 4-4 showing the rutile topology. 
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Figure. 4.27.  TGA of [Gd2(BHC)(H2O)8](H2O)2 nanoparticles (4-4) synthesized at 60 °C 
(blue) and 120 °C (red), and [Gd2(BHC)(H2O)8](H2O)2 single crystals (black). 
 
The synthesis of two different NMOFs based on the Gd/BHC building blocks is a 
result of the different metal-ligand coordination modes in 4-3 and 4-4.  PXRD studies further 
showed that the synthesis of 4-3 vs. 4-4 is pH dependent but not temperature dependent.  This 
work illustrates the ability to synthesize different NMOFs from the same metal/ligand 
combination by exploiting the versatile metal-ligand coordination modes.   
 
4.2.3 Relaxivity Measurements 
In order to evaluate the potential use of these NMOFs as contrast agents for magnetic 
resonance imaging, the relaxivity values of 4-2 and 4-3 were measured using a 3 T and a 9.4 
T MR scanner, respectively.  Nanoparticles of 4-2 were found to have fairly high longitudinal 
and transverse relaxivities.  The r1 for 4-2 measured at 3 T on a per Gd3+ basis was 8.5 mM-
1s-1 and the r2 was 14.5 mM-1s-1 (Fig. 4.28).  For comparison the r1 of commercially available 
Gd3+ containing contrast agents is on the order of 4-5 mM-1s-1.  These results indicate the 
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potential of these NMOFs for T1-weighted imaging.  The 4-3 particles were found to have a 
modest longitudinal relaxivity (r1) of 1.5 mM-1s-1 and an impressive transverse relaxivity (r2) 
of 122.6 mM-1s-1 on a per Gd basis at 9.4 T (Fig. 4.29-4.30).  Based on the particle size and 
the calculated crystal density, we determined the r1 and r2 values to be ~8.36 x 105 and ~6.83 
x 107 mM-1s-1 on a per particle basis, respectively.  This magnitude of r2 relaxivity is very 
large compared to other Gd containing nanoparticle contrast agents, and clearly indicates the 
potential of these nanoparticles in T2-weighted MR imaging.21-23  For comparison, Gd2O3 
nanoparticles synthesized by Tillement et. al. had r2 relaxivities of 28.9 mM-1s-1 when 
measured at 7 T.22 
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Figure. 4.28.  Relaxivity of adipic acid-Gd nanorods (4-2) measured at 3 T.  r1 = 8.5 mM-1s-1, r2 
= 14.5 mM-1s-1. 
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Figure 4.29.  Relaxivity of [Gd2(BHC)(H2O)6] nanoparticles (4-3) measured at 9.4 T.  r1 = 1.5 
mM-1s-1, r2 = 122.6 mM-1s-1. 
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Figure 4.30.  T1 (left) and T2-weighted (right) phantom images of [Gd2(BHC)(H2O)6] 
NMOFs (4-3) at 9.4 T (Gd3+ concentrations listed in mM). 
 
 
4.2.4 Luminescent Measurements 
NMOFs 4-3a and 4-3b exhibit characteristic Eu and Tb luminescence under 
ultraviolet excitation (Fig. 4.31-4.32).24  Emission and excitation spectra were obtained using 
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diluted ethanolic dispersions of the doped nanoparticles with excitation and emission 
wavelengths of 250 nm and 614 nm for 4-3a (Eu3+ doped) and 309 nm and 544 nm for 4-3b 
(Tb3+ doped).  The combination of luminescent and paramagnetic properties allows for 
possible multimodal imaging, i.e. optical and MR. 
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Figure 4.31.  Excitation (black) and emission (red) spectra of Eu-doped [Gd2(BHC)(H2O)6] 
NMOFs (4-3a).  The emission spectrum was taken with an excitation wavelength of 250 nm.  
The inset shows a photo taken of a suspension of 4-3a in ethanol under uv light (254 nm). 
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Figure 4.32.  Excitation (black) and emission (green) spectra of Tb-doped 
[Gd2(BHC)(H2O)6] NMOFs (4-3b).  The emission spectrum was taken with an excitation 
wavelength of 309 nm.  The inset shows a photo taken of a suspension of 4-3b in ethanol 
under uv light (254 nm). 
 
 
4.3. Conclusion 
In summary, we have synthesized four different Gd containing NMOFs with three 
different bridging ligands using both a room temperature microemulsion synthesis and a 
surfactant-assisted method at elevated temperatures.  In one case, two NMOFs of different 
particle sizes and morphologies were obtained using identical building blocks as a result of 
different metal-ligand coordination modes that are dependent on the pH of the reaction.  We 
have also shown the potential use of these NMOFs as contrast agents for magnetic resonance 
and optical imaging.   
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4.4 Experimental Details 
 4.4.1 Materials and Methods 
All starting materials and surfactants were purchased from Aldrich and used without 
further purification.  All solvents were purchased from Fisher.  Thermogravimetric analysis 
(TGA) was performed using a Shimadzu TGA-50 equipped with a platinum pan and heated 
at a rate of 3 °C per minute, under air.  Powder X-ray diffraction (PXRD) analyses were 
carried out using a Rigaku Multiflex powder diffractometer using Cu radiation or on a Bruker 
SMART APEX II diffractometer using Cu radiation.  In the latter, the PXRD patterns were 
processed with the APEX 2 package using phase ID plug-in.  A Hitachi 4700 field emission 
scanning electron microscope (SEM) and a JEM 100CX-II transmission electron microscope 
(TEM) were used to determine particle size and morphology.  A Cressington 108 Auto 
Sputter Coater equipped with a Au/Pd (80/20) target and an MTM-10 thickness monitor was 
used to coat the samples with a 5 nm thick conductive layer before taking SEM images.  
Each SEM sample was prepared by suspending the nanoparticles in ethanol.  A drop of the 
suspension was then placed on a glass slide and the solvent was allowed to evaporate.  TEM 
samples were also prepared from ethanolic particle dispersions on amorphous carbon coated 
copper grids.  An Applied Research Laboratories (ARL) SpectraSpan 7 DCP spectrometer 
and a Varian 820-MS Inductively Couple Plasma mass spectrometer were used to measure 
Gd3+ concentrations.  Excitation and emission spectra were taken on a Shimadzu RF-5301PC 
fluorimeter. 
The methyl ammonium salts of the ligands were made by dissolving the ligand in a 
40 wt % solution of methyl amine in water.  The excess methyl amine and water were then 
evaporated under reduced pressure, and the isolated salt was then redissolved in distilled 
 127
water to give an aqueous solution of desired concentration.  The sodium salts of the ligands 
were made by dissolving the ligand and the appropriate amount of NaOH in water, and then 
diluting to give the desired concentration.    
T1 and T2 values were acquired on a Siemens 3 T Allegra (Siemens Medical Systems, 
Erlangen, Germany) with a CP head coil, and a 9.4 T Bruker BioSpec (Bruker Biospin, 
Ettlingen, Germany) system with a 35 mm quadrature RF transmit and receive coil.  For the 3 
T scanner, a 3D FLASH sequence was utilized to compute T1 maps with seven different flip 
angles (2, 5, 10, 20, 30, 40, and 60).  Imaging parameters were:  FOV=190 x 190*64 mm3, 
Matrix size=128 x 128 * 32, TR/TE= 40/1.64 ms, total data acquisition time was 19 minutes.  
A 2-D multiple echo spin echo sequence was used to estimate T2 maps.  In total, 32 echoes 
with an echo spacing of 6.2 ms were obtained.  The first echo time was 6.2 ms.  TR was 3000 
ms.  FOV and matrix size were set to 190 x 190 mm2 and 128 x 128.  The slice thickness was 
2 mm.  The total data acquisition time was about 6 minutes and 29 seconds.  For the 9.4 T 
scanner, two 2D multiple echo spin echo sequences were used to estimate T2 maps for a wide 
range of T2.  FOV and matrix size were set to 35 x 30 mm2 and 128 x 128.  The slice 
thickness was 1 mm.  In total, 32 echoes with an echo spacing of 3.7 ms for sequence 1 and 
40 echoes with an echo spacing of 10 ms for sequence 2 were obtained.  The TR/TE1 were 
3.7/3000 ms and 10/4114 ms for each sequence, respectively.  The total data acquisition time 
was about 10 minutes.  T1 maps were obtained with a variable TR rapid acquisition relaxation 
enhanced (RARE) sequence with a TE=5.14 ms.  Twenty two variable TRs (TR=18, 25, 40, 
60, 90, 120, 160, 200, 250, 300, 380, 500, 700, 1000, 1500, 2000, 2500, 3000, 4000, 5000, 
6000, 7000 ms) were used with a FOV of 35x30 mm2 and a matrix size of 128 x 128.  RARE 
factor was 3 and total data acquisition was about 24 minutes. 
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 4.4.2 Synthesis of NMOFs 
 Succinic Acid-Gd nanoparticles (4-1) were prepared via the high temperature 
surfactant assisted method.  0.0911 g (0.25 mmol) of cetyltrimethylammonium bromide 
(CTAB) was added to 2 round bottom flasks.  5 mL of a 0.5 M solution of 1-hexanol in n-
heptane was then added, and the mixture was stirred for 10 minutes at room temperature.  A 
W = 5 microemulsion was then formed by the addition of 24 µL of a 0.075 M succinic acid 
methylammonium salt aqueous solution and 24 µL of a 0.10 M GdCl3 aqueous solution to 
the two separate 5 mL 0.05 M CTAB/0.5 M 1-hexanol/n-heptane mixtures while vigorously 
stirring at room temperature.  The separate microemulsions were stirred vigorously for 10 
minutes at room temperature, after which the they were combined, and the resultant 10 mL 
microemulsion with W = 5 was transferred to a Teflon-lined Parr reactor and heated to 120 
°C for 16 hours.  After cooling to room temperature, the nanoparticles were isolated via 
centrifugation at 13,000 rpm for 15 minutes.  After the removal of the supernatant, the 
particles were washed by redispersement via sonication in 5 mL of ethanol.  The ethanol 
suspension was then centrifuged again for 15 minutes at 13,000 rpm, to recover the 
nanoparticles.   
 Adipic Acid-Gd (4-2) nanoparticles were prepared either via the CTAB/1-hexanol/n-
heptane/water microemulsion system or the high temperature surfactant-assisted method.  
For the microemulsion synthesis, a W = 10 microemulsion was prepared by the addition of 
48 µL of a 0.075 M adipic acid sodium salt aqueous solution and 48 µL of a 0.10 M GdCl3 
aqueous solution to separate 5 mL aliquots of a 0.05 M CTAB/1-hexanol/n-heptane solution 
while vigorously stirring at room temperature.  The separate microemulsions were stirred 
vigorously for 10 minutes at room temperature, after which the two microemulsions were 
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combined, and the resultant 10 mL microemulsion with W = 5 was stirred for an additional 2 
hours at room temperature.  The nanoparticles were isolated via centrifugation at 10,000 rpm 
for 10 minutes.  After the removal of the supernatant, the particles were washed by 
redispersement via sonication in 5 mL of ethanol.  The ethanol suspension was then 
centrifuged again for 10 minutes at 10,000 rpm, to recover the nanoparticles.  For the high 
temperature surfactant assisted method, 0.0911 g (0.25 mmol) of CTAB was added to 2 
round bottom flasks.  5 mL of a 0.5 M solution of 1-hexanol in n-heptane was then added, 
and the mixture was stirred for 10 minutes at room temperature.  A W = 5 microemulsion was 
then formed by the addition of 24 µL of a 0.075 M adipic acid sodium salt aqueous solution 
and 24 µL of a 0.05 M GdCl3 aqueous solution to the two separate 5 mL 0.05 M CTAB/0.5 
M 1-hexanol/n-heptane mixtures while vigorously stirring at room temperature.  The separate 
microemulsions were stirred vigorously for 10 minutes at room temperature, after which the 
they were combined, and the resultant 10 mL microemulsion with W = 5 was transferred to a 
Teflon-lined Parr reactor and heated to 120 °C for 2.5 hours.  After cooling to room 
temperature, the nanoparticles were isolated via centrifugation at 13,000 rpm for 15 minutes.  
After the removal of the supernatant, the particles were washed by redispersement via 
sonication in 5 mL of ethanol.  The ethanol suspension was then centrifuged again for 15 
minutes at 13,000 rpm, to recover the nanoparticles. 
[Gd2(BHC)(H2O)6] nanoparticles (4-3) were prepared via the high temperature 
surfactant-assisted method.  0.0911 g (0.25 mmol) of CTAB was added to 2 round bottom 
flasks.  5 mL of a 0.5 M solution of 1-hexanol in n-heptane was then added to each flask, and 
the mixture was stirred for 10 minutes at room temperature.  Two W = 10 microemulsions 
were then formed by the addition of 48 µL of a 0.1 M mellitic acid methylammonium salt 
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aqueous solution and 48 µL of a 0.1 M GdCl3 aqueous solution to the two separate 5 mL 0.05 
M CTAB/0.5 M 1-hexanol/n-heptane mixtures while vigorously stirring at room temperature.  
The separate microemulsions were stirred vigorously for 10 minutes at room temperature, 
after which they were combined, and the resultant 10 mL microemulsion with W = 10 was 
transferred to a Teflon-lined Parr reactor and heated to 120 °C for 18 hours.  After cooling to 
room temperature, the nanoparticles were isolated via centrifugation at 13,000 rpm for 15 
minutes.  After the removal of the supernatant, the particles were washed by redispersement 
via sonication in 5 mL of ethanol.  The ethanol suspension was then centrifuged again for 15 
minutes at 13,000 rpm, to recover the nanoparticles.  Yield: 2.02 mg (84.4 %).  Nanoparticles 
of [Gd2(BHC)(H2O)6] were successfully doped with the photoluminescent lanthanide ions 
Eu3+ or Tb3+ by preparing nanoparticles of 4-3 using 5 mol % of the corresponding Eu3+ or 
Tb3+ salt.   
[Gd2(BHC)(H2O)8](H2O)2 nanorods (4-4) were prepared via a surfactant-assisted 
method at 60 °C.  0.4555 g (1.25 mmol) of CTAB was added to 2 round bottom flasks.  25 
mL of a 0.5 M solution of 1-hexanol in iso-octane was then added to each flask, and the 
mixtures were stirred for 10 minutes at room temperature.  Two W = 10 microemulsions were 
then formed by the addition of 225 µL of a 0.1 M mellitic acid aqueous solution and 225 µL 
of a 0.2 M GdCl3 aqueous solution to the two separate 25 mL 0.05 M CTAB/0.5 M 1-
hexanol/iso-octane mixtures while vigorously stirring at room temperature.  The separate 
microemulsions were stirred vigorously for 10 minutes at room temperature, after which the 
they were combined, and the resultant 50 mL microemulsion with W = 10 was transferred to 
a microwave vessel.  The reaction was then rapidly heated to 60 °C in a 400 W microwave.  
Once reaching 60 °C, the reaction was held at this temperature for 15 minutes.  After cooling 
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to room temperature, the nanoparticles were isolated via centrifugation at 13,000 rpm for 15 
minutes.  After the removal of the supernatant, the particles were washed by redispersement 
via sonication in 5 mL of ethanol.  The ethanol suspension was then centrifuged again for 15 
minutes at 13,000 rpm, to recover the nanoparticles.  Yield: 1.63 mg (11.1 %).  Micron sized 
particles of 4-4 can also be synthesized in 9.1 % yield using this procedure, increasing the 
reaction temperature to 120 °C.   
 
4.4.3 Single Crystal Data 
Single crystals of [Gd2(BHC)(H2O)8](H2O)2  (4-4) were formed by first dissolving 
0.855 mg (2.50 µmol) of mellitic acid in 0.5 mL of distilled water.  50 µL of a 0.1 M GdCl3 
(5.0 µmol) was then added.  The vial was capped and placed in a 60 °C oven, overnight. 
Single-crystal X-ray diffraction data were measured at 293 K on a Bruker SMART 
Apex II CCD-based X-ray diffractometer system equipped with a Mo-target X-ray tube (λ = 
0.71073 Å).  Crystal data for 4-4: Monoclinic, space group: P21/n, a = 8.4856(12) Å, b = 
13.1281(17) Å, c = 9.5225(13) Å, α = 90º, β = 94.620(3)º, γ = 90º, V = 1057.4(2) Å3, Z = 2, 
ρcalcd = 2.546 g/cm3, μ(Mo Kα) = 6.328 mm-1, 2θmax=55.0°, Data/restrains/parameters: 
2188/0/163 , R1(I > 2σ(I)) = 0.0301, wR2 = 0.1076, R1(all data) = 0.0317, wR2(all data) = 
0.1099, GOF = 0.992. 
 
4.4.4 Calculations 
Calculation to explain peak shift in PXRD of 4-3 as compared to the 
[La2(BHC)(H2O)6] single crystal phase. 
θλ sin2dn =  
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Calculated La phase (2 0 0) reflection: 2θ = 12.96° 
Experimental Gd phase (2 0 0) reflection: 2θ = 13.18° 
λ = 1.5418 Å, n = 1 
La phase – d-spacing: 
831.6
)48.6sin(2
5418.1
sin2
=
=
=
d
d
nd θ
λ
 
a = 2d 
a = 13.662 Å 
Gd phase – d-spacing: 
717.6
)59.6sin(2
5418.1
sin2
=
=
=
d
d
nd θ
λ
 
a = 2d 
a = 13.434 
Difference in length a = 0.228 Å (i.e., experimentally, the a axis length is 0.228 shorter for 
the Gd phase than the La phase). 
Difference in ionic radii × 2 = 0.188 Å (i.e., based on lanthanide contraction, the a axis 
length is expected to be 0.188 shorter for the Gd phase than the La phase) 
Calculation of number of Gd per particle 
density of 1 = 2.809 g/cm3 
cell volume = 897.185 Å3 
Approximate size of NMOF = 25 nm x 50 nm x 100 nm 
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NMOF volume = 1.25 x 10-16 cm3 
Mass of NMOF = 3.511 x 10-16 g 
NMOFs are 41.45 wt% Gd, so one NMOF contains 1.4554 x 10-16 g of Gd 
1.4554 x 10-16 g of Gd ~ 5.574 x 105 atoms/particle 
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Manganese-Based Nanoscale Metal-Organic Frameworks for Magnetic Resonance 
Imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Portions of this chapter were adapted from Taylor, K. M. L.; Rieter, W. J.; Lin, W. J. Am. 
Chem. Soc. 2008, 130 (44), 14358-14359.) 
 
 
 
 
 
5.1 Introduction 
 
 Magnetic resonance imaging (MRI) is a powerful non-invasive diagnostic tool that 
provides high spatial resolution images and does not involve radioactivity.1  Intrinsically low 
sensitivity of MRI however necessitates the use of contrast agents that are often administered 
in high doses.2-3  Paramagnetic and superparamagnetic nanomaterials have recently emerged 
as promising MR contrast agents owing to their ability to carry large payloads of magnetic 
centers.4-9  They can work at very low concentrations and be made target-specific by 
conjugation with affinity molecules.10 
The majority of the commercially available MRI contrast agents are Gd(III) 
complexes formed with chelating ligands such as DTPA or DOTA.  The stability of these 
complexes is a major concern due to the high toxicity of free Gd3+ ions (LD50 for the Gd(III) 
aqua ion is 0.1 mmol/kg body weight for mice11).  There are currently only two Mn(II) 
containing contrast agents approved for use:  MnCl2 and Mn(DPDP).  These manganese 
contrast agents differ from the gadolinium contrast agents in that they work by releasing free 
Mn2+ ions in order to increase the longitudinal relaxation rate.  Mn2+ ions are much less toxic 
than Gd3+ ions and have been shown to exhibit very high in vivo longitudinal (r1) MR 
relaxivities by binding to intracellular proteins.12  The ideal situation for a manganese-
containing contrast agent would be to have a compound that has a good short-term stability 
in water, so that it can be delivered to the desired cells, and then once inside the cells it 
would break down to release free Mn2+ ions.   
 We have synthesized two Mn containing nanoscale metal-organic frameworks 
(NMOFs) and evaluated their potential as MRI contrast enhancing agents.  The as-
synthesized NMOFs have a relatively low stability in aqueous media, and therefore have 
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been stabilized with a silica shell, which also allows for the conjugation of targeting moieties 
and organic fluorophores.  The silica shell stabilization allows for delivery of the particles to 
sites of interest, where they will then release free Mn2+ ions which will increase the 
longitudinal relaxivity. 
 
5.2 Results and Discussion 
 5.2.1 NMOF Synthesis 
 Two different Mn NMOFs were synthesized with the bridging ligands terephthalic 
acid (BDC) and trimesic acid (BTC) using reverse-phase microemulsions.  Nanorods with 
the formula Mn(BDC)(H2O)2 (5-1) were synthesized by first forming two separate CTAB/1-
hexanol/n-heptane/water microemulsions with W-values of 5, one containing MnCl2 and the 
other containing the methyl ammonium salt of terephthalic acid, [NMeH3]2(BDC) (1:1 
BDC:Mn molar ratio).  After forming, the two microemulsions were combined and stirred for 
an additional 18 hours at room temperature.  The NMOFs were then isolated by centrifuging, 
and were washed with ethanol to remove the surfactant.  Nanoparticles of Mn3(BTC)2(H2O)6, 
(5-2), were similarly prepared using a CTAB/1-hexanol/iso-octane/water microemulsion with 
a W-value of 10.  In this case the trisodium salt of trimesic acid, Na3(BTC), was used along 
with MnCl2 in a molar ratio of 2:3.  After combining the two separate microemulsions the 
reaction was stirred at room temperature for 1 hour, after which time the particles were 
isolated by centrifuging, and were washed with ethanol. 
We also carried out surfactant-assisted synthesis of 5-1 and 5-2 under microwave 
heating in an attempt to alter their morphologies.  For the surfactant-assisted synthesis of 5-1 
two separate CTAB/1-hexanol/n-heptane/water microemulsions containing MnCl2 and 
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[NMeH3]2(BDC) in 1:1 molar ratio with a W-value of 10 were formed.  The microemulsions 
were then combined and heated at 120 °C for 10 minutes in an 800 W microwave.  Similarly, 
5-2 was synthesized by first forming two CTAB/1-hexanol/iso-octane/water microemulsions 
containing Na3(BTC) and MnCl2 (in 2:3 molar ratio) with a W-value of 10.  The two 
microemulsions were then combined and heated at 120 °C for 10 minutes in an 800 W 
microwave.   
 
5.2.2 Silica Coating 
In order to stabilize 5-2 against dissolution and facilitate further functionalization 
with a fluorophore and cell-targeting peptide, the particles were coated with a shell of 
amorphous silica.  The particles were first coated with poly(vinylpyrrolidone) (PVP).  After 
the particles had formed in the microemulsion, an aliquot of a 5 mM aqueous solution of 
PVP (MW=40,000) corresponding to 10 mol% was added to the microemulsion.  In the case 
of the microwave heated reactions, the reactions were allowed to cool to room temperature, 
after which time an aliquot of PVP was added and the reactions were stirred at room 
temperature for an additional 18 hours.  The particles were then isolated by centrifuging and 
were washed with ethanol to remove the surfactant and excess PVP.   
Silica-coated Mn3(BTC)2(H2O)6 nanoparticles (5-2’) were prepared by treating the 
PVP-coated particles with tetraethylorthosilicate (TEOS) under sol-gel conditions.  An 
aliquot of an ethanol suspension of PVP coated NMOFs was diluted with additional ethanol 
to give a particle concentration of about 0.5 mg/mL.  An aliquot of aqueous ammonia 
corresponding to 3 vol% (based on total volume of ethanol used) was diluted in ethanol then 
added to the particle suspension.  Finally, an aliquot of tetraethylorthosilicate (TEOS) 
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corresponding to ~3.8 µL/mg of particle was added and the reaction was stirred for two hours 
at room temperature.  The particles were then isolated by centrifuging and were washed with 
ethanol.  In order to obtain a thicker silica shell, the above reaction was repeated starting 
from the particles with a thin silica shell.  
 
5.2.3 Surface Functionalization 
In order to make the NMOFs target specific the surface was further functionalized 
with a cyclic arginine-glycine-aspartate (RGD) peptide.  An organic fluorophore (rhodamine 
B) was also added to the surface to make the particles visible using confocal microscopy.  
Both the c(RGDfK) peptide and rhodamine B isothiocyanate were first reacted with a 
propyltriethoxysilane derivative.  This allowed for covalent attachment of the peptide and 
fluorophore to the silica shell through the triethoxysilane functional group (Scheme 5.1)  
The peptide and fluorophore were immobilized onto the silica shell using the 
following procedure.  An aliquot of a suspension of 5-2’ was diluted to a final concentration 
of 2 mg/mL in ethanol.  An aliquot of aqueous ammonia corresponding to 4 vol% was then 
added.  Finally, aliquots of a 4 mg/mL solution of the modified c(RGDfK) in DMSO and a 6 
mM solution of RITC-APS in ethanol, corresponding to 10 wt% and 1.5 wt% respectively, 
were added to the particle suspension.  The reaction was then stirred at room temperature for 
24 hours.  The particles were then isolated by centrifuging and were washed with ethanol. 
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Scheme 5.1.  Schematic showing the coating and surface functionalization of NMOFs 5-2. 
 
5.2.4 Characterization of NMOFs 
The NMOFs were characterized using a variety of methods.  First, the size, 
morphology, and polydispersity of the particles were determined using scanning electron and 
transmission electron microscopies (SEM and TEM).  SEM and TEM micrographs show that 
particles of 5-1 synthesized at room temperature adopt a rod-like morphology with diameters 
of 50-100 nm and lengths of 750 nm-several µm (Fig. 5.1-5.3).  NMOFs of 5-1 synthesized 
at 120 °C show similar size and morphology to the particles synthesized at room temperature 
(Fig. 5.4).  SEM and TEM micrographs show that particles of 5-2 synthesized at room 
temperature are fairly uniform and adopt an unusual spiral rod morphology with diameters of 
50-100 nm and lengths of 1-2 µm (Fig. 5.5-5.7).  Unlike 5-1, 5-2 synthesized at 120 °C under 
microwave heating shows much different size and morphology when compared to the sample 
synthesized at room temperature.  SEM images showed that the particles obtained under 
microwave heating have a block-like morphology, with lengths ranging from ~50 to 300 nm 
in the three dimensions (Fig. 5.8-5.9). 
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Figure 5.1.  SEM images of Mn(BDC)(H2O)2 nanorods (5-1) synthesized at room 
temperature. 
 
Figure 5.2.  TEM images of Mn(BDC)(H2O)2 nanorods (5-1) synthesized at room 
temperature. 
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Figure 5.3.  Size distributions of Mn(BDC)(H2O)2 nanorods (5-1) synthesized at room 
temperature.  Left, diameter; Right, length. 
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Figure 5.4.  SEM images of Mn(BDC)(H2O)2 nanorods (5-1) synthesized at 120 °C under 
microwave heating. 
 
Figure 5.5.  SEM images of Mn3(BTC)2(H2O)6 nanoparticles (5-2) synthesized at room 
temperature. 
 
Figure 5.6. TEM images of Mn3(BTC)2(H2O)6 nanoparticles (5-2) synthesized at room 
temperature. 
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Figure 5.7.  Size distributions of Mn3(BTC)2(H2O)6 spiral nanorods (5-2) synthesized at room 
temperature.  Left, diameter; Right, length. 
 
Figure 5.8. SEM images of Mn3(BTC)2(H2O)6 nanoparticles (5-2) synthesized at 120 °C 
under microwave heating. 
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Figure 5.9.  Size distributions of Mn3(BTC)2(H2O)6 nanoparticles (5-2)synthesized at 120 °C 
under microwave heating. 
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Powder X-ray diffraction (PXRD) was used to determine the crystallinity and phase 
of the NMOFs obtained.  For 5-1 the PXRD pattern corresponded to a known bulk phase of 
Mn(BDC)(H2O)2 (Fig. 5.10-5.11).13  This formula was also confirmed using 
thermogravimetric analysis (TGA) and inductively coupled plasma – mass spectrometry 
(ICP-MS).  The TGA shows an initial weight loss of 11.5 wt% corresponding to the loss of 
two water molecules (expected:14.13 wt%, % difference: 20.5%) and a second weight loss of 
approximately 54.5 wt%, leaving 34 wt% remaining (Fig. 5.12).  Assuming the final product 
is MnO2, 34 wt% remaining corresponds to 21.49 wt% Mn (expected: 21.54 wt%, % 
difference: 0.23%).  ICP-MS analysis showed that the NMOFs are 22.6 wt% Mn (calculated: 
21.5 %, % difference: 4.99%).  The PXRD and TGA results also show that the NMOFs 
synthesized at room temperature and at 120 °C are of the same phase. 
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Figure 5.10.  Simulated PXRD pattern of the known Mn(BDC)(H2O)2 phase13 (pink), and 
experimental PXRD patterns for the bulk Mn(BDC)(H2O)2 particles (black), the 
Mn(BDC)(H2O)2 nanorods synthesized at room temperature (green), and the 
Mn(BDC)(H2O)2  nanorods synthesized at 120 °C (blue).   
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Figure 5.11.  Crystal Structure of known Mn(BDC)(H2O)2 phase.13 
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Figure 5.12.  TGA of Mn(BDC)(H2O)2 nanoparticles (5-1) synthesized at room temperature 
(blue), at 120 °C (green), and the bulk sample (pink).   
 
The NMOFs of 5-2 are crystalline based on PXRD, but do not correspond to any 
known phase of Mn-BTC MOFs (Fig. 5.13).14-15  Numerous attempts to grow single crystals 
of the corresponding phase were unsuccessful.  The composition of 5-2 [Mn3(BTC)2(H2O)6] 
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was established based on TGA and ICP-MS results.  The TGA showed an initial weight loss 
of 12.1 wt% corresponding to the loss of six water molecules (Calculated: 13.2 wt%, % 
difference = 8.3%), followed by a loss of about 50.9 wt% leaving 36.9 wt% remaining (Fig. 
5.14).  Assuming the final product is MnO2, 36.9 wt% remaining corresponds to 23.3 wt% 
Mn (expected: 24.0 wt%, % difference: 2.70%).  ICP-MS analysis showed that the NMOFs 
are 24.2 wt% Mn (calculated: 24.0 wt%, % difference: 0.83%). 
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Figure 5.13.  PXRD pattern of Mn3(BTC)2(H2O)6 bulk particles (pink), the Mn3(BTC)2(H2O)6 
nanoparticles synthesized at room temperature (black), the Mn3(BTC)2(H2O)6 nanoparticles 
synthesized at 120 °C (green), and the silica coated Mn3(BTC)2(H2O)6 nanoparticles (blue). 
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Figure 5.14.  TGA of Mn3(BTC)2(H2O)6 nanoparticles (5-2) synthesized at room 
temperature (blue), at 120 °C (green), and the bulk sample (pink). 
 
 
5.2.5 Characterization of Silica Coating 
The PVP and silica coating of NMOFs 5-2 was characterized using SEM, TEM, and 
TGA.  Upon coating with PVP less aggregation is seen in the SEM images (Fig. 5.15), and 
additional weight loss is seen in the TGA resulting from the increase in organic component 
(Fig. 5.16).  Upon coating with a silica shell, no difference is seen in the particle size and 
morphology in the SEM images (Fig. 5.17) or in the PXRD pattern (Fig. 5.13), however the 
presence of the silica shell can be seen in TEM images (Fig. 5.18-5.19).  The presence of the 
silica shell also results in an increase in the weight percent remaining after TGA (Fig. 5.16).   
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Figure 5.15.  SEM images of poly(vinylpyrrolidone)-modified Mn3(BTC)2(H2O)6 
nanoparticles (5-2) synthesized at room temperature. 
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Figure 5.16.  TGA of as synthesized Mn3(BTC)2(H2O)6 nanoparticles (5-2) (blue), PVP-coated 
(green), and silica coated (5-2’) (pink).   
 
 
 
 
 
 
 
0
20
40
60
0 100 200 300 400 500 600
Temperature (°C)
W
ei
gh
t %
 151
 
Figure 5.17.  SEM images of silica-coated Mn3(BTC)2(H2O)6 nanoparticles (5-2’) synthesized at 
room temperature. 
 
 
Figure 5.18.  TEM images of silica-coated Mn3(BTC)2(H2O)6 nanoparticles (5-2’) synthesized at 
room temperature. 
 
 
Figure 5.19.  TEM images of silica-coated Mn3(BTC)2(H2O)6 nanoparticles (5-2’) 
synthesized at 120 °C. 
 
5.2.6 Stability of NMOFs 
In order to evaluate the stability of the NMOFs, release profiles were performed in 
both water and phosphate buffered saline (PBS) at 37 °C.  In both water and PBS the silica 
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coating greatly slowed the dissolution and release of free Mn (Fig. 5.20-5.23).  For the 
uncoated NMOFs, 5-2, the half-life in water was found to be approximately 3.5 hours, while 
the silica coated NMOFs had a half-life of approximately 7.5 hours.  The half-life is defined 
as the point where 50% of the Mn2+ ions have been released from the particles.  In PBS the 
half-life was reduced to 18 minutes for the uncoated particles and 1.44 hours for the silica 
coated particles.  In PBS complete release of Mn2+ ions is never observed, likely due to the 
formation of insoluble manganese phosphate species.  For the calculation of half-life in PBS, 
it was assumed that the final data point represented 100% dissolution.  These results indicate 
the stabilization of the NMOFs by the silica coating, and suggest that silica-coated particles 
should have adequate time to reach the site of interest where they will then release free Mn2+ 
to give T1-weighted contrast enhancement.   
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Figure 5.20.  Dissolution curves of uncoated (blue) and silica coated (red) Mn3(BTC)2(H2O)6 
nanoparticles (5-2 and 5-2’) in water at 37 °C.  Percentage released versus time. 
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Figure 5.21.  Dissolution curves of uncoated (blue) and silica coated (red) Mn3(BTC)2(H2O)6 
nanoparticles (5-2 and 5-2’) in water at 37 °C.  [Mn] versus time. 
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Figure 5.22.  Dissolution curves of uncoated (blue) and silica coated (red) Mn3(BTC)2(H2O)6 
nanoparticles (5-2 and 5-2’) in PBS at 37 °C.  Percentage released versus time. 
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Figure 5.23.  Dissolution curves of uncoated (blue) and silica coated (red) Mn3(BTC)2(H2O)6 
nanoparticles (5-2 and 5-2’) in PBS at 37 °C.  [Mn] versus time. 
 
 
5.2.7 Relaxivity Measurements 
 
The MR relaxivities of 5-1 and 5-2 were determined using a 3 T scanner.  The 
relaxivities are determined by measuring the T1 and T2 values for a series of nanoparticle 
suspensions with [Mn] ranging from approximately 0.05 mM to 0.5 mM.  The exact [Mn] 
concentration of the suspensions is then determined afterwards using ICP-MS.  The slope of 
a plot of 1/T vs. [Mn] is the relaxivity value.  Nanorods of 5-1 were found to have a 
longitudinal relaxivity (r1) of 5.5 mM-1s-1 and a transverse relaxivity (r2) of 80.0 mM-1s-1 on a 
per Mn basis (Fig. 5.24), whereas nanorods of 5-2 exhibited an r1 of 7.8 mM-1s-1 and an r2 of 
70.8 mM-1s-1 on a per Mn basis (Fig. 5.25).  These results are similar to what is obtained for 
free Mn2+ ions in solution; MnCl2 has an r1 of 7.2 mM-1s-1 and an r2 of 72.3 mM-1s-1 (Fig. 
5.26).  Consistent with this, nanorods of 5-2 had an r1 of 4.6 mM-1s-1 and an r2 of 141.2 mM-
1s-1 on a per Mn basis at 9.4 T (Fig. 5.27).  5-2’ has slightly lower r1 of 4.0 mM-1s-1 and r2 of 
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112.8 mM-1s-1 at 9.4 T (Fig. 5.28).  The slight decrease of MR relaxivities is expected due to 
the reduced influence of the Mn centers on the surrounding water molecules.   
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Figure 5.24.  Relaxivity of Mn(BDC)(H2O)2 nanorods (5-1) measured at 3 T.  r1 = 5.5 mM-1s-1, 
r2 = 80.0 mM-1s-1. 
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Figure 5.25.  Relaxivity of Mn3(BTC)2(H2O)6 nanoparticles (5-2) measured at 3.0 T.  r1 = 
7.8 mM-1s-1, r2 = 70.8 mM-1s-1.   
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Figure 5.26.  Relaxivity of MnCl2 at 3 T.  r1 = 7.2 mM-1s-1, r2 = 72.3 mM-1s-1. 
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Figure 5.27.  Relaxivity of Mn3(BTC)2(H2O)6 nanoparticles (5-2) measured at 9.4 T.  r1 = 
4.6 mM-1s-1, r2 = 141.2 mM-1s-1.   
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Figure 5.28.  Relaxivity of Mn3(BTC)2(H2O)6 nanoparticles with a silica shell (5-2’) 
measured at 9.4 T.  r1 = 4.0 mM-1s-1, r2 = 112.8 mM-1s-1.   
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5.2.8 In Vitro and In Vivo Experiments 
We evaluated the efficacy of 5-2’ particles that have been surface-functionalized with 
rhodamine B and c(RGDfK) as MR and optical contrast agents in vitro.  Human colon cancer 
(HT-29) cells were incubated with rhodamine B-functionalized nanoparticles of 5-2’ with 
and without the c(RGDfK) targeting peptide.  In vitro MR imaging of HT-29 cells showed 
the selective uptake of 5-2’ and thus the intracellular delivery of Mn2+ ions.  As shown in 
Figure 5.29, the HT-29 cells incubated with the targeted particles gave much higher signals 
in T1-weighted MR images than those that were not incubated with nanoparticles as well as 
those that were incubated with the non-targeted particles.  Little difference was seen in the T2 
weighted images (Fig. 5.30).  ICP-MS analysis supported the enhanced uptake of 5-2’ by 
HT-29 cells: the cell pellets (~3.2 million cells) contained 0.05, 0.33, and 2.29 µg of Mn after 
incubating with no particles, non-targeted 5-2’, and targeted 5-2’, respectively.  Confocal 
microscopic imaging studies further confirmed the enhanced uptake of the particles with the 
targeting peptide, compared to those without the targeting peptide (Fig. 5.31-5.32).  These 
results demonstrate the target specific uptake of the c(RGDfK)-modified Mn NMOFs by 
angiogenic cancer cells, presumably via receptor-mediated endocytosis.  Finally, we also 
demonstrated the in vivo utility of Mn NMOFs for Mn2+ ion delivery.  T1-weighted contrast 
enhancement was observed in a mouse liver, kidneys, and aorta ~1 hour after tail vein 
injection of 5-2’ at a 10 µmol/kg Mn dose, apparently caused by the Mn2+ ions released from 
the nanoparticles (Fig. 5.33). 
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1 cm 
 
Figure 5.29.  In vitro T1-weighted MR images of HT-29 cells incubated with no 5-2’ (left), 
non-targeted 5-2’ (middle), and c(RGDfK)-targeted 5-2’ (right).   
 
1 cm 
 
Figure 5.30.  In vitro T2-weighted MR images of HT-29 cells incubated with no 5-2’ (left), 
non-targeted 5-2’ (middle), and c(RGDfK)-targeted 5-2’ (right).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 160
    
    
   
 
Figure 5.31.  Confocal images of HT-29 cells that were incubated with no 5-2’ (left), non-
targeted 5-2’ (middle), and c(RGDfK)-targeted 5-2’ (right).  The top, middle, and bottom images 
show the bright-field image, signal from the DRAQ5 nuclear stain (blue), and the signal from 
rhodamine B (red), respectively. 
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Figure 5.32.  Merged confocal images of HT-29 cells that were incubated with no 5-2’ (left), 
non-targeted 5-2’ (center), c(RGDfK)-targeted 5-2’ (right).  The blue color was from 
DRAQ5 used to stain the cell nuclei while the green color was from rhodamine B.  The bars 
represent 20 µm.   
 
 
Figure 5.33.  T1-weighted images of the midbody of a mouse model before contrast (left), 13 
minutes (middle) and 65 minutes (right) after the injection of 5-2’ (at a 10 μmol/kg Mn 
dose). 
 
 
5.3 Conclusion 
 In summary, we have synthesized Mn NMOFs with controllable morphologies and 
demonstrated their potential for MR contrast enhancement.  Surface functionalization of the 
Mn NMOFs with a cell-targeting molecule enhances their delivery to cancer cells to allow 
for target-specific MR imaging.  Such a core-shell nanostructure platform can be used for 
targeted delivery of other imaging and therapeutic agents. 
 162
5.4 Experimental Details 
 5.4.1 Materials and Methods 
 All starting materials and surfactants were purchased from Aldrich and used without 
re purchased from Fisher.  Microwave reactions were 
ter were then 
evapora
further purification.  All solvents we
carried out in a CEM MARS 5 microwave.  Thermogravimetric analysis (TGA) was 
performed using a Shimadzu TGA-50 equipped with a platinum pan and heated at a rate of 3 
°C per minute under air.  Powder X-ray diffraction (PXRD) analyses were carried out using a 
Rigaku Multiflex powder diffractometer using Cu radiation or on a Bruker SMART APEX II 
diffractometer using Cu radiation.  In the latter, the PXRD patterns were processed with the 
APEX 2 package using phase ID plug-in.  Scanning electron microscopy (SEM) was used to 
image the particles obtained from each reaction.  A Hitachi 4700 field emission scanning 
electron microscope was used.  A Cressington 108 Auto Sputter Coater equipped with a 
Au/Pd (80/20) target and an MTM-10 thickness monitor was used to coat the samples with a 
conductive layer before taking SEM images.  Each SEM sample was prepared by first 
suspending the nanomaterial in ethanol, then a drop of the suspension was placed on a glass 
slide and the solvent was allowed to evaporate.  An Applied Research Laboratories (ARL) 
SpectraSpan 7 DCP spectrometer and a Varian 820-MS Inductively Coupled Plasma-Mass 
Spectrometer were used to measure Mn2+ concentrations, for both stability tests and to 
accurately determine concentrations in samples from relaxivity measurements.  
The methyl ammonium salts of the ligands were made by dissolving the ligand in a 
40 wt % solution of methyl amine in water.  The excess methyl amine and wa
ted under reduced pressure, and the isolated salt was then redissolved in distilled 
water to give an aqueous solution of desired concentration.  The sodium salts of the ligands 
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were made by dissolving the ligand and the appropriate amount of NaOH in water, and then 
diluting to give the desired concentration.   
MR images were acquired on a Siemens 3 T Allegra (Siemens Medical Systems, 
Erlangen, Germany) with a CP head coil, and a 9.4 T Bruker BioSpec (Bruker Biospin, 
Ettlingen, Germany) system with a 35 mm quadrature RF transmit and receive coil.  For the 3 
T scanner, a 3D FLASH sequence was utilized to compute T1 maps with seven different flip 
angles (2, 5, 10, 20, 30, 40, and 60).  Imaging parameters were:  FOV=190 x 190*64 mm3, 
Matrix size=128 x 128 * 32, TR/TE= 40/1.64 ms, total data acquisition time was 19 minutes.  
A 2-D multiple echo spin echo sequence was used to estimate T2 maps.  In total, 32 echoes 
with an echo spacing of 6.2 ms were obtained.  The first echo time was 6.2 ms.  TR was 3000 
ms.  FOV and matrix size were set to 190 x 190 mm2 and 128 x 128.  The slice thickness was 
2 mm.  The total data acquisition time was about 6 minutes and 29 seconds.  For the 9.4 T 
scanner, two 2D multiple echo spin echo sequences were used to estimate T2 maps for a wide 
range of T2.  FOV and matrix size were set to 35 x 30 mm2 and 128 x 128.  The slice 
thickness was 1 mm.  In total, 32 echoes with an echo spacing of 3.7 ms for sequence 1 and 
40 echoes with an echo spacing of 10 ms for sequence 2 were obtained.  The TR/TE1 were 
3.7/3000 ms and 10/4114 ms for each sequence, respectively.  The total data acquisition time 
was about 10 minutes.  T1 maps were obtained with a variable TR rapid acquisition relaxation 
enhanced (RARE) sequence with a TE=5.14 ms.  Twenty two variable TRs (TR=18, 25, 40, 
60, 90, 120, 160, 200, 250, 300, 380, 500, 700, 1000, 1500, 2000, 2500, 3000, 4000, 5000, 
6000, 7000 ms) were used with a FOV of 35x30 mm2 and a matrix size of 128 x 128.  RARE 
factor was 3 and total data acquisition was about 24 minutes. 
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5.4.2 Synthesis and Surface Functionalization of Nanoscale Metal-Organic 
Frameworks. 
Room temperature synthesis of Mn(BDC)(H2O)2 nanorods (5-1).  
Mn(BDC)(H2O)2 nanoparticles were prepared via the CTAB/1-hexanol/iso-octane/water 
microe
 of 180 µL of a 0.1 M benzene 
dicarbo
mulsion system.  Two W = 5 microemulsions were prepared by the addition of 0.675 
mL of a 0.05 M benzene dicarboxylic acid methyl ammonium salt aqueous solution and 
0.675 mL of a 0.05 M MnCl2 aqueous solution to two separate 150 mL aliquots of a 0.05 M 
CTAB/0.5 M 1-hexanol/iso-octane mixture while vigorously stirring at room temperature.  
The separate microemulsions were stirred vigorously for 10 minutes at room temperature, 
after which the two microemulsions were combined, and the resultant 300 mL 
microemulsion with W = 5 was stirred for an additional 18 hours at room temperature.  The 
nanoparticles were isolated via centrifugation at 13,000 rpm for 10 minutes.  After the 
removal of the supernatant, the particles were washed by redispersement via sonication in 30 
mL of ethanol.  The ethanol suspension was then centrifuged again for 10 minutes at 13,000 
rpm to recover the nanoparticles.  Yield:  4.9 mg (66.3 %).  
High Temperature Synthesis of Mn(BDC)(H2O)2 nanorods (5-1).  Two 
microemulsions with W = 10 were prepared by the addition
xylic acid methylammonium salt aqueous solution and 180 µL of a 0.1 M MnCl2 
aqueous solution to separate 10 mL aliquots of a 0.1 M CTAB/0.5 M 1-hexanol/iso-octane 
mixture while vigorously stirring at room temperature.  The separate microemulsions were 
stirred vigorously for 10 minutes at room temperature, after which the two microemulsions 
were combined, and the resultant 20 mL microemulsion with W = 10 was transferred to a 
microwave vessel.  The reaction was then rapidly heated to 120 °C in the microwave.  Once 
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reaching 120 °C, the reaction was held at this temperature for 10 minutes.  After cooling, the 
nanoparticles were isolated via centrifugation at 13,000 rpm for 10 minutes.  After the 
removal of the supernatant, the particles were washed by redispersement via sonication in 5 
mL of ethanol.  The ethanol suspension was then centrifuged again for 10 minutes at 13,000 
rpm to recover the nanoparticles.  Yield:  3.6 mg (91.3 %) 
Room temperature synthesis of Mn3(BTC)2(H2O)6 nanorods (5-2).  
Mn3(BTC)2(H2O)6 nanorods were prepared via the CTAB/1-hexanol/iso-octane/water 
microe
pared by the addition of 90 µL of a 0.2 M 1,3,5-
benzen
mulsion system.  Two W = 10 microemulsions were prepared by the addition of 240 
µL of a 0.1 M 1,3,5-benzenetricarboxylic acid sodium salt aqueous solution and 240 µL of a 
0.15 M MnCl2 aqueous solution to two separate 25 mL aliquots of a 0.05 M CTAB/0.5 M 1-
hexanol/iso-octane mixture while vigorously stirring at room temperature.  The separate 
microemulsions were stirred vigorously for 10 minutes at room temperature, after which the 
two microemulsions were combined, and the resultant 50 mL microemulsion with W = 10 
was stirred for an additional 1 hour at room temperature.  The nanoparticles were isolated via 
centrifugation at 13,000 rpm for 10 minutes.  After the removal of the supernatant, the 
particles were washed by redispersement via sonication in 5 mL of ethanol.  The ethanol 
suspension was then centrifuged again for 10 minutes at 13,000 rpm to recover the 
nanoparticles. Yield:  5.1 mg (74.2 %). 
High temperature synthesis of Mn3(BTC)2(H2O)6 nanoparticles (5-2).  Two 
microemulsions with W = 10 were pre
etricarboxylic acid sodium salt aqueous solution and 90 µL of a 0.3 M MnCl2 aqueous 
solution to separate 10 mL aliquots of a 0.05 M CTAB/0.5 M 1-hexanol/iso-octane mixture 
while vigorously stirring at room temperature.  The separate microemulsions were stirred 
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vigorously for 10 minutes at room temperature, after which the two microemulsions were 
combined, and the resultant 20 mL microemulsion with W = 10 was transferred to a 
microwave vessel.  The reaction was then rapidly heated to 120 °C in the microwave.  Once 
reaching 120 °C, the reaction was held at this temperature for 10 minutes.  After cooling, the 
nanoparticles were isolated via centrifugation at 13,000 rpm for 10 minutes.  After the 
removal of the supernatant, the particles were washed by redispersement via sonication in 5 
mL of ethanol.  The ethanol suspension was then centrifuged again for 10 minutes at 13,000 
rpm to recover the nanoparticles.  Yield: 4.85 mg (93.1 %) 
Synthesis of Poly(vinylpyrrolidone)-modified Mn3(BTC)2(H2O)6 nanoparticles.  
PVP-coated Mn3(BTC)2(H2O)6 nanoparticles were prepared via the CTAB/1-hexanol/iso-
octane/water microemulsion system.  A W = 10 microemulsion was prepared by the addition 
of 48 µL of a 0.1 M 1,3,5-benzenetricarboxylic acid sodium salt aqueous solution and 48 µL 
of a 0.15 M MnCl2 aqueous solution to separate 5 mL aliquots of a 0.05 M CTAB/0.5 M 1-
hexanol/iso-octane mixture while vigorously stirring at room temperature.  The separate 
microemulsions were stirred vigorously for 10 minutes at room temperature, after which the 
two microemulsions were combined, and the resultant 10 mL microemulsion with W = 10 
was stirred for an additional 1 hour at room temperature.  After the particles had formed, 96 
µL of a 5 mM aqueous solution of PVP (10 mol%) was added to the microemulsion.  The 
reaction was then stirred at room temperature for an additional 2 hours. The coated 
nanoparticles were isolated via centrifugation at 13,000 rpm for 10 minutes.  After the 
removal of the supernatant, the particles were washed by redispersement via sonication in 5 
mL of ethanol.  The ethanol suspension was then centrifuged again for 10 minutes at 13,000 
rpm to recover the nanoparticles.  Similarly, Mn3(BTC)2(H2O)6 nanoparticles synthesized at 
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120 °C were cooled to room temperature, and an aliquot of an aqueous solution of PVP was 
added.  The resulting mixture was stirred at room temperature for 18 hours to afford PVP-
coated Mn3(BTC)2(H2O)6 nanoparticles. 
Synthesis of silica-coated Mn3(BTC)2(H2O)6 nanoparticles (5-2’).  Silica-coated 
Mn3(BTC)2(H2O)6 nanoparticles were prepared by treating the PVP-coated particles with 
tetraethylorthosilicate (TEOS) under sol-gel conditions.  9.0 mg of PVP coated 
Mn3(BTC)2(H2O)6 particles suspended in 9 mL of ethanol were placed in a round bottom 
flask.  0.54 mL of aqueous ammonia was diluted in an additional 9 mL of ethanol and added 
to the particle suspension (3 vol.% NH4OH).  34 µL of TEOS was then added to the stirring 
suspension, and the mixture was then stirred for an additional two hours at room temperature.  
The coated nanoparticles were isolated via centrifugation at 10,000 rpm for 10 minutes.  
After the removal of the supernatant, the particles were washed by redispersement via 
sonication in 5 mL of ethanol.  The ethanol suspension was then centrifuged again for 10 
minutes at 10,000 rpm to recover the nanoparticles.  To obtain at thicker silica shell, the 
above procedure was repeated.  For example, 7 mg of nanoparticles with a thin silica shell 
dispersed in 7 mL of ethanol were placed in a round bottom flask.  0.42 mL of aqueous 
ammonia was diluted in an additional 7 mL of ethanol and added to the particle suspension (3 
vol.% NH4OH).  27 µL of TEOS was then added to the stirring suspension, and the mixture 
was then stirred for an additional two hours at room temperature.  The coated nanoparticles 
were isolated via centrifugation at 10,000 rpm for 10 minutes.  After the removal of the 
supernatant, the particles were washed by redispersement via sonication in 5 mL of ethanol.  
The ethanol suspension was then centrifuged again for 10 minutes at 10,000 rpm to recover 
the nanoparticles.   
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Synthesis of tri(ethoxy)silylpropyl carbamoyl c(RGDfK).  Cyclic(RGDfK) (2.0 
mg, 3.313 μmol) was placed in a small round bottom flask and dried under high vacuum for 
1 hour. of 
thanol.  3.3 µL (3.1 mg, 0.0141 mmol) of 3-
aminop
g to 10 wt% and an aliquot of 
the 6 m
issolution studies of Mn(BDC)(H2O)2 nanorods.  1.5 mL of a suspension of 
Mn(BD nol (2.55 mg) was placed inside a piece of dialysis tubing 
(MWCO 3500).  The dialysis tubing was submerged in either distilled water or 8 mM 
  The c(RGDfK) was then dissolved in 0.5 mL of anhydrous DMSO and 0.2 μL 
Hünig base.  0.86 μL (3.44 μmol) of (3-isocyanatopropyl)triethoxysilane was then added, and 
the reaction was stirred under argon for 18 hours.  The solution (4 mg c(RGDfK)/mL 
DMSO) was placed in a freezer for later use. 
Synthesis of Rhodamine-APS.  6.8 mg (0.0127 mmol) of rhodamine B 
isothiocyanate was dissolved in 1.1 mL of e
ropyltriethoxy silane was then added, and the reaction was stirred at room 
temperature, under N2, and in the dark for 24 hours.  At the completion of the reaction the 
solution was diluted to a total volume of 2 mL with additional ethanol to make a solution 
with a rhodamine-APS concentration of approximately 6 mM. 
Synthesis of Rhodamine and c(RGDfK)-functionalized Mn3(BTC)2(H2O)6.  An 
aliquot of a 4 mg/mL c(RGDfK) DMSO solution correspondin
M solution of rhodamine-APS corresponding to 1.5 wt% were added to a dispersion 
of 5-2’ in 4 % NH4OH in ethanol (~2 mg/mL). The mixture was stirred at room temperature 
for 24 hours. The c(RGDfK)-functionalized nanoparticles were then isolated via 
centrifugation and washed with ethanol. 
 
5.4.3 Dissolution Studies 
D
C)(H2O)2 nanorods in etha
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phosph
ubing was submerged in either 
distilled
al Analysis of 5-1.  0.61 mg of Mn(BDC)(H2O)2 NMOFs (5-1) were 
digested in 2.865 mL of 15.8 M nitric acid, overnight.  The sample was then diluted to a total 
volume ion was further diluted to a total volume of 10 mL to 
give a 2
her diluted to a total volume of 10 mL to 
give a 2
ate buffer at 37 °C, with gentle stirring.  Aliquots of the solution were then removed 
at different time points.  The water was evaporated and the residue was redissolved in either 
1.2 mL of 1 M nitric acid for DCP measurements, or the aliquot was diluted and made into 4 
mL of a 2% nitric acid solution for ICP-MS measurements. 
Dissolution studies of Mn3(BTC)2(H2O)6 nanoparticles.  7.8 mg of Mn3(BTC)2-
(H2O)6 nanoparticles were dispersed in 2 mL of ethanol.  The suspension was placed inside a 
piece of dialysis tubing (MWCO 3500).  The dialysis t
 water or 8 mM phosphate buffer at 37 °C, with gentle stirring.  Aliquots of the 
solution were then removed a different time points.  The water was evaporated and the 
residue was redissolved in either 1.2 mL of 1 M nitric acid for DCP measurements, or the 
aliquot was diluted and made into 4 mL of a 2% nitric acid solution for ICP-MS 
measurements. 
 
5.4.4 ICP-MS Characterization 
Element
 of 50 mL, and 1 mL of this solut
% nitric acid solution of ICP-MS analysis.   
Elemental Analysis of 5-2.  1.24 mg of Mn3(BTC)2(H2O)6 NMOFs (5-2) were 
digested in 2.865 mL of 15.8 M nitric acid, overnight.  The sample was then diluted to a total 
volume of 50 mL, and 1 mL of this solution was furt
% nitric acid solution of ICP-MS analysis.   
 
 170
5.4.5 Imaging Studies 
In vitro labeling and fluorescence imaging of live cancer cells.  HT-29 cells were 
grown i  6-well plates on sterile glass cover slips at 37 °C in a 5% CO2 incubator containing 
10% FBS and 1% penicillin/streptomycin.  Cells were incubated in 1 mL fresh media with 
0.6 mg
ls were incubated in 1 mL fresh media and with 0.6 mg 5-2’ either with or 
withou
06 cells per flask) was 
observe
n
 5-2’ either with or without RGD targeting ligand for 1 hour at 37 °C in 5% CO2. Cells 
were washed three times with 2 mL of PBS (pH 7.4) per well, before the addition of 2 mL of 
fresh media.  Subsequently, 2 µL of DRAQ5 (5 mM) was added and allowed to incubate for 
30 minutes before imaging by laser scanning confocal fluorescence microscopy at the UNC 
Michael Hooker Microscopy Facility.  Images were merged and processed using Adobe 
Photoshop CS2.   
Elemental analysis of cancer cells incubated with 5-2’.  HT-29 cells were grown in 
6-well plates at 37 °C in a 5% CO2 incubator containing 10% FBS and 1% penicillin/ 
streptomycin.  Cel
t RGD targeting ligand for 1 hour at 37 °C in 5% CO2.  Cells were washed three times 
with 2 mL of PBS (pH 7.4) per well, before the addition of 2 mL of fresh media.  Finally, the 
cells were digested in 2 % nitric acid for ICP-MS elemental analysis. 
In Vitro MR Image Acquisition.  HT-29 cells were cultured in  25 cm3 T-flasks with 
McCoy’s 5A media (Cellgro) containing 10% FBS and 1% penicillin/streptomycin (12 mL) 
at 37°C and 5% CO2 until approximately 70% confluency (~3.2×1
d.  Cells were then washed with PBS (Aldrich), and incubated in 10 mL media with 
1.145 mg RGD-functionalized nanoparticles of 5-2’, 1.145 mg unfunctionalized 
nanoparticles of 5-2’, or negative control (media only).  After 30 minutes, the media was 
removed and cells were washed 3 times with PBS (10 mL) prior to trypsinizing and 
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 kg of body weight 
was int
 
  
centrifugation at 1500 rpm for 5 minutes.  Cell pellets were placed into small PCR tubes with 
200 µL PBS, then re-centrifuged (1500 rpm, 1 min) before MR imaging.  
In vivo T1-weighted midbody MR imaging.  An 8-week old female DBA/1J mouse 
was imaged in a Bruker 9.4 T Small Animal scanner.  After pre-contrast image acquisition of 
the animal midbody, a dose of 5-2’ corresponding to 10 µmol of Mn per
ravenously injected via the tail vein.  The animal was imaged at time points of 13 and 
65 minutes post-contrast administration. 
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CHAPTER 6 
 
Iron-Based Nanoscale Metal Organic Frameworks for Drug Delivery and Imaging 
 
6.1 Introduction 
 As discussed in the previous two chapters, metal-organic frameworks (MOFs) are a 
class of hybrid materials that have infinite tunability resulting from the large number of 
metals and the limitless number of organic bridging ligands that can be used.  MOFs can also 
be designed to exhibit unprecedentedly high porosity.  There have been several reports on 
M(III) containing MOFs that have extremely high surface areas and large pores.1-7  Three of 
these MOFs, known as MIL-53, MIL-88B, and MIL-101, are built using the same organic 
bridging ligand, terephthalic acid (BDC), connected by M(III) ions, where M = Cr(III), 
Fe(III), or Al(III).   
 MIL-53 has the formula MIII(OH)·[O2C-C6H4-CO2]·H2O (MIII = Cr, Fe).5  The pore 
size of this MOF changes depending on the treatment of the material.  As synthesized the 
pores contain free BDC molecules.  These guest molecules can be removed upon calcination 
to give the high temperature structure.  At room temperature, the MOF adsorbs atmospheric 
water to give the so-called low temperature structure which contains water molecules as 
guests.  The surface area and pore sizes of these materials change depending on the guest 
present in the framework.  The as-synthesized material shows no capacity for N2 adsorption, 
while both the high temperature and low temperature materials do.  The high temperature 
materials have Langmuir surface areas of greater than 1500 m2/g, and the hydrated low 
temperature materials have Langmuir surface areas of 1150 m2/g.5  Figure 6.1 shows the so-
called breathing effect of the material.4 
 
Figure 6.1.  View of the pore systems of (a) MIL-53as, (b) MIL-53ht, and (c) MIL-53lt. 
 MIL-88B and MIL-101 are also built from M(III) and BDC, but have different 
structures from MIL-53.  MIL-88B has the formula [M3IIIO(H2O)2X(BDC)3]·guest (M = Fe, 
Cr; X = F, Cl, acetate)7, and MIL-101 has the formula Cr3F(H2O)2O(BDC)3·nH2O (where n 
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is ~25).1  To date, the MIL-101 structure has only been reported using CrIII.  The MIL-101 
material has one of the highest surface areas reported for a MOF, with a Langmuir surface 
area that ranges for 4500 to 5500 m2/g for the as-synthesized material or 5900 m2/g for the 
activated material.1  MIL-101 contains two types of mesoporous cages within the framework, 
which have internal free diameters of ~29 Å and 34 Å.  These values correspond to 
e MIL-53 
ateria
e(III) NMOFs we utilized a surfactant free, solvothermal method, with 
microw
olecules can be covalently attached to the framework 
by reacting with these amine groups.   
accessible pore volumes of ~12,700 Å3 and ~20,600 Å3, respectively.1 
 Férey and co-workers have shown that they can use the large pores in these MOFs for 
loading of organic drug molecules.  They have shown that MIL-101 can adsorb 138 wt% 
ibuprofen, and MIL-53 can adsorb 20 wt%.8-9  The release of ibuprofen from the MOFs was 
evaluated using simulated body fluid at 37 °C.  It was found that the MIL-101 MOFs release 
ibuprofen slowly in several stages, reaching completion only after 6 days.8  Th
m l showed an even slower release, reaching completion only after 3 weeks.9 
 In order for these materials to be useful as in vivo drug delivery vehicles, the particle 
size must be carefully controlled.  As previously discussed, we have been able to synthesize 
nanoscale metal-organic frameworks (NMOFs) using several different methods, including 
reverse phase microemulsions, and high temperature surfactant assisted syntheses.  In order 
to synthesize these F
ave heating. 
A recent report showed that the BDC could be replaced with 2-aminoterephthalic acid 
in forming the three MOFs discussed above (MIL-53, MIL-88B, and MIL-101).10  The 
incorporation of an amine group in the framework of the materials allows for the possibility 
of post-synthetic modifications; other m
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Several groups have recently demonstrated post-synthetic modification using MOFs.  
The first report came from Stephen Lee and coworkers in 1999.  In this report they showed 
that they could react an alcohol functional group present in the channel of a MOF with 
trifluoroacetic anhydride to form the ester.11  In 2000, Kim and coworkers demonstrated the 
N-alkylation of pyridyl groups present in a homo-chiral MOF without changing the 
framework structure.12  In 2005, our group demonstrated the post-synthetic modification of a 
MOF resulting in an active heterogeneous catalyst.  In this case, Ti(OiPr)4 was reacted with 
the dihydroxy groups of a BINOL ligand present in the MOF to form the active catalyst.13  In 
2007, a report by Wang and Cohen, showed the post-synthetic modification of IRMOF-3, 
which is a MOF synthesized from Zn(NO3)2 and 2-aminoterephalic acid.14  They showed that 
they were able to react acetic anhydride with the amine groups present in the framework.  
Using 1H NMR integration, the percent conversion (acetylation) of IRMOF-3 was estimated 
to be greater than 80% after 5 days.14 
We have synthesized a series of Fe(III) NMOFs with either the MIL-101 or MIL-88B 
structure using terephthalic acid and 2-aminoterephthalic acid in varying ratios.  We have 
also been able to further functionalize these materials with imaging agents and anti-cancer 
drugs, using post-synthetic modification. 
  
6.2 Results and Discussion 
 6.2.1 Fe(III) NMOF Synthesis 
 Fe(III) NMOF particles were synthesized using a high temperature, surfactant free 
method, with microwave heating.  Terephthalic acid (BDC) was used as the bridging ligand, 
and dimethylformamide (DMF) was used as the solvent.  The particles were formed by 
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simply heating a solution of FeCl3 and terephthalic acid (1:1 ratio) in DMF to 150 °C using 
an 800 Watt microwave, and holding at this temperature for 10 minutes.  The particles were 
then isolated by centrifuging and were washed with DMF and ethanol to remove any 
unreacted starting materials.  Similar Fe(III) NMOFs could also be synthesized by replacing 
all or a percentage of the terephthalic acid with 2-aminoterephthalic acid (Table 6.1).  
Incorporation of the amino group allows for post-synthetic modification of the NMOFs. 
Table 6.1.  Composition and phase of Fe(III) NMOFs. 
Compound Mol% NH2BDC Mol% NH2BDC by NMR Phase 
6-1 0 - MIL-101 
6-2 5 6.6 MIL-101 
6-3 10 16 MIL-101 
6-4 12.5 - MIL-101 
6-5 15 - MIL-101 
6-6 17.5 17.4 MIL-101 
6-7 20 25 MIL-88B 
6-8 50 - MIL-88B 
6-9 100 - MIL-88B 
 
 
6.2.2 Characterization 
 The particles were characterized using a variety of methods.  The particle size and 
morphology was first determined using scanning electron microscopy (SEM).  The particles 
were found to have similar size and morphology regardless of the percentage of 
incorporation of 2-aminoterephthalic acid.  The particles had an unusual octahedron 
morphology and an average diameter of about 200 nm (Fig. 6.2-6.10).  Some reactions also 
resulted in the formation of micron sized particles, which could be easily separated from the 
desired particles by centrifuging at low speeds (3000 rpm).  
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Figure 6.2.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles (6-1). 
  
Figure 6.3.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 5 mol% 
NH2-BDC (6-2). 
 
  
 
Figure 6.4.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 10 mol% 
NH2-BDC (6-3). 
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Figure 6.5.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 12.5 
mol% NH2-BDC (6-4). 
 
  
 
Figure 6.6.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 15 mol% 
NH2-BDC (6-5). 
 
  
 
Figure 6.7.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 17.5 
mol% NH2-BDC (6-6). 
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Figure 6.8.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 20 mol% 
NH2-BDC (6-7). 
 
  
 
Figure 6.9.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 50 mol% 
NH2-BDC (6-8). 
 
  
 
Figure 6.10.  SEM images of Fe3O(DMF)3Cl(BDC)3 nanoparticles synthesized with 100 
mol% NH2-BDC (6-9). 
 
 Powder X-ray diffraction (PXRD) was used to determine the crystallinity and phase 
of the NMOFs obtained.  Comparisons to the simulated powder pattern for the known 
Cr3F(H2O)2O[(O2C)-C6H4-(CO2)]3·nH2O MOF (MIL-101), showed that the NMOFs 
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synthesized with 100% terephthalic acid (6-1) are the same phase (Fig. 6.11).1  The Fe(III) 
analog of the Cr(III) MIL-101 MOF has not been previously reported.  When the terephthalic 
acid was replaced with 2-aminoterephthalic acid, PXRD experiments showed that these 
particles were not the same phase.  It was found that the powder pattern for these particles 
matched the simulated powder pattern for the [Fe3O(H2O)2X(1,4-BDC)3]·guest (X=F, Cl, 
acetate) MOF known as MIL-88B (Fig. 6.12).7  For NMOFs 6-2 through 6-8 PXRD 
diffraction studies revealed that the phase obtained was dependent on the amount of 2-
aminoterephthalic acid incorporated.  NMOFs 6-2 through 6-6 (5 through 17.5% aminoBDC) 
were the MIL-101 phase, and particles with higher incorporation of 2-aminoterephthalic acid 
(6-7 and 6-8, 20 and 50%) were the MIL-88B phase (Fig. 6.13-6.14). 
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Figure 6.11.  PXRD pattern of NMOFs 6-1 (red) compared to the simulated pattern for MIL-
101 (blue). 
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Figure 6.12.  PXRD pattern of NMOFs 6-9 (red) compared to the simulated pattern for MIL-
88B (blue). 
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Figure 6.13.  PXRD pattern of NMOFs 6-2 (red), 6-3 (green), 6-4 (pink), 6-5 (black), and 6-
6 (light blue) compared to the simulated pattern for MIL-101 (dark blue). 
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Figure 6.14.  PXRD pattern of NMOFs 6-7 (red) and 6-8 (green) compared to the simulated 
pattern for MIL-88B (blue). 
 
 Since these particle synthesis reactions always gave low yields (~20%), the actual 
amount of incorporated 2-aminoterephthalic acid was determined by NMR.  The particles 
were first digested using silica-supported triaminetetraacetate sodium salt.  After the 
digestion was complete, the silica was removed by centrifuging and the supernatant was 
dried.  A methylation reaction was then performed by redissolving the residue obtained from 
drying the supernatant in methanol and adding a catalytic amount of concentrated sulfuric 
acid.  The reaction was then heated to reflux overnight.  The product was then extracted with 
ethyl acetate.  NMR was then used to determine the ratio between the methyl esters of 
terephthalic acid and 2-aminoterephthalic acid.  In most cases the incorporation of 2-
aminoterephthalic acid was slightly higher than the ratio added (Table 6.1). 
 The surface area of the NMOFs was evaluated using nitrogen sorption measurements.  
Uptake measurements on 6-1 indicated that the particles have Langmuir surface areas of 
ranging from approximately 3700 m2/g to 4535 m2/g and an average pore diameter ranging 
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from approximately 4.3 to 6.2 Å using the HK (Horvath-Kawazoe) method (Fig. 6.15-6.16).  
This surface area is lower than what was reported for the Cr(III) MIL-101 MOFs (4500-5900 
m2/g).1  The NMOFs synthesized with 100% 2-aminoterephthalic acid were also 
characterized using nitrogen uptake measurements.  These NMOFs were found to have an 
average Langmuir surface area of 2550 m2/g and an average HK pore diameter of 5.9 Å (Fig. 
6.17-6.18). 
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Figure 6.15.  Nitrogen sorption isotherm of NMOFs 6-1 synthesized using oven (blue-
adsorption, pink-desorption) and microwave heating (green-adsorption, red-desorption). 
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Figure 6.16.  Pore size distribution (HK method) for NMOFs 6-1 synthesized using oven 
heating (blue) or microwave heating (green). 
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Figure 6.17.  Nitrogen sorption isotherm of NMOFs 6-9 (blue-adsorption, pink-desorption). 
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Figure 6.18.  Pore size distribution (HK Method) for NMOFs 6-9. 
 
  
6.2.3 Post-Synthetic Modification 
 Using the primary amine groups in the structure of the framework different molecules 
can be covalently attached through post-synthetic modification.  This allows for the use of 
the NMOFs as delivery vehicles for various cargoes, by attaching the cargo to the 
framework.  We have demonstrated this idea for the use of delivering imaging agents and 
anti-cancer drugs using the amine functionalized NMOFs.  We have been able to attach 
several optical contrast agents, as well as a Gd3+ complex for potential MR imaging.  We 
have also been able to attach a Pt(IV) complex, which can be reduced in vivo to form the 
anti-cancer drug cisplatin. 
 Initial attempts at post synthetic modification were performed using 6-9.  The organic 
fluorophore, fluorescein, was covalently attached by reacting fluorescein isothiocyanate 
(FITC) with 6-9, in ethanol.  Once the reaction was complete the particles were isolated by 
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centrifuging, and were extensively washed with ethanol to remove any unbound fluorescein.  
The fluorescence from the bound fluorescein is quenched by the framework, so in order to 
determine the loading the particles were digested using ethylenediaminetetraacetate (EDTA).  
2-aminoterephthalic acid was also reacted with FITC to form the molecular complex.  This 
compound was then used to construct a calibration curve.  The emission intensity of the 
particle digestion solution was then used to calculate the amount of fluorescein that had been 
grafted.  The fluorescein loading was found to range from approximately 3 to 5.3 wt%.  
 Rhodamine B was also grafted onto 6-9.  Two different approaches were used to 
couple the carboxylate group from rhodamine B to the primary amine in the framework.  The 
first approach involved reaction rhodamine B with thionyl chloride to form the acyl chloride.  
This was then reacted with dried 6-9 in DMF.  The particles were isolated by centrifuging 
and extensively washed to remove any free dye.  The particles were then digested using 
EDTA and the emission intensity was measured.  Again the molecular complex was made by 
reacting rhodamine B with 2-aminoterephthalic acid, and this compound was used to 
construct a calibration curve.  Using this method a loading of only 0.2 wt% was obtained.  In 
order to increase the loading an alternate coupling method was employed.  In this case 
rhodamine B was first reacted with 1,1-carbonyldiimidazole (CDI) to activate the carboxylate 
group.  The rhodamine B imidazole was then reacted with 6-9 in DMF.  The particles were 
then isolated by centrifuging, and were extensively washed to remove any free rhodamine B.  
Again the particles were digested and the concentration of rhodamine B was determined by 
measuring the emission intensity.  Using this coupling method, a slightly higher loading of 
1.85 wt% was obtained. 
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 The third and final dye that was loaded into the NMOFs by post-synthetic 
modification was a derivative of boron-dipyrromethene (BODIPY) or 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene.  The 8-position was modified to contain a CH2-Br group, which 
could then react with the primary amine in the framework.  This dye has several advantages 
over the other two, including higher photostability and hydrophobicity.  It is much easier to 
remove any unreacted BODIPY dye from the NMOFs by washing with organic solvents.  
This dye was grafted onto 6-3 and 6-6 by simply combining the particles with a solution of 
the Br-BODIPY in tetrahydrofuran (THF) and stirring at room temperature for 2 days.  The 
particles were then isolated by centrifuging, and any unreacted dye was removed by washing 
with THF.  Again the loading was determined by digesting the particles with EDTA.  In this 
case the absorbance was used to quantify the amount of BDC-NH-BODIPY in the digested 
sample, and a calibration curve was constructed using the molecular BDC-NH-BODIPY 
compound that was synthesized independently.  The loadings for this dye ranged from 
approximately 5.6 wt% to 11.6 wt%. 
 In an attempt to formulate a new nanoparticle based contrast agent for MRI, a Gd 
chelate was also grafted onto the amine containing NMOFs.  This was done by first reacting 
DPTA dianhydride with particles 6-9.  The anhydride can then react with the primary amines 
in the framework to form an amide bond.  Once the DTPA had been grafted, Gd3+ ions were 
loaded into the DTPA chelating ligand by adding a solution of GdCl3 to a suspension of the 
DTPA functionalized NMOFs in water, and adjusting the pH to approximately 7.  After 
loading of the Gd, the particles were extensively washed, and were dialyzed against distilled 
water to remove any free Gd3+ ions.  
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 The Gd loaded particles were characterized using several methods including SEM, 
thermogravimetric analysis (TGA), PXRD, and inductively coupled–mass spectroscopy 
(ICP-MS).  SEM images showed no change in the particles after DTPA functionalization or 
Gd loading (Fig. 6.19).  TGA showed an increase in organic weight loss of approximately 2.6 
wt% for the DPTA functionalized NMOFs, and in increase in weight remaining of 
approximately 6.6 wt% for the Gd loaded particles, consistent with the increase in inorganic 
component (Fig. 6.20).  Powder X-ray diffraction confirmed that there was no change in the 
phase after the grafting of the Gd complex (Fig. 6.21).  ICP-MS was used to determine the 
Gd loading by comparing the ratio of Fe to Gd in a digested sample of functionalized 
particles.  The Fe/Gd ratio was found to range from approximately 4.1 to 6.0.   
     
 
Figure 6.19.  SEM images of NMOFs 6-9 as synthesized (left), after functionalization with 
DTPA (center), and after Gd loading (right). 
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Figure 6.20.  TGA of NMOFs 6-9 as synthesized (black), after functionalization with DTPA 
(blue), and after Gd loading (red). 
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Figure 6.21.  PXRD of 6-9 as synthesized (black), after functionalization with DTPA (blue), 
and after loading with Gd (red). 
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 The final post-synthetic modification attempted involved the grafting of a Pt(IV) 
complex.  This complex can be reduced to the Pt(II) anti-cancer drug cisplatin in vivo.  Two 
different approaches were tested to determine the most efficient grafting method.  The initial 
method consisted of reacting succinic anhydride with the primary amine groups of the 
frameworks 6-7 to 6-9.  The acyl chloride was then formed by adding thionyl chloride to a 
suspension of the carboxylic acid functionalized NMOFs in dry dichloromethane.  After the 
reaction was complete the solvent and excess thionyl chloride were removed under vacuum.  
The resulting acyl chloride was then reacted with c,c,t-[Pt(IV)Cl2(NH3)2(OH)(OEt)] in 
anhydrous DMF.  The particles were again isolated by centrifuging, extensively washed, and 
then dialyzed against distilled water to remove any free Pt complexes.   
 The Pt loaded particles were characterized using SEM, TGA, PXRD, and ICP-MS.  
The SEM images indicated some degradation of the particles after functionalizing with 
succinic acid (Fig. 6.22).  This could be a result of the succinic acid competing for 
coordination of the iron.  TGA analysis shows an increase of 6.94 wt% remaining after 
grafting of the Pt complex onto the succinic acid functionalized NMOFs, consistent with the 
increase in inorganic component (Fig. 6.23).  PXRD showed interesting results.  For 6-7 
(20% aminoBDC) there was no change in the phase after grafting of the Pt complex, the 
material remained the MIL-88B phase (Fig. 6.24).  For NMOFs 6-8 and 6-9, the material 
appeared to transform from the MIL-88B phase to the MIL-101 phase after grafting of the Pt 
complex (Fig. 6.25-6.26).  The Pt loading by ICP-MS varied greatly from batch to batch.  
Initial loadings gave Fe/Pt ratios as high as 2.5, however these results proved to be 
irreproducible and much lower loadings were consistently obtained for subsequent batches. 
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Figure 6.22.  SEM images of NMOFs 6-9 after functionalization with succinic acid (left) and 
after Pt loading (right). 
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Figure 6.23.  TGA of NMOFs 6-7 after functionalization with succinic acid (blue) and after 
loading with Pt (pink). 
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Figure 6.24.  PXRD pattern of NMOFs 6-7 as synthesized (blue) and after Pt loading (pink) 
compared to the simulated pattern for MIL-88B (black). 
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Figure 6.25.  PXRD of NMOFs 6-8 as synthesized (blue), succinic acid functionalized 
(pink), and Pt loaded (green). 
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Figure 6.26.  PXRD of NMOFs 6-9 as synthesized (blue), succinic acid functionalized 
(pink), and Pt loaded (green). 
 
 Based on the fact that the SEM showed degradation of the particles, and sufficient 
loadings were irreproducible an alternate method for Pt complex grafting was developed.  In 
addition, based on the fact that the MIL-101 phase has larger pores compared to the MIL-
88B phase, NMOFs 6-3 and 6-6 were used to maximize the Pt loading.  This method of Pt 
complex grafting consisted of first forming the c,c,t-[Pt(IV)Cl2(NH3)2(OEt)-
(O2CCH2CH2CO2H)] complex.  CDI coupling was then performed using by reacting 1,1-
carbonydiimidazole with c,c,t-[Pt(IV)Cl2(NH3)2(OEt)(O2CCH2CH2CO2H)].  The dried 
NMOFs 6-3 or 6-6 were then added to the DMF solution of the complex, and the reaction 
was stirred at room temperature.  The particles were then isolated by centrifuging, and were 
washed several times with DMF. 
 The particles were again characterized using SEM, PXRD, and ICP-MS.  SEM 
imaging showed no change in the particle size or morphology after Pt loading using this 
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method (Fig. 6.27-6.28).  PXRD showed that the Pt loaded particles retained the MIL-101 
structure (Fig. 6.29-6.30).  The ICP-MS results showed that the Fe/Pt ratio for 6-3 was 4.8.  
The theoretical maximum for the Pt loading if all of the amine groups react would give a 
Fe/Pt ratio of 1.79, so a Fe/Pt ratio of 4.8 represents a 37.3% conversion.  For 6-6, ICP-MS 
results revealed an Fe/Pt ratio of 4.1, which represents a 40.2% conversion. 
  
Figure 6.27.  SEM images of NMOFs 6-3 as synthesized (left) and after Pt loading using 
CDI coupling method (right). 
 
  
 
Figure 6.28.  SEM images of NMOFs 6-6 as synthesized (left) and after Pt loading using 
CDI coupling method (right). 
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Figure 6.29.  PXRD of NMOFs 6-3 as synthesized (blue) and after Pt loading using CDI 
coupling method (red).   
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Figure 6.30.  PXRD of NMOFs 6-6 as synthesized (blue) and after Pt loading using CDI 
coupling method (red).   
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6.2.4 Stability 
In order to determine if these Fe containing NMOFs were stable enough for in vitro 
and in vivo experiments, their stability was evaluated in phosphate buffer at 37 °C.  The Pt 
loaded NMOFs were used to evaluate the stability.  Approximately 2.5 mg of Pt loaded 6-6 
was placed inside a piece of dialysis tubing (MWCO = 3500) along with a few mL of the 
phosphate buffer.  The bag was then submerged in 8 mM phosphate buffer that had been 
heated to 37 °C.  Aliquots of the dialysis solution were then removed at various time points, 
and the Pt concentration was determined using ICP-MS.  The Pt loaded NMOFs were used to 
determine the stability because upon dissolution in phosphate buffer the Fe forms some 
insoluble complex, likely some form of iron phosphate, which is not released from the bag, 
therefore ICP-MS analysis for Fe does not give true stability results.  The ICP-MS results 
showed that the particles had a half life of just over 1 hour, i.e. about half of the Pt had been 
released (Fig. 6.31). 
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metal organic frameworks
incorporating an amine containing ligand, we
d to incorporate different functionalities.  We have shown that we can incorporate 
organic fluorophores and Gd3+ complexes to allow for the potential of optical and MR 
imaging.  We have also shown that we can successfully incorporate a Pt(IV) complex, which 
upon delivery can be reduced to the active Pt(II) anticancer drug. 
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6.4 Experimental Details 
 6.4.1 Materials and Methods 
All starting materials were purchased from Aldrich and used without further 
purification.  All solvents were purchased from Fisher.  Microwave reactions were carried 
out in a CEM MARS 5 microwave.  Thermogravimetric analysis (TGA) was performed 
using a Shimadzu TGA-50 equipped with a platinum pan and heated at a rate of 3 °C per 
minute under air.  Powder X-ray diffraction (PXRD) analyses were carried out using a 
Rigaku Multiflex powder diffractometer using Cu radiation or on a Bruker SMART APEX II 
diffractometer using Cu radiation.  In the latter, the PXRD patterns were processed with the 
e using phase ID plug-in.  A Hitachi 4700 field emission scanning electron 
microscope (SEM) and a JEM 100CX-II transmission electron microscope (TEM) were used 
to deter
S Inductively Coupled Plasma-Mass Spectrometer was used to measure Fe, 
Gd, and
APEX 2 packag
mine particle size and morphology.  A Cressington 108 Auto Sputter Coater equipped 
with a Au/Pd (80/20) target and an MTM-10 thickness monitor was used to coat the samples 
with a 5 nm thick conductive layer before taking SEM images.  Each SEM sample was 
prepared by suspending the nanoparticles in ethanol.  A drop of the suspension was then 
placed on a glass slide and the solvent was allowed to evaporate.  TEM samples were also 
prepared from ethanolic particle dispersions on amorphous carbon coated copper grids.  A 
Varian 820-M
 Pt concentrations.  
  
6.4.2 NMOF Synthesis 
Synthesis of MIL-101 Nanoparticles (6-1).  Fe3O(DMF)3Cl(BDC)3 nanoparticles 
(6-1)  were prepared using microwave heating.  0.0575 g (0.346 mmol) of terephthalic acid 
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and 0.0935 g (0.346 mmol) of FeCl3·H2O were dissolved in 15 mL of DMF.  The solution 
was placed in a HP500 microwave vessel, and the vessel was sealed.  The reaction was then 
rapidly heated to 150 °C, and was held at this temperature for 10 minutes.  After cooling to 
room te
d to 150 °C, and was held at this temperature for 10 minutes.  After cooling to 
room te
eated to 150 °C, and was held at this temperature for 10 minutes.  After cooling 
to room
mperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol.   
Synthesis of 5% amino-MIL Nanoparticles (6-2).  Nanoparticles of “5 %” amino 
BDC (6-2) were prepared using a similar procedure as above.  0.1097 g (0.6603 mmol) of 
terephthalic acid, 0.0063 g (0.0346 mmol) of 2-aminoterephthalic acid, and 0.186 g (0.692 
mmol) of FeCl3·H2O were dissolved in 30 mL of DMF.  The solution was placed in two 
HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction was then 
rapidly heate
mperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
Synthesis of “10%” amino-MIL Nanoparticles (6-3).  Nanoparticles of “10%” 
amino BDC (6-3) were prepared using a similar procedure as above.  0.1035 g (0.6228 
mmol) of terephthalic acid, 0.0125 g (0.0692 mmol) of 2-aminoterephthalic acid, and 0.186 g 
(0.692 mmol) of FeCl3·H2O were dissolved in 30 mL of DMF.  The solution was placed in 
two HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction was 
then rapidly h
 temperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
Synthesis of “12.5%” amino-MIL Nanoparticles (6-4).  Nanoparticles of “12.5%” 
amino BDC (6-4) were prepared using a similar procedure as above.  0.1976 g (1.189 mmol) 
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of terephthalic acid, 0.0313 g (0.173 mmol) of 2-aminoterephthalic acid, and 0.374 g (1.384 
mmol) of FeCl3·H2O were dissolved in 60 mL of DMF.  The solution was placed in four 
HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction was then 
rapidly heated to 150 °C, and was held at this temperature for 10 minutes.  After cooling to 
room te
d to 150 °C, and was held at this temperature for 10 minutes.  After cooling to 
room te
as then 
rapidly
mperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
Synthesis of “15%” amino-MIL Nanoparticles (6-5).  Nanoparticles of “15%” 
amino BDC (6-5) were prepared using a similar procedure as above.  0.1954 g (1.176 mmol) 
of terephthalic acid, 0.0376 g (0.2076 mmol) of 2-aminoterephthalic acid, and 0.374 g (1.384 
mmol) of FeCl3·H2O were dissolved in 60 mL of DMF.  The solution was placed in four 
HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction was then 
rapidly heate
mperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
Synthesis of “17.5%” amino-MIL Nanoparticles (6-6).  Nanoparticles of “17.5%” 
amino BDC (6-6) were prepared using a similar procedure as above.  0.1897 g (1.142 mmol) 
of terephthalic acid, 0.0439 g (0.2422 mmol) of 2-aminoterephthalic acid, and 0.374 g (1.384 
mmol) of FeCl3·H2O were dissolved in 60 mL of DMF.  The solution was placed in four 
HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction w
 heated to 150 °C, and was held at this temperature for 10 minutes.  After cooling to 
room temperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
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Synthesis of “20%” amino-MIL Nanoparticles (6-7).  Nanoparticles of “20%” 
amino BDC (6-7) were prepared using a similar procedure as above.  0.1839 g (1.111 mmol) 
of terephthalic acid, 0.0503 g (0.2775 mmol) of 2-aminoterephthalic acid, and 0.374 g (1.384 
mmol) of FeCl3·H2O were dissolved in 15 mL of DMF.  The solution was placed in a HP500 
microw      
n was placed in four 
HP500 microwave vessels (15 mL each), and the vessels were sealed.  The reaction was then 
rapidly erature for 10 minutes.  After cooling to 
room te
ere isolated 
by cent
ave vessel, and the vessel was sealed.  The reaction was then rapidly heated to  
150 °C, and was held at this temperature for 10 minutes.  After cooling to room temperature, 
the particles were isolated by centrifuging, and were washed with DMF and ethanol. 
Synthesis of “50%” amino-MIL Nanoparticles (6-8).  Nanoparticles of “50%” 
amino BDC (6-8) were prepared using a similar procedure as above.  0.1150 g (0.692 mmol) 
of terephthalic acid, 0.1254 g (0.692 mmol) of 2-aminoterephthalic acid, and 0.374 g (1.384 
mmol) of FeCl3·H2O were dissolved in 60 mL of DMF.  The solutio
 heated to 150 °C, and was held at this temp
mperature, the particles were isolated by centrifuging, and were washed with DMF 
and ethanol. 
Synthesis of 100% amino-MIL Nanoparticles (6-9).  Nanoparticles of 100% amino 
BDC (6-9) were prepared using a similar procedure as above.  0.2507 g (1.384 mmol) of 2-
aminoterephthalic acid and 0.374 g (1.384 mmol) of FeCl3·H2O were dissolved in 60 mL of 
DMF.  The solution was placed in four HP500 microwave vessels (15 mL each), and the 
vessels were sealed.  The reaction was then rapidly heated to 150 °C, and was held at this 
temperature for 10 minutes.  After cooling to room temperature, the particles w
rifuging, and were washed with DMF and ethanol. 
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6.4.3 Synthesis of Fluorophore Standards 
Synthesis of BDC-NH-FITC.  The molecular compound BDC-NH-FITC was 
synthesized to use as a standard for determining the amount of fluorescein grafted onto the 
NMOFs.  1 mg (0.0055 mmol) of 2-aminoterephthalic acid and 2.15 mg (0.0055 mmol) of 
fluorescein isothiocyanate were dissolved in 1 mL of absolute ethanol.  The reaction was 
then stirred at room temperature, under Ar, overnight.  The solvent was then evaporated, and 
1.08 mg of the product was dissolved in water after adjusting the pH to 10.1.  The sample 
was diluted to a total volume of 2 mL and this solution was used to construct a calibration 
curve for quantifying the amount of fluorescein in the digested NMOF samples. 
e B.  The molecular compound BDC-NH-
rhodam
f 2-
aminot
fluorescein isothiocyanate was dissolved in 3 mL of absolute ethanol.  10 mg of 
Synthesis of BDC-NH-Rhodamin
ine B was synthesized to use as a standard for determining the amount of rhodamine 
B grafted onto the NMOFs.  20 mg (0.04175 mmol) of rhodamine B was dissolved in 1.5 mL 
of dry CH2Cl2.  5 µL (8.16 mg, 0.0655 mmol) of thionyl chloride was then added, and the 
reaction was stirred at room temperature, under Ar, overnight.  The solvent and excess 
thionyl chloride were then removed under vacuum.  7.56 mg (0.0417 mmol) o
erephthalic acid and 1.2 mL of dry DMF were then added, and the reaction was stirred 
at room temperature, for two days.  The product was then precipitated upon the addition of 
diethyl ether, isolated by centrifuging, and washed once with additional diethyl ether.  Yield: 
15.69 mg (0.0245 mmol) 58.8%. 
 
6.4.4 Post-Synthetic Modifications 
FITC Functionalized amino-MIL Nanoparticles.  7.5 mg (0.0193 mmol) of 
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Fe3O(DMF)3Cl(NH2-BDC)3 nanoparticles (6-9) were added, and the reaction was stirred at 
room temperature, under Ar, in the dark, for 48 hours.  The particles were then isolated by 
centrifu
tirred at room temperature, under Ar, for 3 days.  The 
particle
6-9 was added, and the reaction was 
stirred 
11.7 µmol) of Br-BODIPY 
was dissolved in 2 mL of THF and was added to the particle suspension.  The reaction was 
ging, and were washed with ethanol, until a colorless supernatant was observed. 
Rhodamine B Functionalized amino-MIL Nanoparticles Method 1.  73.65 mg 
(0.15375 mmol) of rhodamine B was dissolved in 6 mL of dry CH2Cl2.  12 µL (0.02012 g, 
0.1691 mmol) of thionyl chloride was then added, and the reaction was stirred at room 
temperature, under Ar, overnight.  The solvent and excess thionyl chloride were then 
removed under vacuum.  100 mg of dried amino-MIL particles were then added along with 5 
mL of dry DMF, and the reaction was s
s were then isolated by centrifuging, and were washed once with DMF, then 
extensively washed with ethanol.  After the supernatant appeared colorless the particles were 
dried under vacuum.  
Rhodamine B Functionalized amino-MIL Nanoparticles Method 2.  14.73 mg 
(0.03075 mmol) of rhodamine B and 5.98 mg (0.0369 mmol) of 1,1-carbonyldiimidazole 
were dissolved in 1 mL of anhydrous DMF.  The reaction was then heated to 60 °C for 1 
hour.  After cooling to room temperature 20 mg of 
at room temperature, under Ar, for 3 days.  The particles were then isolated by 
centrifuging and washed extensively with ethanol.  After the supernatant appeared colorless 
the particles were dried under vacuum. 
BODIPY Functionalized amino-MIL Nanoparticles.  6.5 mL of a suspension of   
6-3 in ethanol was centrifuged to isolate 20.9 mg of particles.  The particles were washed 
once with THF before being redispersed in 5 mL of THF.  4 mg (
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then sti
anhydride was dissolved in 10 mL of anhydrous DMF.  100 
mg of 
A functionalized 6-9 particles were then added, and the mixture was 
stirred 
The Pt was then loaded by first suspending 15.4 mg of succinic acid functionalized 
amino-MIL particles 2 mL of dry CH2Cl2.  5 µL (8.16 mg, 0.069 mmol) of thionyl chloride 
rred at room temperature for 2 days.  The particles were then isolated by centrifuging, 
and were washed with THF until a colorless supernatant was observed.  A similar procedure 
was used to functionalize particles 6-6 with BODIPY. 
Gd Loaded amino-MIL Nanoparticles.  The amino-MIL particles (6-9) were first 
functionalized with DTPA using the following procedure.  69 mg (0.193 mmol) of 
diethylenetriaminepentaacetic di
Fe3O(DMF)3Cl(NH2-BDC)3 nanoparticles (6-9) were added, and the reaction was 
stirred at room temperature, under Ar, for 3 days.  The particles were then isolated by 
centrifuging, were washed with DMF, and dried under vacuum.   
The Gd was then loaded by first adding 0.775 mL of a 0.2 M GdCl3 solution (0.155 
mmol) to 10 mL of distilled water.  The pH of the solution was adjusted to 7.0 using dilute 
NaOH.  80 mg of DTP
at room temperature, overnight.  The particles were isolated by centrifuging and then 
dialyzed against 300 mL of 18 MΩ water for 5 hours to remove any free Gd3+.  The particles 
were then dried under vacuum.  
Pt Loaded amino-MIL Nanoparticles.  The amino-MIL particles (6-7) were first 
functionalized with succinic acid, using the following procedure.  4.5 mg (0.045 mmol) of 
succinic anhydride was dissolved in 2 mL of anhydrous DMF.  20 mg of nanoparticles 6-2 
were added, and the reaction was stirred at room temperature, under Ar, for 3 days.  The 
particles were then isolated by centrifuging, were washed with DMF and ethanol, and then 
dried under vacuum.   
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was the
rst synthesizing the c,c,t-[Pt(IV)Cl2(NH3)2(OEt)(O2CCH2CH2CO2H)] 
omplex using a previously published procedure.13  For loading into 6-6, 22 mg (0.0476 
mol) of c,c,t-[Pt(IV)Cl2(NH3)2(OEt)(O2CCH2CH2CO2H)] was dissolved in 3 mL of 
nhydrous DMF along with 9.3 mg (0.0574 mmol) of 1,1-carbonyldiimidazole.  The reaction 
as then heated at 60 °C for 1 hour, under Ar.  After cooling to room temperature, 85 mg of 
ried 6-6 was then added and the reaction was stirred at room temperature for 2 days.  The 
n isolated by centrifuging, and was washed with DMF and ethanol before 
n added, and the reaction was stirred at room temperature, under Ar, for 24 hours.  
The solvent and excess thionyl chloride were then removed under vacuum.  15 mg (0.041 
mmol) of c,c,t-Pt(NH3)2Cl2(OH)(OEt) was then added, along with 3.5 mL of dry DMF.  The 
reaction was then stirred at room temperature, under Ar, for 48 hours.  The particles were 
isolated by centrifuging and were washed twice with DMF.  The particles were then dialyzed 
against 300 mL of 18 MΩ water for 4 hours to remove any free complex.  The particles were 
then dried under vacuum.  A similar procedure was used for loading Pt into NMOFs 6-8 and 
6-9. 
An alternate method was used to load the Pt(IV) complex in NMOFs 6-3 and 6-6.  
This method involved fi
c
m
a
w
d
product was the
being dialyzed against distilled water for 5 hours.  A similar procedure was used to load the 
Pt(IV) complex in 6-3. 
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Hybrid Silica Nanoparticles for Bacterial Spore Detection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Portions of this chapter were adapted from Taylor, K. M. L.; Lin, W. J. Mater. Chem. 
submitted.) 
 
 
 
 
 
 
 
7.1 Introduction 
 
Bacterial endospores are dormant structures produced by bacterial cells in order to 
survive harsh conditions.  The endospores are resistant to stresses such as heat, radiation, 
desiccation, and chemical disinfectants, making them difficult to remove.1  Certain species of 
endospores are used to check the performance of sterilization techniques, while other species, 
such as Bacillus anthracis have been used as delivery vehicles in anthrax attacks.2  
 Rapid detection of B. anthracis spores is a major concern in the event of biological 
warfare.  Inhalation of as few as 104 spores can result in death if medical attention is not 
received within 24-48 hours.3  Several methods are currently used for detecting the presence 
of bacterial endospores, including immunoassays,4-5 polymerase chain reactions (PCR),6-8 
surface-enhanced Raman spectroscopy,9-11 and Tb(III) luminescence.1,12-16  Tb(III) 
luminescence detection has been shown to be a rapid, sensitive, and inexpensive method for 
endospore detection.  The luminescence detection is based on the sensing of dipicolinic acid 
(DPA) which can account for up to 15% of the dry mass of endospores.  Coordination of 
DPA to Tb(III) results in luminescence after UV excitation at the absorbance maximum of 
DPA.  It has been shown that energy transfer from the ligand (DPA) to the terbium excited 
states is responsible for the enhanced luminescence when compared to aquated Tb(III) ions. 
 TbCl3 has been used as a sensor for DPA detection, but has several disadvantages 
including non-selective binding of other aromatic ligands resulting in false positives; binding 
of other anions, such as phosphate, which may inhibit DPA binding resulting in false 
negatives; and finally non-radiative quenching from coordinating water which reduces the 
quantum yield, and thus the overall sensitivity of the assay.  A recent report by Ponce and 
coworkers discussed the use of a macrocyclic ligand to occupy 6 of the Tb coordination sites, 
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leaving 3 adjacent sites available for DPA coordination.15  This prevents water molecules 
from coordinating to the Tb(III) centers after DPA binding, thus eliminating deleterious 
quenching by coordinating water molecules to provide a sensitive molecular DPA sensor 
based on luminescence enhancement.   
 We have synthesized and evaluated two novel hybrid nanoparticle platforms for DPA 
detection that involve the immobilization of Tb(III) EDTA complexes onto either silica 
nanoparticles or silica coated nanoscale metal-organic frameworks (NMOFs).  The EDTA 
ligand serves to occupy 6 of the Tb coordination sites and can also be easily modified to 
contain one or two triethoxysilane groups to allow for covalent attachment to the silica 
nanoparticles.  The use of a nanoparticle platform for immobilizing the Tb complexes 
provides a mechanism for incorporating an internal standard in the particle core, which 
would then eliminate the need for instrument specific calibration curves for quantifying the 
amount of DPA in an unknown sample. 
 
7.2 Results and Discussion 
 7.2.1 Synthesis of Nanoparticle Sensors 
Three different EDTA based ligands were synthesized for this work.  Initially, the 
EDTA dianhydride was mono-functionalized with aminopropyltriethoxysilane (APTES) to 
allow for a single point covalent attachment of the complex to the silica particle.  After 
coordination of the Tb ion, this complex (7-1) has an overall neutral charge.  By reacting the 
EDTA dianhydride with two equivalents of APTES, the bis functionalized ligand and Tb 
complex (7-2) were then formed.  This complex provides two covalent attachment points of 
the complex to the nanoparticle, and the complex has an overall positive charge.  Finally, a 
 213
third complex was formed by functionalizing the ETDA dianhydride with two different 
groups.  One side of the dianhydride was first reacted with pentylamine, while the other side 
was functionalized with APTES.  The resulting Tb complex (7-3) then had an overall 
positive charge and one functional group to allow for covalent attachment to the nanoparticle 
platform (Scheme 7.1). 
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Scheme 7.1.  Solid silica nanoparticles coated with three different modified EDTA-Tb 
complexes. 
 
 Two different types of nanoparticle platforms were synthesized for this work.  First, 
solid silica nanoparticles were synthesized from the basic condensation of 
tetraethylorthosilicate (TEOS) in a water-in-oil microemulsion with a W-value of 15.  After 
allowing 24 hours for particle formation, an aliquot of an aqueous solution of the Tb complex 
was added, and the reaction was continued at room temperature for an additional 18 hours.  
The particles were then precipitated upon the addition of ethanol, isolated by centrifuging 
and washed with ethanol and water to remove unreacted starting material and the surfactant.  
To ensure complete complexation of the immobilized EDTA derivatives, Tb3+ was re-loaded 
by treating the nanoparticles with additional TbCl3 in water at a pH of 9.5.  A similar 
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procedure was used to synthesize silica nanoparticles with a luminescent core.  In this case an 
aqueous solution of Ru(bpy)32+ was added along with the water and TEOS when forming the 
initial microemulsion. 
 The second type of nanoparticle platform used for this work was based on a nanoscale 
metal-organic framework.  Eu-doped Gd NMOFs with the formula 
Eu0.02Gd0.98(BDC)1.5(H2O)2 were synthesized using a previously published procedure.17  The 
NMOFs were then coated with an organic polymer, polyvinylpyrrolidone (PVP), followed by 
coating with an 8-9 nm thick silica shell.  Tb complex 7-1 was then grafted onto the surface 
of the silica shell under basic conditions in ethanol. 
  
7.2.2 Characterization 
 The nanoparticle sensors were characterized by a variety of methods.  First, 
transmission electron microscopy (TEM) was used to determine the particle size and 
morphology.  The solid silica nanoparticles particles obtained are uniform spheres, 
approximately 37 nm in diameter, while the NMOFs are nanorods approximately 40 nm in 
diameter and 100 nm in length (Fig. 7.1 and 7.2).  No measurable change is seen in the 
particle size or morphology after immobilization of the Tb complexes (Fig. 7.1).  The amount 
of Tb complex immobilized on the particles was then estimated using thermogravimetric 
analysis (TGA).  TGA of the coated particles shows an initial weight loss for adsorbed 
solvent molecules, followed by a weight loss from ~250°C to 550°C for the organic portion 
of the complex (Fig. 7.3).  The exact Tb concentration of a suspension of the nanoparticle 
sensors was then determined through DPA titration. 
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 a)  b) 
 c)  d) 
 
Figure 7.1.  TEM images of uncoated silica nanoparticles (a), and silica nanoparticles coated 
with Tb complexes 7-1 (b), 7-2 (c), and 7-3 (d). 
 
Figure 7.2.  TEM images of PVP coated NMOFs (left), and silica coated NMOFs with an 8-
9 nm thick silica shell (right). 
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Figure 7.3.  TGA of silica nanoparticles coated with complexes 7-1 (black), 7-2 (red), and 7-
3 (blue). 
 
 
7.2.3 DPA Detection Results 
 
As expected, UV excitation of a suspension of the nanoparticle sensors results in no 
emission.  However, upon the addition of the DPA disodium salt, characteristic Tb emission 
is observed with peaks appearing at 489 nm, 544 nm, and 584 nm (Fig. 7.4 and Scheme 7.2).  
Titration of a suspension of the nanoparticle sensors with DPA results in a linear increase of 
emission intensity until all of the Tb complexes have become coordinatively saturated.  
Based on the number of available coordination sites, a 1:1 stoichiometry for complex 
formation with DPA was expected for all three of the Tb complexes.  This was however not 
observed in all cases.  The Job’s plots revealed that both of the cationic Tb complexes (7-2 
and 7-3) formed a 1:1 complex with DPA whereas the neutral Tb complex (7-1) formed a 
complex with a 2:3 Tb:DPA ratio (presumably reflecting the influence of charge on DPA 
coordination to the Tb center) (Fig. 7.5). The Job’s plots for the nanoparticles revealed that 
all three sensors form the expected 1:1 Tb:DPA complex (Fig. 7.6).    
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Figure 7.4.  Emission spectrum of a suspension of silica nanoparticles functionalized with 
Tb complex 7-2.  The DPA concentration was increased from 0 to 1.5 eq relative to Tb.  The 
peak at 556 nm is a result of second order scattering.  Excitation wavelength was 278 nm. 
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Scheme 7.2.  Schematic showing the light-up process for the nanoparticle sensor with 
immobilized EDTA-Tb complexes (7-1 to 7-3) before and after the addition of DPA. 
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Figure 7.5.  Job’s plots of Tb complexes 7-1 (black diamonds), 7-2 (red triangles), and 7-3 
(blue squares).  The curves for complexes 7-2 and 7-3 are offset by 0.2 and 0.4 normalized 
intensity units, respectively. 
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Figure 7.6.  Job’s plots of nanoparticle sensors functionalized with complexes 7-1 (black 
diamonds), 7-2 (red triangles), and 7-3 (blue squares).  The curves for sensors functionalized 
with complexes 7-2 and 7-3 are offset by 0.2 and 0.4 normalized intensity units, respectively. 
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Using the linear response a calibration curve can be constructed, which can then be 
used to quantitatively determine the amount of DPA in an unknown sample (Fig. 7.7-7.11).  
The nanoparticle sensors are able to detect low concentrations of DPA.  The detection limit 
for each system was determined using the background intensity plus three standard 
deviations.  The nanoparticles functionalized with Tb complex 7-2 provided the lowest 
detection limit for all nanoparticle systems.  Using the major peak at 544 nm, a detection 
limit of 10.3 nM was determined.  The peak at 489 nm can also be used, resulting in a 
slightly higher detection limit of 20.3 nM.  The nanoparticles functionalized with Tb 
complexes 7-1 and 7-3 gave slightly higher limits of detection, but all detection limits were 
below 35 nM. 
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Figure 7.7.  Calibration curve for DPA detection using a 10 µM solution of free monoAPS-
EDTA-Tb complex (7-1) obtained by plotting the intensity at 489 nm (blue) and 544 nm 
(pink) vs. [DPA].  The detection limit was calculated to be 5.02 nM using the peak at 489 nm 
and 4.12 nM using the peak at 544 nm. 
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Figure 7.8.  Calibration curve for DPA detection using a suspension of monoAPS-EDTA-Tb 
(7-1) coated particles with a Tb concentration of 10 µM obtained by plotting the intensity at 
489 nm (blue) and 544 nm (pink) vs. [DPA].  The detection limit was calculated to be 34.6 
nM using the peak at 489 nm and 15.7 nM using the peak at 544 nm. 
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Figure 7.9.  Calibration curve for DPA detection using a 10 µM solution of free bisAPS-
EDTA-Tb (7-2) complex obtained by plotting the intensity at 489 nm (blue) and 544 nm 
(pink) vs. [DPA].  The detection limit was calculated to be 7.11 nM using the peak at 489 nm 
and 9.39 nM using the peak at 544 nm. 
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Figure 7.10.  Calibration curves for DPA detection using silica nanoparticles functionalized 
with Tb complex 7-2 using the intensity at 489 nm (blue) and 544 nm (pink).  Using this 
curve detection limits of 20.3 nM and 10.3 nM were calculated using the peaks at 489 nm 
and 544 nm, respectively. 
 
y = 0.0646x + 1.3444
R2 = 0.9949
y = 0.0465x + 0.4791
R2 = 0.9956
0
10
20
30
40
50
60
70
80
0 200 400 600 800 1000
[DPA] (nM)
In
te
ns
ity
Figure 7.11.  Calibration curve for DPA detection using a suspension of pentylamide-APS-
EDTA-Tb (7-3) coated particles with a Tb concentration of 10 µM obtained by plotting the 
intensity at 489 nm (blue) and 544 nm (pink) vs. [DPA].  The detection limit was calculated 
to be 27.2 nM using the peak at 489 nm and 24.1 nM using the peak at 544 nm. 
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One of the major benefits to using a nanoparticle based sensor is that an internal 
reference can be incorporated into the nanoparticle to allow for ratiometric detection.  This 
eliminates the need for instrument specific calibration curves, and also alleviates the need of 
correcting for dilution.  Two different types of internal standards were evaluated.  First, solid 
silica nanoparticles were synthesized to contain a luminescent Ru(bpy)32+ core (Scheme 7.3).  
Comparison of the Tb emission intensity to the Ru(bpy)32+ emission allows for the 
ratiometric detection of DPA.  The emission intensity from the Ru(bpy)32+ remains constant 
and is independent of the DPA concentration.  Because Ru(bpy)32+ has an absorbance over a 
wide wavelength range the internal reference can be monitored independently of the Tb 
luminescence by exciting at a higher wavelength, such as 488 nm (Fig. 7.12).  For the 
NMOFs we were able to use the Eu emission from the particles as an internal standard (Fig. 
7.13).   
 
=
 
Scheme 7.3.  Schematic showing the nanoparticle sensor with a Ru(bpy)3Cl2 core (left) and 
the Eu-doped NMOF core (right). 
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Figure 7.12.  Emission spectrum of a suspension of Ru(bpy)3Cl2 doped silica nanoparticles 
functionalized with Tb complex 7-2.  The DPA concentration was increased from 0 to 2 
equivalents and the emission spectrum was recorded after exciting at 277 nm.  The inset 
shows the emission spectrum after exciting at 488 nm where the only emission observed is 
that of the Ru(bpy)3Cl2 internal reference.  This emission is independent of DPA 
concentration (black – 0 eq, red – 2 eq.). 
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Figure 7.13.  Emission spectrum of a suspension of Eu-doped NMOFs functionalized with 
complex 7-1.  The DPA concentration was increased from 0 to 10 µM and the emission 
spectrum was recorded after exciting at 278 nm. 
 
In order to evaluate the specificity of this nanoparticle sensor, we have carried out 
DPA detection experiments in buffered solutions and in the presence of biologically 
prevalent interferences such as amino acids.  Using the Eu doped NMOF sensor, the DPA 
detection experiment was carried out in a 10 mM Tris buffered solution at pH 7.6, and a 
similar response was seen compared to the results obtained in an ethanol suspension (Fig. 
7.14 and 7.15).  The DPA detection limit was calculated to be 56.6 nM in the buffered 
solution compared to 48 nM in an ethanol suspension. 
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Figure 7.14.  Dependence of the ratio of Tb to Eu emission intensities for Eu-doped NMOF 
sensors (in ethanol) on DPA concentration (red – 544 nm/592 nm, black – 544 nm/615 nm).  
The inset shows the linear relationship at low [DPA]. 
 
Figure 7.15.  Dependence of the ratio of Tb (544 nm) to Eu (592 nm) emission intensities for 
Eu-doped NMOF sensors on DPA concentration in a 10 mM Tris buffered ethanol in water 
(1:1) solution (black) and in the presence of 0.6 mM L-alanine (red). 
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 To determine if the Tb-EDTA complex was selective for the detection of DPA 
against other biologically relevant carboxylic acid-containing molecules, two suspensions of 
the Eu doped NMOF sensor were made in 10 mM Tris buffered solution at pH 7.6.  DPA was 
then added to both suspensions, one suspension was brought to a [DPA] of 5 µM, while the 
other was brought to a [DPA] of 150 μM.  Aliquots of a 100 mM solution of L-alanine were 
added to the DPA nanoparticle suspensions to achieve final alanine concentrations of 0.3, 
0.6, 0.9, and 1.2 mM.  The luminescent intensities were recorded approximately 5 minutes 
after each addition and the ratio of Tb to Eu luminescent intensities were plotted against the 
[Ala] (Fig. 7.16).  There is a negligible change in the ratios of luminescent intensities even in 
the presence of over 200 fold excess of alanine. 
 
Figure 7.16.  Ratio of Tb (544 nm) to Eu (592 nm) signal intensity vs. Ala concentration for 
a suspension Eu-doped NMOFs functionalized with complex 7-1 in a 10 mM Tris buffered 
ethanol in water (1:1) solution with 5 µM (blue) and 150 µM (pink) DPA. 
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7.2.4 Spore Detection Results 
 The spore detection efficiency of the nanoparticle sensors was also evaluated using 
Bacillus subtilis as a model.  Bacillus subtilis endospores contain 8.9 % DPA by weight.10  
Lyophilized cells were purchased from Aldrich, and two different methods were employed to 
extract DPA.  The first method involved sonication of the B. subtilis cells in 0.02 M nitric 
acid.  A 34% extraction efficiency was reported for this method.10  Complexes 7-1 to 7-3 and 
the corresponding silica nanoparticles coated with 7-1 to 7-3 were used to detect DPA from 
the extracted spore sample.  Only the free complex 7-2 resulted in any increase in emission 
intensity (Fig. 7.17).  The calculated DPA concentration based on the emission intensity was 
approximately 4-8 fold lower than the expected concentration, and a linear increase in 
emission intensity was not observed (Table 7.1).  The pH dependence of the spore detection 
using complex 7-2 was also evaluated, and a peak intensity was observed at pH 7 (Fig. 7.18).   
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Figure 7.17.  Emission spectrum of a 10 µM solution of complex 7-2 before (blue) and after 
the addition of 1 µL (pink), 3 µL (red), and 5 µL (black) of an extracted spore solution with a 
calculated [DPA] of 1.12 mM. 
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Table 7.1.  DPA detection from spores extracted with 0.02 M nitric acid, using complex 7-2. 
 
µL spore 
soln. added 
Calc. [DPA] Measured [DPA] 
(489 nm) 
Measured [DPA] 
(544 nm) 
0 0 nM 4.2 nM -8.4 nM 
1 560 nM 157 nM 147 nM 
3 1680 nM 321 nM 306 nM 
5 2800 nM 358 nM 345 nM 
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Figure 7.18.  Dependence of emission intensity at 544 nM on the pH of a 10 µM solution of 
complex 7-2 containing 16 µL of an extracted spore solution with a calculated [DPA] of 8.89 
µM. 
 
An alternative method was also attempted to extract the DPA.  It is known that 
endospores will release DPA as an initial step of the germination process.  This process 
involves first heat activation by heating a suspension of the lyophilized cells at 70 °C for 30 
minutes, followed by the addition of a germinant; in this case L-alanine was used.1  Similar 
results were seen as with the nitric acid extraction in that only complex 7-2 showed any 
response (Fig. 7.19).  The concentration determined from the luminescence intensity was 
approximately 10 fold lower than the expected concentration assuming complete release of 
DPA (Table 7.2).   
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Figure 7.19.  Emission spectrum of a 10 µM solution of complex 7-2 before (blue) and after 
the addition of 1 µL (pink), 3 µL (red), 5 µL (black), and 7 µL (green) of an extracted spore 
solution with a calculated [DPA] of 2.80 mM. 
 
Table 7.2.  DPA detection from spores extracted using the germination method.  The DPA 
was detected using complex 7-2. 
 
µL spore 
soln. added 
Calc. [DPA] Measured [DPA] 
(489 nm) 
Measured [DPA] 
(544 nm) 
1 1400 nM -3.8 nM -10.8 nM 
3 4200 nM 440 nM 452 nM 
5 7000 nM 709 nM 728 nM 
7 9800 nM 812 nM 847 nM 
 
 
7.3 Conclusion 
 We have developed a nanoparticle sensor that allows for quantitative detection of a 
bacterial spore marker--dipicolinic acid (DPA) at nanomolar concentrations.  Immobilization 
of the Tb complex onto a nanoparticle platform allows for further incorporation of an internal 
reference to allow for ratiometric detection.  We have also shown that the present 
nanoparticle based luminescent sensors exhibit high selectivity for DPA even in large excess 
of other potential competing ligands. 
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7.4 Experimental Details 
7.4.1 Materials and Methods 
All starting materials and solvents were purchased from Aldrich, Fisher, and Gelest, 
and were used without further purification.  Luminescence data were collected on a 
Shimadzu RF-5301PC Spectrofluorophotometer.  A JEM 100CX-II transmission electron 
microscope (TEM) was used to determine particle size and morphology.  TEM samples were 
prepared from ethanolic particle dispersions on amorphous carbon-coated copper grids.  Tb 
concentrations of solutions of the complexes were determined using an Applied Research 
Laboratories (ARL) SpectraSpan 7 Direct Current Plasma (DCP) Spectrometer.  The amount 
of Tb complex immobilized on the particles was determined using thermogravimetric 
analysis and titration with Na2[DPA]. 
  
7.4.2 Ligand Synthesis 
The ligands used in this work were synthesized by reacting 3-aminopropyl-
triethoxysilane with suitable EDTA anhydrides.  Ethylenediamine tetra(acetic acid) mono 
anhydride was first synthesized from the dianhydride, following a published procedure.18  
 Ethylenediamine tetra(acetic acid) mono(3-aminopropyltriethoxysilane) (7-1a)16 was 
synthesized by suspending 0.25 g (0.91 mmol) of EDTA-mono anhydride in 8 mL of 
anhydrous pyridine.  0.21 mL (0.20 g, 0.90 mmol) of 3-aminopropyltriethoxysilane was then 
added, and the mixture was stirred at room temperature under N2 for 16 hours.  The product 
was then precipitated upon the addition of hexanes.  The product was collected by 
centrifuging at 3300 rpm and was washed with additional hexanes to afford pure 7-1a.  
Yield:  0.25 g (56%).  1H NMR (DMSO, 300 MHz): δ 3.71 (s, 4H), δ 3.42 (s, 4H), δ 2.79 (t, 
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JH-H = 6.0 Hz, 2H), δ 2.57 (t, JH-H = 6.0 Hz, 2H).  MS (ESI positive ion): m/z 412.1 (412.1 
expected for the silanetriol [M+H]+). 
 Ethylenediamine tetra(acetic acid) bis(3-aminopropyltriethoxysilane) (7-2a) was 
synthesized by reacting 0.10 g (0.39 mmol) of ethylenediamine tetra(acetic acid) dianhydride 
and 0.19 mL (0.18 g, 0.812 mmol) of 3-aminopropyltriethoxysilane in 2.5 mL of anhydrous 
pyridine at room temperature and under N2 for 16 hours.  The product was precipitated upon 
the addition of hexanes, and collected by centrifuging at 3300 rpm.  Further washing with 
additional hexanes afforded the pure product of 7-2a.  Yield: 0.17 g (62.4%).  1H NMR 
(DMSO, 400 MHz):  δ 7.98 (s, 2H), δ 3.72 (q, JH-H = 6.4 Hz, 12H), δ 3.35 (s, 4H), δ 3.19 (s, 
4H), δ 3.04 (br., 4H), δ 2.69 (s, 4H), δ 1.44 (m, 4H), δ 1.12 (t, JH-H = 7.0 Hz, 18H), δ 0.51 (t, 
JH-H = 8.2 Hz, 2H).  MS (ESI positive ion): m/z 560.8 (559.2 expected for the silane 
monoethoxypentatriol [M+H]+). 
 In order to synthesize ethylenediamine tetra(acetic acid) mono(3-aminopropyl-
triethoxysilane) mono(pentylamide) (7-3a), EDTA-pentylamide was first synthesized by 
suspending 1.42 g (5.19 mmol) of a mixture of EDTA mono anhydride and EDTA (50:50 
mixture) in 45 mL of anhydrous pyridine.  0.36 mL (0.27 g, 3.10 mmol) of amylamine was 
then added, and the reaction was stirred at room temperature, under N2 for 16 hours.  The 
reaction mixture was then centrifuged at 3300 rpm, to separate the pyridine insoluble 
material which was identified as EDTA and a small amount of EDTA mono anhydride.  
Hexanes were then added to the supernatant to precipitate the product, which was collected 
by centrifuging at 3300 rpm.  The product was then washed with additional hexanes and 
dried under vacuum.  NMR of the hexane precipitated product shows that this product is a 
mixture of the desired EDTA-pentylamide, EDTA mono anhydride, and EDTA in a 6.75 : 
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2.25 : 1 molar ratio.  The above procedure was repeated using the isolated product to obtain 
pure EDTA-pentylamide in ~25% yield.  1H NMR (DMSO, 400 MHz):  δ 8.02 (s, 1H), δ 
3.35 (s, 4H), δ 3.19 (s, 2H), δ 3.05 (q, JH-H = 6.7 Hz, 2H), δ 2.72 (m, 4H), δ 1.39 (quin., JH-H 
= 6.9 Hz, 2H), δ 1.24 (m, 4H), δ 0.84 (t, JH-H = 7.0 Hz, 3H). 
 EDTA-pentylamide-mono anhydride was then synthesized by reacting 0.255 g (0.706 
mmol) of EDTA-pentylamide and 150 µL (0.162 g, 1.59 mmol) of acetic anhydride in 1 mL 
of anhydrous pyridine at 65°C for 20 hours.  Hexanes were then added to the reaction 
mixture to precipitate EDTA-pentylamide-mono anhydride which was washed with hexanes 
several times to remove the excess acetic anhydride.  EDTA-pentylamide-mono anhydride 
was then redissolved in 6 mL of anhydrous pyridine followed by the addition of 0.2 mL (0.19 
g, 0.85 mmol) of 3-aminopropyltriethoxysilane.  The reaction mixture was stirred at room 
temperature for 16 hours.  Addition of hexanes and centrifugation at 3300 rpm led to crude 
product of 7-3a which was washed with additional hexanes and dried under vacuum.  7-3a 
was purified by recrystallization from a mixture of methanol (2 mL) and diethyl ether (~20 
mL).  Yield: 0.092 g (23.1% based on the amount of pentylamide-EDTA-mono anhydride 
used).  1H NMR (DMSO, 400 MHz):  δ 3.73 (m, 2H), δ 3.58 (br, 2H), δ 3.43 (m, 4H), δ 3.39 
(q, JH-H = 7.4 Hz, 6H), δ 3.00 (m, 2H), δ 2.66 (m, 4H), δ 1.40 (m, 2H), δ 1.24 (m, 2H), δ 1.13 
(m, 4H), δ 1.09 (t, JH-H = 5.9 Hz, 9H), δ 0.83 (m, 3H), δ 0.57 (m, 2H).  MS (ESI positive 
ion): m/z 475.4 (475.2 expected for the silanetriol).  
  
7.4.3 Tb Complex Synthesis 
The corresponding Tb(III) complexes of 7-1a to 7-3a (7-1 to 7-3) were formed by 
adding 1 eq of TbCl3 to an aqueous solution of the deprotonated form of each ligand.  The 
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synthesis of complex 7-1 is shown here as an example.  To prepare the terbium complex 7-1, 
ligand 7-1a (0.1 g, 0.2 mmol) was dissolved in 3 eq of NaOH (1.21 mL of a 0.5 M solution) 
at room temperature with magnetic stirring.  One equivalent of TbCl3 (1.35 mL of a 0.15 M 
solution) was then added dropwise, and the solution was stirred for an additional 30 minutes.  
Approximately 5 mL of ethanol was then added to the solution to precipitate the complex, 
which was isolated by centrifuging at 3200 rpm for 10 minutes.  The complex was then 
washed with additional ethanol and dried.  Yield: 0.0555 g (39.0%).  The complex was 
dissolved in distilled water, and diluted to a total volume of 5 mL to give a ~ 0.016 M 
solution.   
  
7.4.4 Nanoparticle Synthesis 
The silica nanoparticles were synthesized using a well-established water-in-oil 
reverse microemulsion procedure.  Briefly, to 20 mL of a 0.3 M Triton-X100/1.5 M 1-
hexanol/cyclohexane solution was added 1.22 mL of distilled water and 0.20 mL of 
tetraethylorthosilicate (TEOS).  The mixture was stirred for 10 minutes at room temperature 
to allow for the formation of a microemulsion with a W-value of 15 (W = water/surfactant 
ratio).  0.4 mL of aqueous ammonia was then added to initiate the hydrolysis.  After stirring 
for 24 hours, an aliquot of an aqueous solution of the Tb complex was added to the reaction 
mixture, and the reaction was stirred for an additional 18 hours at room temperature.  20 mL 
of ethanol was added to the reaction to precipitate the particles which were then collected by 
centrifuging at 13500 rpm for 20 minutes.  The particles were then washed twice with 
ethanol and once with water before being redispersed in 5 mL of distilled water.  Using this 
procedure, uniform spherical particles of approximately 37 nm in diameter were obtained. 
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 A similar procedure was used to synthesize the nanoparticles with a luminescent 
Ru(bpy)32+ core.  As an example, monoAPS-EDTA-Tb coated, Ru(bpy)32+ doped, silica 
nanoparticles were synthesized using a Triton-X100/1-hexanol/cyclohexane/water 
microemulsion system.  To 10 mL of a 0.3 M Triton-X100/1.5 M 1-hexanol/cyclohexane 
solution was added, 0.57 mL of distilled water, 40 µL of a 0.1 M Ru(bpy)32+ aqueous 
solution, and 0.10 mL of tetraethylorthosilicate (TEOS).  The mixture was stirred for 10 
minutes at room temperature to allow for the formation of a microemulsion with a W-value 
of 15.  0.2 mL of aqueous ammonia was then added to initiate the hydrolysis.  After stirring 
for 24 hours, 28 µL of a 0.0176 M aqueous solution of monoAPS-EDTA-Tb (7-1) was added 
to the reaction mixture.  The reaction was then stirred for an additional 18 hours at room 
temperature.  10 mL of methanol was added to the reaction to precipitate the particles which 
were then collected by centrifuging at 13500 rpm for 20 minutes.  The particles were then 
washed twice with ethanol and once with water before being redispersed in 1.5 mL of 
distilled water. 
  After synthesis of the nanoparticles and immobilization of complexes 7-1 to 7-3, Tb 
was re-loaded to ensure all of the immobilized ligands formed a Tb complex.  This was done 
by adding an aliquot of TbCl3 solution to a suspension of the nanoparticle sensor in water 
(pH ~ 9.5).  The mixture was then stirred at room temperature for 16 hours, after which time 
the particles were isolated and washed to remove any uncomplexed Tb ions.  The amount of 
TbCl3 added was equal to the initial amount of complex that had been added during the 
nanoparticle sensor synthesis. 
The Eu0.02Gd0.98(BDC)1.5(H2O)2 NMOFs were synthesized using a cationic 
cetyltrimethylammonium bromide (CTAB)/1-hexanol/iso-octane/water reverse 
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microemulsion.  Briefly, 441 µL of a 0.05 M GdCl3 aqueous solution and 9 µL of a 0.05 M 
Eu(NO3)3 aqueous solution were added to a 100 mL aliquot of CTAB (0.05 M) and 1-
hexanol (0.5 M) in iso-octane, resulting in the formation of a microemulsion with a W-value 
of 5.  To a second 100 mL aliquot of CTAB and 1-hexanol in iso-octane was added 450 µL 
of a 0.067 M solution of di(methylammonium)-benzenedicarboxylate forming a second 
microemulsion with a W-value of 5.  After the two separate microemulsions had formed they 
were combined and stirred at room temperature for 2 hours.  1.35 mL of a 5 mM aqueous 
solution of polyvinylpyrrolidone (PVP, MW = 40,000) was then added and the reaction was 
stirred for an additional 12 hours.  The particles were then isolated by centrifuging, and were 
washed with ethanol.   
The PVP coated NMOFs were then coated with a silica shell using sol-gel techniques.  
Briefly, an aliquot of a suspension of the PVP coated NMOFs in ethanol was diluted with 
additional ethanol to reach a final particle concentration of 0.2 mg/mL.  An aliquot 
corresponding to 4% by volume (of ethanol) of aqueous NH4OH was then added, followed 
by tetraethylorthosilicate (TEOS, 5 µL per mg of NMOF).  The reaction was then stirred at 
room temperature for 2 hours, after which time an additional aliquot of TEOS (5 µL per mg 
of NMOF) was added.  The reaction was then continued for 7 hours at room temperature.  
The particles were then isolated by centrifuging and were washed with ethanol.  The 
resulting particles had a silica shell of approximately 8-9 nm in thickness. 
The Tb complex 7-1 was then immobilized on the surface of the silica coated NMOFs 
using the following procedure.  An aliquot of silica coated NMOFs containing 8.8 mg of 
particles was diluted to a total volume of 4 mL.  The pH of the suspension was adjusted to 
approximately 10 with the dropwise addition of aqueous NH4OH.  42 µL of a 0.016 M 
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solution of 7-1 was then added, and the reaction was stirred at room temperature for 16 
hours.  The particles were then isolated by centrifuging, and were washed with water and 
ethanol before being redispersed in 2 mL of ethanol. 
 
7.4.5 DPA Detection 
The optimal stoichiometry for complex formation with dipicolinic acid (DPA) was 
determined using Job’s method of continuous variation.  13 solutions were made by inversely 
varying the concentration of Tb and DPA from 0 to 12 µM.  The samples were then excited 
at 277 nm, and the emission intensity at 545 nm was measured. 
 Calibration curves were made by adding varying amounts of DPA to a nanoparticle 
suspension with a Tb concentration of 10 µM.  After exciting at 277 nm, the intensities at 
489 nm and 544 nm were measured.  The detection limit was determined using the 
background intensity plus three standard deviations. 
  
7.4.6 Extraction of DPA from Bacillus subtilis 
 Method 1 – 6.2 mg of lyophilized B. subtilis cells were added to 1 mL of 0.02 M 
nitric acid and the suspension was sonicated for 15 minutes.  The suspension was then 
centrifuged at 3000 rpm to separate the insoluble material, and the supernatant was 
transferred to another tube.  The estimated [DPA] of the supernatant was determined as 
follows:  
6.2 mg of cells * 8.9 wt% DPA = 0.55 mg DPA 
34% reported extraction efficiency: 0.55 mg * 34% = 0.188 mg DPA = 1.12*10-6 mol/0.001L 
= 1.12 mM 
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 Method 2 – 10.5 mg of lyophilized B. subtilis cells were added to 2 mL of distilled 
water.  The suspension was heated to 70°C for 30 minutes.  After cooling to room 
temperature, 40 µL of a 0.5 M L-alanine solution was added.  The mixture was then stirred at 
room temperature for 2 hours.  The mixture was then centrifuged at 3000 rpm to remove the 
insoluble material.  The [DPA] of the supernatant was calculated to be 2.8 mM, assuming a 
100% extraction efficiency. 
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